

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2007 (25.10.2007)

PCT

(10) International Publication Number
WO 2007/120101 A1

(51) International Patent Classification:

C07D 405/06 (2006.01) *A61P 25/28* (2006.01)
A61K 31/4184 (2006.01) *A61P 35/00* (2006.01)
A61K 31/454 (2006.01) *A61P 9/00* (2006.01)
A61P 1/04 (2006.01) *C07D 235/06* (2006.01)
A61P 25/04 (2006.01) *C07D 403/12* (2006.01)
A61P 25/16 (2006.01) *C07D 405/14* (2006.01)
A61P 25/22 (2006.01) *C07D 413/14* (2006.01)

(21) International Application Number:

PCT/SE2007/000359

(22) International Filing Date: 17 April 2007 (17.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/745,011 18 April 2006 (18.04.2006) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BROWN, William** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **LIU, Ziping** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **PAGE, Daniel** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **QADOUMI, Zena** [CA/CA]; Q7248 Pandora Street, Burnaby, British Columbia V5A 1B9 (CA). **SRIVASTAVA, Sanjay** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **TREMBLAY, Maxime** [CA/CA]; AstraZeneca

R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **WALPOLE, Christopher** [GB/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **WEI, Zhong-yong** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **YANG, Hua** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA).

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS



(57) Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: [Chemical formula should be inserted here. Please see paper copy] I wherein R₁, R₂, R₃ and R₄ are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (CB1) receptor ligands

BACKGROUND OF THE INVENTION

1. Field of the invention

5 The invention is related to therapeutic compounds, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof. Particularly, the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiovascular disorders.

10 2. Discussion of Relevant Technology

Pain management has been an important field of study for many years. It has been well known that cannabinoid receptor (e.g., CB₁ receptor, CB₂ receptor) ligands including agonists, antagonists and inverse agonists produce relief of pain in a variety of animal models by interacting with CB₁ and/or CB₂ receptors. Generally, CB₁ receptors are located
15 predominately in the central nervous system, whereas CB₂ receptors are located primarily in the periphery and are primarily restricted to the cells and tissues derived from the immune system.

While CB₁ receptor agonists, such as Δ^9 -tetrahydrocannabinol (Δ^9 -THC) and anadamide, are useful in anti-nociception models in animals, they tend to exert undesired CNS side effects, e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance,
20 etc. These undesired side effects are known to be mediated by the CB₁ receptors located in CNS. There are lines of evidence, however, suggesting that CB₁ agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile.

Therefore, there is a need for new CB₁ receptor ligands such as agonists that may be
25 useful in managing pain or treating other related symptoms or diseases with reduced or minimal undesirable CNS side effects.

DESCRIPTION OF THE EMBODIMENTS

The present invention provides CB₁ receptor ligands which may be useful in treating pain and/or other related symptoms or diseases.

Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in *Nomenclature of Organic Chemistry, Sections A, B, C, D, E, F, and H*, Pergamon Press, Oxford, 1979, which is incorporated by references herein for its exemplary chemical structure names and rules on naming chemical structures.

The term "C_{m-n}" or "C_{m-n} group" used alone or as a prefix, refers to any group having m to n carbon atoms.

The term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.

The term "hydrocarbon radical" or "hydrocarbyl" used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon.

The term "alkyl" used alone or as a suffix or prefix, refers to a saturated monovalent straight or branched chain hydrocarbon radical comprising 1 to about 12 carbon atoms. Illustrative examples of alkyls include, but are not limited to, C₁₋₆alkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl, and longer alkyl groups, such as heptyl, and octyl. An alkyl can be unsubstituted or substituted with one or two suitable substituents.

The term "alkylene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.

The term "alkenyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms. The double bond of an alkenyl can be unconjugated or conjugated to another unsaturated group. Suitable alkenyl groups include, but

are not limited to C₂₋₆alkenyl groups, such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl. An alkenyl can be unsubstituted or substituted with one or two suitable substituents.

5 The term "alkynyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond and comprising at least 2 up to about 12 carbon atoms. The triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkynyl groups include, but are not limited to, C₂₋₆alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, 10 methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl. An alkynyl can be unsubstituted or substituted with one or two suitable substituents.

 The term "cycloalkyl," used alone or as suffix or prefix, refers to a saturated monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms. Examples of cycloalkyls include, but are not limited to, C₃₋₇cycloalkyl groups, such as 15 cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkyl can be unsubstituted or substituted by one or two suitable substituents. Preferably, the cycloalkyl is a monocyclic ring or bicyclic ring.

 The term "cycloalkenyl" used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon double bond and comprising 20 at least 3 up to about 12 carbon atoms.

 The term "cycloalkynyl" used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms.

 The term "aryl" used alone or as suffix or prefix, refers to a monovalent hydrocarbon 25 radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms.

 The term "arylene" used alone or as suffix or prefix, refers to a divalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms, which serves to link 30 two structures together.

The term "heterocycle" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween. Heterocycle may have aromatic character or may not have aromatic character.

The term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-containing structure or molecule has an aromatic character (*e.g.*, $4n + 2$ delocalized electrons).

The term "heterocyclic group," "heterocyclic moiety," "heterocyclic," or "heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.

The term "heterocyclyl" used alone or as a suffix or prefix, refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom.

The term "heterocyclylene" used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together.

The term "six-membered" used as prefix refers to a group having a ring that contains six ring atoms.

The term "five-membered" used as prefix refers to a group having a ring that contains five ring atoms.

A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-

thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.

A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

The term "heteroaryl" used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character.

The term "heterocycloalkyl" used alone or as a suffix or prefix, refers to a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaturation. Examples of heterocycloalkyl groups include pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranyl. A heterocycloalkyl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 3 to 6 carbon atoms and form 1 to 3 heteroatoms, referred to herein as C₃₋₆heterocycloalkyl.

Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1*H*-azepine homopiperazine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide.

In addition, heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole, and 1,3,4-oxadiazole.

Additionally, heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, thioxanthine, carbazole, carboline, acridine, pyrrolizidine, and quinolizidine.

In addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.

Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiranyl, azetidiny, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-1*H*-azepinyl, homopiperazinyl, 1,3-dioxepanyl, 4,7-dihydro-1,3-dioxepinyl, and hexamethylene oxidyl.

In addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.

Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl,

chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indoliziny, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl.

In addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.

The term "alkoxy" used alone or as a suffix or prefix, refers to radicals of the general formula -O-R, wherein R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.

The term "amine" or "amino" refers to -NH₂.

Halogen includes fluorine, chlorine, bromine and iodine.

"Halogenated," used as a prefix of a group, means one or more hydrogens on the group are replaced with one or more halogens.


"RT", "r.t." or "rt" means room temperature.

"DMF" refers to dimethyl formamide.

"DIPEA" refers to N,N-diisopropylethylamine.

"HATU" refers to 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate.

One aspect of the invention is a compound of formula I, a pharmaceutically acceptable salt thereof, a diastereomer, an enantiomer, or a mixture thereof:



wherein:

R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{1-10} alkoxy, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl-
 5 $C(=O)$ - C_{1-6} alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6}
 alkyl, C_{3-6} heterocyclyl- $C(=O)$ - C_{1-6} alkyl, C_{6-10} aryl, C_{6-10} aryl- $C(=O)$ -, C_{3-10} cycloalkyl, C_{4-8}
 cycloalkenyl, C_{3-6} heterocyclyl and C_{3-6} heterocyclyl- $C(=O)$ -; wherein said C_{1-10} alkyl, C_{2-10}
 alkenyl, C_{1-10} alkoxy, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)$ - C_{1-6} alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl,
 C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)$ - C_{1-6} alkyl, C_{6-10}
 10 aryl, C_{6-10} aryl- $C(=O)$ -, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, C_{3-6} heterocyclyl or C_{3-6} heterocyclyl-
 $C(=O)$ - is optionally substituted by one or more groups selected from carboxy, $-(C=O)-NH_2$,
 halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, $-N(R^6)-C(=O)R^5$, $-S(=O)_2-$
 NR^5R^6 , $-C(=O)-NR^5R^6$, $-NH-C(=O)-NR^5R^6$ and $-NR^5R^6$;

R^2 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-8}
 15 cycloalkyl, C_{3-8} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocycloalkyl- C_{1-6}
 alkyl, C_{4-8} cycloalkenyl and C_{3-6} heterocycloalkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl,
 C_{2-10} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl,
 C_{3-6} heterocycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl or C_{3-6} heterocycloalkyl used in defining R^2 is
 optionally substituted by one or more groups selected from carboxy, $-(C=O)-NH_2$, halogen,
 20 cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$;

R^3 and R^4 are independently selected from $-H$, $-OH$, amino, R^7 and $-O-R^7$, wherein R^7
 is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6}
 cycloalkyl- C_{1-4} alkyl, phenyl and benzyl, wherein R^3 and R^4 are not $-H$ at the same time, and
 wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl,
 25 phenyl or benzyl in defining R^7 is optionally substituted by one or more groups selected from
 carboxy, halogen, cyano, nitro, methoxy, ethoxy, hydroxy, and $-NR^5R^6$; or R^3 and R^4 together
 with the nitrogen connected thereto form a 5- or 6-membered heterocycle ring, wherein said

ring is optionally substituted by one or more groups selected from carboxy, halogen, cyano, nitro, methoxy, ethoxy, hydroxy, $-(CH_2)_m-C(=O)NR^5R^6$, $-(CH_2)_mNH-C(=O)NR^5R^6$, $-(CH_2)_m-N(R^5)C(=O)R^6$, $-(CH_2)_m-N(R^5)C(=O)-OR^6$, $-(CH_2)_m-C(=O)-OR^6$, $-(CH_2)_m-O-C(=O)-R^6$, $-(CH_2)_m-OR^6$, and $-NR^5R^6$; and

wherein R^5 and R^6 are independently selected from $-H$, C_{1-6} alkyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, C_{3-6} cycloalkyl- C_{0-m} alkyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, C_{2-6} alkenyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, and a divalent C_{1-6} alkylene optionally substituted with $-OH$, methoxy, ethoxy or halogen that together with another divalent R^5 or R^6 form a portion of a ring; and

m is 0, 1, 2 or 3.

In a particular embodiment, R^1 is selected from C_{3-7} cycloalkyl- C_{1-2} alkyl and C_{2-6} heterocycloalkyl- C_{1-2} alkyl, wherein said C_{3-7} cycloalkyl or C_{2-6} heterocycloalkyl is optionally substituted with one or more groups selected from carboxy, $-C(=O)-NH_2$, halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and amino.

In another particular embodiment, R^1 is selected from cyclohexylmethyl and tetrahydropyranylmethyl wherein said cyclohexylmethyl or tetrahydropyranylmethyl is optionally substituted with one or more groups selected from carboxy, $-C(=O)-NH_2$, halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and amino.

In a further embodiment, R^1 is selected from cyclohexylmethyl and tetrahydropyranylmethyl wherein said cyclohexylmethyl or tetrahydropyranylmethyl is optionally substituted with one or more groups selected from methyl, hydroxy, chloro, fluoro and bromo.

In an even further embodiment, R^1 is selected from cyclohexylmethyl and tetrahydropyran-4-ylmethyl wherein said cyclohexylmethyl or tetrahydropyran-4-ylmethyl is optionally substituted with one or more groups selected from chloro and fluoro.

In a yet further embodiment, R^1 is selected from cyclohexylmethyl, (4,4-difluorocyclohexyl)methyl, (4-fluorocyclohexyl)methyl and tetrahydro-2H-pyran-4-ylmethyl.

In another particular embodiment, R^2 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-2} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, or

C₃₋₆cycloalkyl-C₁₋₂alkyl is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, and hydroxy.



In a further embodiment, R² is selected from ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1,1-dimethyl-1-propyl, 3-methyl-1-butyl, and 2,2 dimethyl-1-propyl, wherein said propyl, isopropyl, n-butyl, isobutyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1,1-dimethyl-1-propyl, 3-methyl-1-butyl, or 2,2 dimethyl-1-propyl is optionally substituted by one or more groups selected from halogen, methoxy and ethoxy.

In an even further embodiment, R² is selected from 1,1-difluoroethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1,1-dimethyl-1-propyl, 3-methyl-1-butyl, and 2,2 dimethyl-1-propyl.

In an even further embodiment, R² is selected from t-butyl, 1,1-difluoroethyl and 1,1-dimethyl-1-propyl.


In another particular embodiment, R³ and R⁴ together with the nitrogen connected thereto form a 5- or 6-membered heterocycle ring, wherein said ring is optionally substituted by one or more groups selected from carboxy, halogen, cyano, nitro, methoxy, ethoxy, hydroxy, carboxy, -(CH₂)_m-C(=O)NR⁵R⁶ and -NR⁵R⁶, wherein R⁵ and R⁶ are independently selected from -H, C₁₋₆alkyl optionally substituted with -OH, methoxy, ethoxy or halogen, C₃₋₆cycloalkyl-C_{0-m}alkyl optionally substituted with -OH, methoxy, ethoxy or halogen, C₂₋₆alkenyl optionally substituted with -OH, methoxy, ethoxy or halogen, and a divalent C₁₋₆alkylene optionally substituted with -OH, methoxy, ethoxy or halogen that together with another divalent R⁵, R⁶ or R⁷ form a portion of a ring; and


m is 0, 1, 2 or 3.



In a further embodiment, of formula I is represented by

wherein R⁸ is selected from hydrogen, C₁₋₄alkyl, halogenated C₁₋₄alkyl, hydroxy-C₁₋₄alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₂alkyl, methoxy-C₁₋₄alkyl, ethoxy-C₁₋₄alkyl, and C₂₋₄alkenyl; R⁹ is selected from hydrogen, hydroxy, halogen, isocyanato, methoxy, ethoxy, C₁₋₄alkyl, halogenated C₁₋₄alkyl, phenyl, benzyl, amino, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₂alkyl, and C₁₋₄alkoxymethyl; X is selected from -O-C(=O)-, -C(=O)-NH-, -NH-C(=O)-, -C(=O)-NHCH₂-, -

NH-C(=O)CH₂-, -NH-C(=O)-NH-, -O-C(=O)-NH-, -C(=O)-O-, and -NH-C(=O)-O-;  is a 5 or 6-membered heterocycle which optionally contains one additional heteroatom selected

from O and N on its ring in addition to the nitrogen shown. Particularly,  is selected from piperidinyl, isoxazolindinyl, azetidiny, morpholinyl, pyrazolyl, pyrrolyl and pyrrolidinyl.

5 In a further embodiment, R³ and R⁴ together with the nitrogen connected thereto form a 5- or 6-membered heterocycle ring selected from piperidinyl, isoxazolindinyl, azetidiny, morpholinyl, pyrazolyl, pyrrolyl and pyrrolidinyl, wherein said piperidinyl, isoxazolindinyl, azetidiny, morpholinyl, pyrazolyl, pyrrolyl or pyrrolidinyl is optionally substituted by one or more groups selected from methyl, cyclopropyl, amino, cyclobutanylcabonylamino, hydrocarbonyl, 2-hydroxyethylaminocarbonyl, isopropylaminocarbonyl, 10 cyclobutanylcabonylamino, ethylaminocarbonyl, cyclopropylaminocarbonyl, methoxycarbonyl, ethoxycarbonyl, hydroxycarbonyl, t-butoxycarbonyl, t-butoxycarbonylamino, allylaminocarbonyl, methylaminocarbonyl, fluoro, aminocarbonyl, 2-fluoroethylaminocarbonyl, propylaminocarbonyl, cyclopropylmethylaminocarbonyl, cyclobutylmethylaminocarbonyl, phenyl, trifluoromethyl, methoxy, ethyl, methoxymethyl, benzyl, t-butoxycarbonylamino, ethylaminocarbonylamino, isocyanato, cyclopropylaminocarbonylamino, 2-hydroxyethylaminocarbonylamino, hydroxy, ethylaminocarboxy, acetylaminocarbonyl, propionylaminocarbonyl, ethylaminocarbonylmethyl, 2-fluoroethylaminocarbonylmethyl, 2,2-difluoroethylaminocarbonyl, 2,2- 15 difluoroethylaminocarbonylmethyl, acetylaminomethyl, cyclopropylcarbonylaminomethyl, propionylaminomethyl, and methylaminocarbonylmethyl.

In another embodiment, R³ and R⁴ are independently selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl, benzyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₂₋₆alkenyl and C₁₋₆alkoxy.

25 It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by

chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.

It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes
5 any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the formula I.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the formula I.

10 Within the scope of the invention are also salts of the compounds of the formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion. It may also be possible to make a
15 corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by
20 conventional purification techniques.

In one embodiment, the compound of formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or *p*-toluenesulphonate.

25 We have now found that the compounds of the invention have activity as pharmaceuticals, in particular as modulators or ligands such as agonists, partial agonists, inverse agonist or antagonists of CB₁ receptors. More particularly, the compounds of the invention exhibit activity as agonist of the CB₁ receptors and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer
30 pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however

not be interpreted as exhaustive. Additionally, compounds of the present invention are useful in other disease states in which dysfunction of CB₁ receptors is present or implicated.

Furthermore, the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders,
5 gastrointestinal disorders and cardiovascular disorders.

Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

10 Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labeled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).

Compounds of the invention are useful for the treatment of diarrhea, depression, anxiety
15 and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung edema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic
20 brain injury, stroke, cardioprotection following myocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties
25 are often used to achieve a balance of effects needed to maintain the anesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.

Another aspect of the present invention is the use of a compound according to Formula I, for the inhibition of transient lower esophageal sphincter relaxations (TLESRs) and thus for
30 treatment or prevention of gastroesophageal reflux disorder (GERD). The major mechanism

behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, e.g. *Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, pp. 517-535*, has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESRs), i.e. relaxations not triggered by swallows. In yet further embodiments of the present invention, the compound according to Formula I are useful for the prevention of reflux, treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.

A further aspect of the present invention is the use of a compound according to Formula I, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations, for the treatment or prevention of GERD, for the prevention of reflux, for the treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.

Still another aspect of the present invention is the use of a compound according to Formula I for the manufacture of a medicament for the treatment or prevention of functional gastrointestinal disorders, such as functional dyspepsia (FD). Yet another aspect of the present invention is the use of a compound according to Formula I for the manufacture of a medicament for the treatment or prevention of irritable bowel syndrome (IBS), such as constipation predominant IBS, diarrhea predominant IBS or alternating bowel movement predominant IBS. Exemplary irritable bowel syndrome (IBS) and functional gastrointestinal disorders (FGD), such as functional dyspepsia (FD), are illustrated in *Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Mueller-Lissner SA. C. Functional Bowel Disorders and Functional Abdominal Pain. In: Drossman DA, Talley NJ, Thompson WG, Whitehead WE, Corazziari E, eds. Rome II: Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment. 2 ed. McLean, VA: Degnon Associates, Inc.; 2000:351-432 and Drossman DA, Corazziari E, Talley NJ, Thompson WG and Whitehead WE. Rome II: A multinational consensus document on Functional Gastrointestinal Disorders. Gut 45(Suppl.2), III-II81.9-1-1999.*

Also within the scope of the present invention is the use of any of the compounds according to the Formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.

Thus, the invention provides a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

In a further aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be construed accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.

The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

In one embodiment of the invention, the route of administration may be oral, intravenous or intramuscular.

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician,

when determining the individual regimen and dosage level at the most appropriate for a particular patient.

For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations
5 include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

A solid carrier can be one or more substance, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet-disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely
10 divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by,
15 for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.

Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

20 The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.

Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for
25 oral administration.

Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic
5 gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (percent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total
10 composition.

A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.

15 Within the scope of the invention is the use of any compound of formula I as defined above for the manufacture of a medicament.

Also within the scope of the invention is the use of any compound of formula I for the manufacture of a medicament for the therapy of pain.

Additionally provided is the use of any compound according to Formula I for the
20 manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such therapy.

25 Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically
30 acceptable carrier for therapy, more particularly for therapy of pain.

Further, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.

In a further embodiment, a compound of formula I or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of formula I may be administered concurrently, simultaneously, sequentially or separately with one or more pharmaceutically active compound(s) selected from the following:

(i) antidepressants such as amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, elzasonan, escitalopram, fluvoxamine, fluoxetine, gepirone, imipramine, ipsapirone, maprotiline, nortriptyline, nefazodone, paroxetine, phenelzine, protriptyline, reboxetine, robalzotan, sertraline, sibutramine, thionisoxetine, transylcypromaine, trazodone, trimipramine, venlafaxine and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(ii) atypical antipsychotics including for example quetiapine and pharmaceutically active isomer(s) and metabolite(s) thereof; amisulpride, aripiprazole, asenapine, benxisoxidil, bifeprunox, carbamazepine, clozapine, chlorpromazine, debenzapine, divalproex, duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine, lithium, loxapine, mesoridazine, olanzapine, paliperidone, perlapine, perphenazine, phenothiazine, phenylbutylpiperidine, pimozide, prochlorperazine, risperidone, quetiapine, sertindole, sulpiride, suproclonine, suriclone, thioridazine, trifluoperazine, trimetozine, valproate, valproic acid, zopiclone, zotepine, ziprasidone and equivalents thereof;

(iii) antipsychotics including for example amisulpride, aripiprazole, asenapine, benxisoxidil, bifeprunox, carbamazepine, clozapine, chlorpromazine, debenzapine, divalproex, duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine, loxapine, mesoridazine, olanzapine, paliperidone, perlapine, perphenazine, phenothiazine, phenylbutylpiperidine, pimozide, prochlorperazine, risperidone, sertindole, sulpiride, suproclonine, suriclone, thioridazine, trifluoperazine, trimetozine, valproate, valproic acid, zopiclone, zotepine, ziprasidone and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(iv) anxiolytics including for example alnespirone, azapirone, benzodiazepines, barbiturates such as adinazolam, alprazolam, balezepam, bentazepam, bromazepam, brotizolam, buspirone, clonazepam, clorazepate, chlordiazepoxide, cyprazepam, diazepam, diphenhydramine, estazolam, fenobam, flunitrazepam, flurazepam, fosazepam, lorazepam, lormetazepam, meprobamate, midazolam, nitrazepam, oxazepam, prazepam, quazepam, 5 reclazepam, tracazolate, trepipam, temazepam, triazolam, uldazepam, zolazepam and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(v) anticonvulsants including, for example, carbamazepine, valproate, lamotrigine, gabapentin and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

10 (vi) Alzheimer's therapies including, for example, donepezil, memantine, tacrine and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(vii) Parkinson's therapies including, for example, deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine 15 agonists and inhibitors of neuronal nitric oxide synthase and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(viii) migraine therapies including, for example, almotriptan, amantadine, bromocriptine, butalbital, cabergoline, dichloralphenazone, eletriptan, frovatriptan, lisuride, naratriptan, pergolide, pramipexole, rizatriptan, ropinirole, sumatriptan, zolmitriptan, 20 zomitriptan, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(ix) stroke therapies including, for example, abciximab, activase, NXY-059, citicoline, crobenetine, desmoteplase, repinotan, traxoprodil and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(x) over active bladder urinary incontinence therapies including, for example, 25 darafenacin, falvoxate, oxybutynin, propiverine, robalzotan, solifenacin, tolterodine and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(xi) neuropathic pain therapies including, for example, gabapentin, lidoderm, pregablin and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;

(xii) nociceptive pain therapies such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, valdecoxib, diclofenac, loxoprofen, naproxen, paracetamol and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;


(xiii) insomnia therapies including, for example, allobarbitol, alonimid, amobarbital, benzoctamine, butabarbital, capuride, chloral, cloperidone, clorethate, dexclamol, ethchlorvynol, etomidate, glutethimide, halazepam, hydroxyzine, mecloqualone, melatonin, mephobarbital, methaqualone, midaflur, nisobamate, pentobarbital, phenobarbital, propofol, roletamide, triclofos, secobarbital, zaleplon, zolpidem and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof; and

(xiv) mood stabilizers including, for example, carbamazepine, divalproex, gabapentin, lamotrigine, lithium, olanzapine, quetiapine, valproate, valproic acid, verapamil, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

Such combinations employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active compound or compounds within approved dosage ranges and/or the dosage described in the publication reference.


Another aspect of the invention is a method of preparing the compounds of the present invention.

In one embodiment, the method of the invention is a method for preparing a compound of formula I,



I

comprising the step of reacting a compound of formula II,




II

with a compound of R^3R^4NH , optionally in the presence of a base, such as NaH or DMAP, a solvent such as THF or MeCN, wherein Y is selected from Cl, Br, F, methoxy and OH; and R^1 , R^2 , R^3 and R^4 are defined as above.


Compounds of the present invention may be prepared according to the synthetic
5 routes as depicted in Schemes 1-5.

Scheme 1




R^1 , R^2 , R^3 , and R^4 are as defined in the specifications.

Scheme 2




R¹, R², R⁸, and R⁹ are as defined in the specifications.
Z is C or N

Scheme 3



R^1 , R^2 , and R^8 are independently as defined above.
 Z is C or N; n is 1 or 2.

Scheme 4



X, R¹, R², R⁸, and R⁹ are as defined above.

Biological Evaluation

hCB₁ and hCB₂ receptor binding

Human CB₁ receptor from Receptor Biology (hCB₁) or human CB₂ receptor
5 from BioSignal (hCB₂) membranes are thawed at 37 °C, passed 3 times through a 25-
gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5
mM EDTA, 5 mM MgCl₂, and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots
containing the appropriate amount of protein are distributed into 96-well plates. The
IC₅₀ of the compounds of the invention at hCB₁ and hCB₂ are evaluated from 10-point
10 dose-response curves done with ³H-CP55,940 at 20000 to 25000 dpm per well (0.17-
0.21 nM) in a final volume of 300 µl. The total and non-specific binding are
determined in the absence and presence of 0.2 µM of HU210 respectively. The plates
are vortexed and incubated for 60 minutes at room temperature, filtered through
Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or

Packard harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl₂, 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 °C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 µl/well of MS-20 scintillation liquid.

hCB₁ and hCB₂ GTPγS binding

5 Human CB₁ receptor from Receptor Biology (hCB₁) or human CB₂ receptor membranes (BioSignal) are thawed at 37 °C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTPγS binding buffer (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl₂, pH 7.4, 0.1% BSA). The EC₅₀ and E_{max} of the compounds of the invention are evaluated from 10-point dose-response curves done in 300µl with the appropriate
10 amount of membrane protein and 100000-130000 dpm of GTPg³⁵S per well (0.11 – 0.14 nM). The basal and maximal stimulated binding is determined in absence and presence of 1 µM (hCB₂) or 10 µM (hCB₁) Win 55,212-2 respectively. The membranes are pre-incubated for 5 minutes with 56.25 µM (hCB₂) or 112.5 µM (hCB₁) GDP prior to distribution in plates (15 µM (hCB₂) or 30 µM (hCB₁) GDP final). The plates are vortexed and incubated for 60 minutes at
15 room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl₂, 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 °C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 µl/well of MS-20 scintillation liquid. Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of
20 a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist.

Based on the above assays, the dissociation constant (K_i) for a particular compound of the invention towards a particular receptor is determined using the following equation:

$$K_i = IC_{50} / (1 + [rad] / K_d),$$

25 Wherein IC₅₀ is the concentration of the compound of the invention at which 50% displacement has been observed;

[rad] is a standard or reference radioactive ligand concentration at that moment; and

K_d is the dissociation constant of the radioactive ligand towards the particular receptor.

Using the above-mentioned assays, the K_i towards human CB₁ receptors for certain
30 exemplified compounds of the invention is measured to be in the range of 0.88 - 8710 nM.

The EC₅₀ towards human CB₁ receptors for certain exemplified compounds of the invention is measured to be in the range of about 0.58-1768 nM. The E_{max} towards human CB₁ receptors for certain exemplified compounds of the invention is measured to be in the range of about 106-149 %.

The following table shows certain biological activities for some of the exemplified compounds.

Name	hCB1 KI (nM)	hCB1 EC50 (nM)	hCB1 Emax (%)	Solubility (μ M)
1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-cyclopropyl-1H-pyrazole-4-carboxamide	0.88	0.58	121.91	6.16
1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-methyl-1H-pyrazole-4-carboxamide	1.61	1.21	118.38	2.52
1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-isopropyl-1H-pyrazole-4-carboxamide	1.82	3.41	125.04	0.26
(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-propylpiperidine-3-carboxamide	2.03	1.69	133.75	16.78
(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-cyclopropylpiperidine-3-carboxamide	2.05	1.71	135.85	29.42

1- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropyl-1H-pyrrole-3-carboxamide	5.68	10.49	141.84	5.64
4-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-cyclopropylmorpholine-2-carboxamide	11.35	10.44	119.59	42.45
1- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-ethyl-1H-pyrazole-4-carboxamide	14.57	57.18	127.40	337.31
(2S)-4-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-ethylmorpholine-2-carboxamide	18.04	43.77	155.57	43.36
N-Cyclopropyl-1- {[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide	19.06	17.76	118.77	6.20
1- {[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-ethyl-1H-pyrrole-3-carboxamide	24.16	84.25	138.14	27.99
1- {[2-(1,1-Difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-ethyl-1H-pyrrole-3-carboxamide	87.99	N/A	N/A	7.45
2-tert-Butyl-5-[(3-phenylpyrrolidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole	110.09	N/A	N/A	7.29


1-{[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrazol-3-amine	252.02	N/A	N/A	43.03
2-tert-Butyl-5-[(3-phenylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole	277.95	N/A	N/A	0.79
1-{[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-methylpyrrolidine-3-carboxamide	833.36	N/A	N/A	2600.00
2-tert-Butyl-5-(morpholin-4-ylsulfonyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole	1531.76	N/A	N/A	128.35

EXAMPLES


The invention will further be described in more detail by the following Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.

Example 1

2-tert-Butyl-N,N-diethyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonamide




Step A: 2-tert-butyl-N,N-diethyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonamide




2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (61.2 mg, 0.165 mmol) (see following Steps B, C, D, E, F, G and H for preparation), was added to a solution of diethylamine (0.2 mL, 1.93 mmol) and DMAP (50 mg, 0.41 mmol) in MeCN (5 mL). The reaction mixture was stirred overnight at room temperature, diluted with EtOAc (60 mL), washed with NH₄Cl (2x5 mL), NaCl (2x5 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 20.5 mg (30%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.13 (t, J=7.13 Hz, 6 H), 1.46 - 1.63 (m, 4 H), 1.66 (s, 9 H), 2.25 - 2.48 (m, 1 H), 3.22 - 3.29 (m, 4 H), 3.31 - 3.41 (m, 2 H), 3.94 (m, 2 H), 4.50 (d, J=7.42 Hz, 2 H), 7.89 (dd, J=8.79, 1.76 Hz, 1 H), 7.96 - 8.04 (m, 1 H), 8.14 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺=408.0; Anal. Calcd for C₂₁H₃₃N₃O₃S+1.00 TFA+ 0.1 H₂O+0.30 EtOAc(549.84): C, 52.86; H, 6.71; N, 7.64 Found: C, 52.91; H, 6.52; N, 7.61.

Step B: *N*-(4-Fluoro-3-nitrophenyl)acetamide



4-Fluoro-3-nitro-aniline (54.2 g, 0.347 mol) was added in portions to acetic anhydride (200 mL) at room temperature. The reaction mixture was stirred overnight at room temperature. The brown solid was collected and dried *in vacuo* to give the title compound. Yield: 67.5 g (98%). ¹H NMR (400 MHz, CHLOROFORM-D) δ 2.04 (s, 3 H), 7.51 (dd, J=11.23, 9.08 Hz, 1 H), 7.80 (ddd, J=9.08, 4.00, 2.93 Hz, 1 H), 8.47 (dd, J=7.03, 2.73 Hz, 1 H), 10.38 (s, 1 H).


Step C: *N*-{3-Nitro-4-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}acetamide



4-Aminomethyl tetrahydropyran (13.7 g, 0.119 mol) was added to a solution of *N*-(4-Fluoro-3-nitrophenyl)acetamide (20.2 g, 0.102 mol) and TEA (20.9 mL, 15.2 g, 0.15 mol) in EtOH (350 mL). The reaction mixture was stirred overnight at reflux. The orange-red solid was collected by filtration, washed with water and dried *in vacuo*. The filtrate was concentrated. The residue was dissolved in EtOAc, washed with H₂O, brine and dried over anhydrous Na₂SO₄. The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Total yield:

28.9 g (97%). ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.4 (m, 2 H), 1.7 (m, 2 H), 1.89 – 2.00 (m, 1H), 2.18 (s, 3 H), 3.22 (dd, J=6.44, 5.66 Hz, 2 H), 3.42 (dt, J=11.86, 2.05 Hz, 2 H), 4.02 (dd, J=10.94, 3.71 Hz, 2 H), 6.84 (d, J=9.37 Hz, 1 H), 7.20 (br.s, 1 H), 7.81 (dd, J=9.37, 2.54 Hz, 1 H), 8.09 (d, J=2.54 Hz, 1 H), 8.10 – 8.12 (m, 1 H).


Step D: *N*-{3-Amino-4-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}acetamide



N-{3-Nitro-4-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}acetamide (28.9 g, 98.5 mmol) was dissolved in 1.0 L of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under H₂ atmosphere (40 psi) using a Parr hydrogenation apparatus overnight at room temperature. The solution was filtered through celite and the solvent was evaporated. Yield:


25.9 g (99%). ^1H NMR (400 MHz; CHLOROFORM-D) δ 1.4 (m, 2 H), 1.7 (m, 2 H), 1.82 – 1.91 (m, 1H), 2.13 (s, 3 H), 2.99 (d, $J=6.64$, 2 H), 3.42 (dt, $J=11.86$, 2.05 Hz, 2 H), 4.02 (dd, $J=10.94$, 3.71 Hz, 2 H), 6.84 (d, $J=9.37$ Hz, 1 H), 7.20 (br.s, 1 H), 7.81 (dd, $J=9.37$, 2.54 Hz, 1 H), 8.09 (d, $J=2.54$ Hz, 1 H), 8.10 – 8.12 (m, 1 H).

Step E: *N*-{5-(acetylamino)-2-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}-2,2-dimethylpropanamide




N-{3-Amino-4-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}acetamide (25.9 g, 98.6 mmol) and DIPEA (20.6 mL, 15.4 g, 118 mmol) were dissolved in 500 mL of DCM. Trimethylacetyl chloride (12.7 mL, 12.5g, 103 mmol) was added dropwise at 0 °C and the solution was stirred for 3 h at 0 °C and 1h at room temperature. The pink solid was collected by filtration, washed with H_2O and dried *in vacuo*. Yield: 33.1 g (97%); MS (ESI) $(\text{M}+\text{H})^+ =$ 348.05.

Step F: *N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]acetamide




N-{5-(acetylamino)-2-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}-2,2-dimethylpropanamide (33.1 g, 95.3 mmol) was dissolved in AcOH (250 mL). The solution was heated at 120°C for 8h. Upon evaporation of the solvent, the residue was dissolved in EtOAc (500 mL), washed with 2*N* NaOH (3x50 mL), brine (50 mL) and dried over anhydrous Na₂SO₄. The crude product was recrystallized from EtOAc. Yield: 29.0 g (92%). ¹H NMR (400 MHz, CHLOROFORM-D): δ 1.48 – 1.54 (m, 4 H), 1.56 (s, 9 H), 2.20 (s, 3 H), 2.24 – 2.35 (m, 1 H), 3.28 – 3.35 (m, 2 H), 3.96 (t, *J*= 2.83 Hz, 1 H), 3.99 (t, *J*= 3.03 Hz, 1 H), 4.19 (d, *J*=7.42 Hz, 2 H), 7.27 (d, *J*=8.59 Hz, 1 H), 7.34 (br.s, 1 H), 7.57 (dd, *J*=8.79, 1.95 Hz, 1 H), 7.67 (d, *J*=1.95 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 330.04.

Step G: 2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-amine



N-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]acetamide (20.7 g, 62.8 mmol) was dissolved in 37% HCl (120 mL). The solution was heated at 95°C for 20 h. After concentration, 20.4 g (100%) of a purple solid was obtained. ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.47 – 1.52 (m, 4 H), 1.54 (s, 9 H), 2.23 – 2.31 (m, 1 H), 3.28 – 3.36 (m, 2 H), 3.96 (t, *J*= 3.12 Hz, 1 H), 3.97 – 4.00 (m, 1 H), 4.13 (d, *J*=7.62 Hz, 2 H), 6.66 (dd, *J*=8.40, 2.15 Hz, 1 H), 7.06 (d, *J*=2.15 Hz, 1 H), 7.10 (d, *J*=8.40 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 288.0.


Step H: 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride



2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-amine hydrochloride (10.2 g, 31.4 mmol) was dissolved in concentrated hydrochloric acid (100 mL) and acetic acid (25 mL). A solution of NaNO₂ (2.6 g, 37.7 mmol) in H₂O (5 mL) was added dropwise. The temperature was kept below -2 °C. After stirring for 30 min at -2 °C, the diazonium solution was poured into a saturated solution of SO₂ in AcOH (100 mL) at 0 °C. A solution of CuCl₂ (2.5 g, 18.8 mmol) in H₂O (5 mL) was added. The resulting mixture was stirred for 2 h at 0 °C and 4 h at room temperature, diluted with ice-H₂O (100 mL), and extracted with CH₂Cl₂ (8x200 mL). The combined organic phases were dried over MgSO₄. After concentration, 10.9 g (93%) of a yellow solid was obtained. ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.46 - 1.58 (m, 4 H), 1.59 (s, 9 H), 2.17 - 2.49 (m, 1 H), 3.22 - 3.43 (m, 2 H), 3.93 - 4.07 (m, 2 H), 4.27 (d, *J*=7.42 Hz, 2 H), 7.50 (d, *J*=8.79 Hz, 1 H), 7.92 (dd, *J*=8.69, 1.86 Hz, 1 H), 8.46 (d, *J*=1.76 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 370.92.

Example 2

2-*tert*-Butyl-5-(piperidin-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole




Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (61 mg, 0.17 mmol), piperidine (0.2

mL, 2.0 mmol) and DMAP (50 mg, 0.41 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 31 mg (45%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.40 (m, 2 H), 1.47 - 1.64 (m, 8 H), 1.65 (s, 9 H), 2.25 - 2.48 (m, 1 H), 2.92 - 3.05 (m, 4 H), 3.29 - 3.39 (m, 2 H), 3.88 - 3.98 (m, 2 H), 4.50 (d, J=7.62 Hz, 2 H), 7.82 (dd, J=8.69, 1.66 Hz, 1 H), 8.01 (d, J=8.79 Hz, 1 H), 8.06 (d, J=1.56 Hz, 1 H); MS (ESI) (M+H)⁺ = 420.0; Anal. Calcd for C₂₂H₃₃N₃O₃S+1.10 TFA+0.50 H₂O+0.10 CH₃OH(557.23): C, 52.38; H, 6.42; N, 7.54; Found: C, 52.38; H, 6.43; N, 7.58.

Example 3


2-*tert*-Butyl-5-(isoxazolidin-2-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (61 mg, 0.17 mmol), isoxazolidine hydrochloride (44 mg, 0.40 mmol), DIPEA (0.2 mL, 149 mg, 1.15 mmol) and DMAP (50 mg, 0.41 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 24 mg (36%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.43 - 1.61 (m, 4 H), 1.63 (s, 9 H), 2.02 - 2.19 (m, 2 H), 2.25 - 2.42 (m, 1 H), 3.29 - 3.38 (m, 2 H), 3.64 - 3.73 (m, 2 H), 3.86 (t, J=7.13 Hz, 2 H), 3.88 - 3.96 (m, 2 H), 4.49 (d, J=7.42 Hz, 2 H), 7.98 (d, J=1.56 Hz, 1 H), 7.99 (s, 1 H), 8.24 (d, J=0.78 Hz, 1 H); MS (ESI) (M+H)⁺ = 408.0; Anal. Calcd for C₂₀H₂₉N₃O₄S+1.20 TFA+0.20 EtOAc(561.99): C, 49.58; H, 5.70; N, 7.48; Found: C, 49.74; H, 5.53; N, 7.46.

Example 4


2-*tert*-Butyl-5-[(4-methylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole



- 5 Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (72 mg, 0.19 mmol), 4-methylpiperidine (0.2 mL, 168 mg, 1.69 mmol) and DMAP (69 mg, 0.61 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 38 mg (45% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄)
- 10 δ 0.90 (d, *J*=5.86 Hz, 3 H), 1.16 - 1.34 (m, 3 H), 1.49 - 1.64 (m, 4 H), 1.67 (s, 9 H), 1.67 - 1.73 (m, 2 H), 2.23 - 2.32 (m, 2 H), 2.33 - 2.44 (m, 1 H), 3.31 - 3.40 (m, 2 H), 3.73 - 3.82 (m, 2 H), 3.91 - 3.98 (m, 2 H), 4.52 (d, *J*=7.42 Hz, 2 H), 7.84 (dd, *J*=8.79, 1.76 Hz, 1 H), 8.03 (d, *J*=8.20 Hz, 1 H), 8.08 (d, *J*=1.17 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 434.0; Anal. Calcd for C₂₃H₃₅N₃O₃S+1.10 TFA+0.40 CH₃OH (571.86): C, 53.77; H, 6.65; N, 7.35; Found: C, 53.76;
- 15 H, 6.69; N, 7.33.

Example 5


5-(Azetidin-1-ylsulfonyl)-2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole




Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (76 mg, 0.20 mmol), azetidine (34 uL, 26 mg, 0.50 mmol) and DMAP (82 mg, 0.67 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 37 mg (46% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.52 - 1.65 (m, 4 H), 1.68 (s, 9 H), 1.99 - 2.13 (m, 2 H), 2.32 - 2.47 (m, 1 H), 3.32 - 3.43 (m, 2 H), 3.74 - 3.84 (m, 4 H), 3.90 - 4.01 (m, 2 H), 4.54 (d, J=7.42 Hz, 2 H), 7.92 (dd, J=8.79, 1.56 Hz, 1 H), 8.09 (d, J=8.79 Hz, 1 H), 8.15 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 392.0; Anal. Calcd for C₂₀H₂₉N₃O₃S+1.20 TFA +0.40 EtOAc+ 0.1 H₂O (556.60): C, 50.93; H, 5.94; N, 7.55; Found: C, 50.98; H, 5.68; N, 7.50.

Example 6


2-*tert*-Butyl-*N*-cyclobutyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (76 mg, 0.20 mmol), cyclobutylamine (43 uL, 36 mg, 0.50 mmol) and DMAP (82 mg, 0.67 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 35 mg (42% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.48 - 1.66 (m, 6 H), 1.68 (s, 9 H), 1.72 - 1.87 (m, 2 H), 1.95 - 2.08 (m, 2 H), 2.28 - 2.50 (m, 1 H), 3.31 - 3.41 (m, 2 H), 3.68 - 3.83 (m, 1 H), 3.90 - 3.99 (m, 2 H), 4.53 (d, J=7.62 Hz, 2 H), 7.96 (dd, J= 8.80, 1.6 Hz, 1 H), 8.04(d, J=9.0 Hz, 1 H), 8.19 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 406.0; Anal. Calcd for C₂₁H₃₁N₃O₃S+1.20 TFA +0.60 EtOAc+ 0.2 H₂O (598.86): C, 51.75; H, 6.29; N, 7.02; Found: C, 51.70; H, 6.25; N, 7.03.

Example 7**2-*tert*-Butyl-*N*-cyclopropyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide**


Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (76 mg, 0.20 mmol), cyclopropylamine (35 μ L, 29 mg, 0.50 mmol) and DMAP (82 mg, 0.67 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 34 mg (43% yield) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 0.45 - 0.51 (m, 2 H), 0.51 - 0.58 (m, 2 H), 1.49 - 1.65 (m, 4 H), 1.68 (s, 9 H), 2.10 - 2.22 (m, 1 H), 2.30 - 2.45 (m, 1 H), 3.31 - 3.41 (m, 2 H), 3.89 - 3.99 (m, 2 H), 4.54 (d, $J=7.62$ Hz, 2 H), 7.99 (dd, $J=8.8, 1.8$ Hz, 1 H), 8.07 (d, $J=8.8$ Hz, 1 H), 8.24 (d, $J=1.17$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 392.0$; Anal. Calcd for $\text{C}_{20}\text{H}_{29}\text{N}_3\text{O}_3\text{S}+1.30 \text{ TFA}+0.40 \text{ EtOAc}+0.5 \text{ H}_2\text{O}$ (584.02): C, 49.77; H, 5.95; N, 7.20; Found: C, 49.78; H, 5.86; N, 7.20.

Example 8**2-*tert*-Butyl-*N*-cyclohexyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide**


Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (76 mg, 0.20 mmol), cyclohexylamine (57 uL, 50 mg, 0.50 mmol) and DMAP (82 mg, 0.67 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 39 mg (44% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.09 - 1.23 (m, 6 H), 1.49 - 1.59 (m, 4 H), 1.58 - 1.66 (m, 4 H), 1.68 (s, 9 H), 2.31 - 2.46 (m, 1 H), 2.96 - 3.10 (m, 1 H), 3.31 - 3.40 (m, 2 H), 3.90 - 3.99 (m, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.99 (dd, J=8.7, 1.7 Hz, 1 H), 8.05 (d, J=8.8 Hz, 1 H), 8.21 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 434.0; Anal. Calcd for C₂₃H₃₅N₃O₃S+1.10 TFA+0.40 EtOAc+ 0.3 H₂O (599.69): C, 53.68; H, 6.71; N, 7.01; Found: C, 53.61; H, 6.74; N, 7.02.

Example 9

2-*tert*-Butyl-5-(morpholin-4-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (76 mg, 0.20 mmol), morpholine (44 uL, 44 mg, 0.50 mmol) and DMAP (82 mg, 0.67 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 43 mg (50% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.47 - 1.62 (m, 4 H), 1.65 (s, 9 H), 2.28 - 2.43 (m, 1 H), 2.92 - 3.04 (m, 4 H), 3.29 - 3.40 (m, 2 H), 3.64 - 3.74 (m, 4 H), 3.88 - 3.98 (m, 2 H), 4.51 (d, J=7.42 Hz, 2 H), 7.83 (dd, J=8.79, 1.76 Hz, 1 H), 8.03 (d, J=8.79 Hz, 1 H), 8.08 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 422.0; Anal. Calcd for C₂₁H₃₁N₃O₄S+0.90 TFA+0.20 EtOAc+ 0.80 H₂O (556.22): C, 50.96; H, 6.36; N, 7.55; Found: C, 50.94; H, 6.46; N, 7.51.

Example 10**2-*tert*-Butyl-*N*-phenyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide**


5

Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (76 mg, 0.20 mmol), aniline (46 μ L, 47 mg, 0.50 mmol) and DMAP (82 mg, 0.67 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 43 mg (50% yield) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.40 - 1.58 (m, 4 H), 1.61 (s, 9 H), 2.21 - 2.38 (m, 1 H), 3.29 - 3.35 (m, 2 H), 3.85 - 3.93 (m, 2 H), 4.45 (d, $J=7.62$ Hz, 2 H), 6.96 - 7.04 (m, 1 H), 7.04 - 7.11 (m, 2 H), 7.11 - 7.21 (m, 2 H), 7.84 - 7.89 (m, 1 H), 7.91 - 7.98 (m, 1 H), 8.06 (d, $J=1.17$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 428.0$; Anal. Calcd for $\text{C}_{23}\text{H}_{29}\text{N}_3\text{O}_3\text{S}+1.10 \text{ TFA}+0.30 \text{ EtOAc}+0.2 \text{ H}_2\text{O}$ (583.03): C, 54.39, H, 5.69; N, 7.21; Found: C, 54.43; H, 5.68; N, 7.22.

15

Example 11**2-*tert*-Butyl-5-(1*H*-pyrazol-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole**


20




Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (76 mg, 0.20 mmol), pyrazole (34 mg, 0.50 mmol) and DMAP (82 mg, 0.67 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 46 mg (56% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.36 - 1.54 (m, 4 H), 1.56 (s, 9 H), 2.15 - 2.41 (m, 1 H), 3.23 - 3.38 (m, 2 H), 3.88 (m, 2 H), 4.37 (d, J=7.62 Hz, 2 H), 6.47 (dd, J=2.73, 1.56 Hz, 1 H), 7.73 (d, J=1.37 Hz, 1 H), 7.77 - 7.85 (m, 1 H), 7.86 - 7.94 (m, 1 H), 8.26 (d, J=1.56 Hz, 1 H), 8.30 (d, J=2.73 Hz, 1 H); MS (ESI) (M+H)⁺ = 403.0; Anal. Calcd for C₂₀H₂₆N₄O₃S+0.50 TFA +0.20 EtOAc (477.15): C, 54.88; H, 5.94; N, 11.74; Found: C, 54.78; H, 5.83; N, 11.69.

Example 12


2-*tert*-Butyl-*N*-methyl-*N*-phenyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (132 mg, 0.36 mmol), *N*-methylaniline (0.1 mL, 99 mg, 0.92 mmol) and DMAP (120 mg, 0.98 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (4:1) on silica gel to give 59 mg (38% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.42 - 1.60 (m, 4 H), 1.63 (s, 9 H), 2.24 - 2.43 (m, 1 H), 3.19 (s, 3 H), 3.28 - 3.41 (m, 2 H), 3.92 (m, 2 H), 4.48 (d, J=7.42 Hz, 2 H), 7.03 - 7.12 (m, 2 H), 7.20 - 7.35 (m, 3 H), 7.60 (dd, J=8.79, 1.76 Hz, 1 H), 7.82 (d, J=1.17 Hz, 1 H), 7.94 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)⁺ = 442.0; Anal. Calcd for C₂₄H₃₁N₃O₃S+1.00 TFA +0.20 EtOAc+ 0.10 H₂O (575.04): C, 55.98; H, 5.92; N, 7.31; Found: C, 55.89; H, 5.87; N, 7.30.

Example 13**2-*tert*-Butyl-*N*-methyl-*N*-(3-methylbutyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide**


Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (82 mg, 0.22 mmol), methyl (3-methylbutyl)amine (45 mg, 0.44 mmol) and DMAP (54 mg, 0.44 mmol) in MeCN (4 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 57 mg (60% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.89 (d, J=6.64 Hz, 6 H), 1.39 (q, J=6.90 Hz, 2 H), 1.46 - 1.61 (m, 5 H), 1.64 (s, 9 H), 2.26 - 2.43 (m, 1 H), 2.70 (s, 3 H), 2.97 - 3.06 (m, 2 H), 3.29 - 3.38 (m, 2 H), 3.86 - 3.97 (m, 2 H), 4.48 (d, J=7.42 Hz, 2 H), 7.81 (dd, J=8.79, 1.76 Hz, 1 H), 7.96 (d, J=8.79 Hz, 1 H), 8.07 (d, J=1.37 Hz, 1 H); MS (ESI) (M+H)⁺ = 436.0; Anal. Calcd for C₂₃H₃₇N₃O₃S+0.70 TFA +0.30 EtOAc+ 0.5 H₂O (550.89): C, 55.82; H, 7.52; N, 7.63; Found: C, 55.90; H, 7.46; N, 7.63.

Example 14**2-*tert*-Butyl-*N*-isobutyl-*N*-methyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide**

Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (82 mg, 0.22 mmol), isobutyl(methyl)amine (38 mg, 0.44 mmol) and DMAP (54 mg, 0.44 mmol) in MeCN (4 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 54 mg (58% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.91 (d, J=6.64 Hz, 6 H), 1.46 - 1.61 (m, 4 H), 1.64 (s, 9 H), 1.82 - 1.95 (m, 1 H), 2.25 - 2.45 (m, 1 H), 2.69 (s, 3 H), 2.74 (d, J=7.42 Hz, 2 H), 3.29 - 3.40 (m, 2 H), 3.87 - 4.00 (m, 2 H), 4.49 (d, J=7.42 Hz, 2 H), 7.82 (dd, J=8.69, 1.66 Hz, 1 H), 7.98 (d, J=8.79 Hz, 1 H), 8.08 (d, J=1.56 Hz, 1 H); MS (ESI) (M+H)⁺ = 422.0; Anal. Calcd for C₂₂H₃₅N₃O₃S+0.90 TFA +0.20 EtOAc (541.85): C, 54.53, H, 6.98; N, 7.75; Found: C, 54.53; H, 6.99; N, 7.77.

Example 15


N,2-Di-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (82 mg, 0.22 mmol), *tert*-butylamine (32 mg, 0.44 mmol) and DMAP (54 mg, 0.44 mmol) in MeCN (4 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 40 mg (41% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.17 (s, 9 H), 1.49 - 1.64 (m, 4 H), 1.66 (s, 9 H), 2.29 - 2.44 (m, 1 H), 3.29 - 3.38 (m, 2 H), 3.87 - 3.97 (m, 2 H), 4.52 (d, J=7.62 Hz, 2 H), 7.97 - 8.05 (m, 2 H), 8.21 (dd, J=1.46, 0.68 Hz, 1 H); MS (ESI) (M+H)⁺ = 408.0; Anal. Calcd for C₂₁H₃₃N₃O₃S+1.200 TFA +0.20 EtOAc+ 0.1 H₂O (563.83): C, 51.55; H, 6.44; N, 7.45; Found: C, 51.59; H, 6.28; N, 7.41.

Example 16


2-*tert*-Butyl-*N*-cyclohexyl-*N*-methyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide



- 5 Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (82 mg, 0.22 mmol), cyclohexyl(methyl)amine (50 mg, 0.44 mmol) and DMAP (54 mg, 0.44 mmol) in MeCN (4 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 58 mg (59% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄)
- 10 δ 1.22 - 1.32 (m, 2 H), 1.33 - 1.44 (m, 4 H), 1.47 - 1.62 (m, 6 H), 1.65 (s, 9 H), 1.66 - 1.74 (m, 2 H), 2.27 - 2.44 (m, 1 H), 2.76 (s, 3 H), 3.29 - 3.38 (m, 2 H), 3.68 - 3.81 (m, 1 H), 3.87 - 3.97 (m, 2 H), 4.50 (d, *J*=7.42 Hz, 2 H), 7.89 (dd, *J*=8.79, 1.76 Hz, 1 H), 8.00 (d, *J*=8.79 Hz, 1 H), 8.12 (d, *J*=1.17 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 448.0; Anal. Calcd for C₂₄H₃₇N₃O₃S+1.00 TFA +0.30 EtOAc+ 0.2 H₂O (591.70): C, 55.21; H, 6.95; N, 7.10; Found: C, 55.22; H, 6.85; N,
- 15 7.08.

Example 17


2-*tert*-Butyl-*N*-methoxy-*N*-methyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide




Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (82 mg, 0.22 mmol), *N*,*O*-dimethylhydroxylamine hydrochloride (43 mg, 0.44 mmol) and DMAP (54 mg, 0.44 mmol) in MeCN (4 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 22 mg (25% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.41 - 1.55 (m, 4 H), 1.57 (s, 9 H), 2.26 - 2.40 (m, 1 H), 2.72 (s, 3 H), 3.30 - 3.37 (m, 2 H), 3.76 (s, 3 H), 3.86 - 3.95 (m, 2 H), 4.38 (d, *J*=7.42 Hz, 2 H), 7.73 (dd, *J*=8.6, 1.6 Hz, 1 H), 7.78 (d, *J*=8.2 Hz, 1 H), 8.10 (d, *J*=0.98 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 396.0; Anal. Calcd for C₁₉H₂₉N₃O₄S+0.30 EtOAc (421.96): C, 57.50; H, 7.50; N, 9.96; Found: C, 57.88; H, 7.48; N, 9.95

Example 18


2-*tert*-Butyl-5-[(3-cyclopropyl-1*H*-pyrazol-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (93 mg, 0.25 mmol), 3-cyclopropyl-1*H*-pyrazole (54 mg, 0.50 mmol) and DMAP (92 mg, 0.75 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 30 mg (27% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.62 - 0.75 (m, 2 H), 0.87 - 0.99 (m, 2 H), 1.43 - 1.59 (m, 4 H), 1.61 (s, 9 H), 1.81 - 1.96 (m, 1 H), 2.24 - 2.42 (m, 1 H), 3.31 - 3.39 (m, 2 H), 3.91 (m, 2 H), 4.43 (d, *J*=7.42 Hz, 2 H), 6.18 (d, *J*=2.73 Hz, 1 H), 7.91 (d, *J*=8.8 Hz, 1 H), 7.95 (dd, *J*=8.7, 1.5 Hz, 1 H), 8.15 (d, *J*=2.73 Hz, 1 H), 8.28 (d, *J*=1.56 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 442.8; Anal. Calcd for C₂₃H₃₀N₄O₃S+1.10 TFA+0.10 H₂O (569.31): C, 53.12; H, 5.54; N, 9.83; Found: C, 53.13; H, 5.62; N, 9.76.

Example 19**2-*tert*-Butyl-5-[(4-methyl-1*H*-pyrazol-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole**

Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (371 mg, 1.0 mmol), 4-methyl-1*H*-pyrazole (164 mg, 2.0 mmol) and DMAP (366 mg, 3.0 mmol) in MeCN (10 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 165 mg (40% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.41 - 1.58 (m, 4 H), 1.61 (s, 9 H), 2.05 (s, 3 H), 2.22 - 2.47 (m, 1 H), 3.30 - 3.40 (m, 2 H), 3.91 (m, 2 H), 4.43 (d, J=7.62 Hz, 2 H), 7.60 (s, 1 H), 7.91 (d, J= 8.2 Hz, 1 H), 7.95 (dd, J= 8.8, 1.8 Hz, 1 H), 8.05 - 8.14 (m, 1 H), 8.28 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 416.8.


Example 20**2-*tert*-Butyl-5-[(3-methyl-1*H*-pyrazol-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole**

Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (371 mg, 1.0 mmol), 3-methyl-1*H*-


pyrazole (164 mg, 2.0 mmol) and DMAP (367 mg, 3.0 mmol) in MeCN (10 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 116 mg (28%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.39 - 1.57 (m, 4 H), 1.59 (s, 9 H), 2.17 (s, 3 H), 2.23 - 2.33 (m, 1 H), 3.27 - 3.36 (m, 2 H), 3.88 (m, 2 H), 4.42 (d, $J=7.62$ Hz, 2 H), 6.31 (d, $J=2.54$ Hz, 1 H), 7.88 - 7.99 (m, 2 H), 8.18 (d, $J=2.73$ Hz, 1 H), 8.28 (d, $J=1.76$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 416.8$.

Example 21

1- $\{[2\text{-}tert\text{-butyl-1-(tetrahydro-2}H\text{-pyran-4-ylmethyl)-1}H\text{-benzimidazol-5-yl]sulfonyl}\}$ -1*H*-pyrazol-3-amine




Step A: 1- $\{[2\text{-}tert\text{-butyl-1-(tetrahydro-2}H\text{-pyran-4-ylmethyl)-1}H\text{-benzimidazol-5-yl]sulfonyl}\}$ -1*H*-pyrazol-3-amine



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (1.46 g, 3.93 mmol), *tert*-butyl 1*H*-pyrazol-3-ylcarbamate (0.80 g, 4.33 mmol) (see following step B for preparation), and DMAP (1.47 g, 12.0 mmol) in MeCN (40 mL). The crude product was purified by MPLC using EtOAc on silica gel to give 0.31 g (19%) of a white solid as the title compound. ^1H NMR (400 MHz, DMSO- D_6) δ 1.25 - 1.44 (m, 4 H), 1.46 (s, 9 H), 2.05 - 2.24 (m, 1 H), 3.15 (m, 2 H), 3.77 (m, 2 H), 4.28 (d, $J=7.03$ Hz, 2 H), 5.38 (s, 2 H), 5.78 (d, $J=2.93$ Hz, 1 H), 7.63 (dd, $J=8.79, 1.76$

Hz, 1 H), 7.82 (d, $J=8.59$ Hz, 1 H), 7.97 (d, $J=1.76$ Hz, 1 H), 8.00 (d, $J=2.93$ Hz, 1 H); MS (ESI) $(M+H)^+ = 417.8$; Anal. Calcd for $C_{20}H_{27}N_5O_3S+1.30$ TFA+0.10 EtOAc (575.78): C, 48.19; H, 5.09; N, 12.16; Found: C, 48.12; H, 5.02; N, 12.29.


5 **Step B. *tert*-butyl 1*H*-pyrazol-3-ylcarbamate**



Di-*tert*-butyl dicarbonate (1.83 g, 8.4 mmol) was added to a solution of 1*H*-pyrazol-3-amine (0.58 g, 7.0 mmol) in THF (15 mL). The reaction mixture was stirred over weekend at room temperature. After evaporation of the solvent, the crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 0.84 g (66%) of a white solid as the title compound. 1H NMR (400 MHz, DMSO- D_6) δ 1.47 (s, 9 H), 3.28 (s, 2 H), 5.74 (d, $J=2.93$ Hz, 1 H), 7.80 (d, $J=2.73$ Hz, 1 H); MS (ESI) $(M+H)^+ = 183.8$.

15 **Example 22**

N-(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazol-3-yl)cyclobutanecarboxamide




20 Cyclobutanecarbonyl chloride (30 mg, 30 μ L, 0.26 mmol) was added to a solution of 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazol-3-amine (37 mg, 0.087 mmol) (see Example 21 for preparation) and DIPEA (34 mg, 46 μ L, 0.26 mmol) in CH_2Cl_2 (10 mL). The reaction mixture was stirred overnight at room temperature.

After evaporation of the solvent, the crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 14.3 mg (33%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.41 - 1.56 (m, 4 H), 1.59 (s, 9 H), 1.76 - 1.88 (m, 1 H), 1.91 - 2.01 (m, 1 H), 2.06 - 2.18 (m, 2 H), 2.17 - 2.27 (m, 2 H), 2.26 - 2.37 (m, 1 H), 3.10 - 3.24 (m, 1 H), 3.25 - 3.35 (m, 2 H), 3.84 - 3.95 (m, 2 H), 4.41 (d, J=7.62 Hz, 2 H), 6.87 (d, J=2.93 Hz, 1 H), 7.88 (d, J=8.9 Hz, 1 H), 7.92 (dd, J=8.8, 1.5 Hz, 1 H), 8.18 (d, J=2.93 Hz, 1 H), 8.25 (d, J=1.56 Hz, 1 H); MS (ESI) (M+H)⁺ = 499.8; Anal. Calcd for C₂₅H₃₃N₅O₄S+0.80 TFA+0.20 EtOAc+0.10 H₂O (612.68): C, 54.11; H, 5.86; N, 11.43; Found: C, 54.12; H, 5.92; N, 11.34.

Example 23


1-{{2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrazole-4-carbaldehyde




Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (3.26 g, 8.8 mmol), 1*H*-pyrazole-4-carbaldehyde (1.01 g, 10.5 mmol) and DMAP (2.15 g, 17.6 mmol) in MeCN (70 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 1.12 g (30%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.39 - 1.56 (m, 4 H), 1.58 (s, 9 H), 2.21 - 2.36 (m, 1 H), 3.29 - 3.33 (m, 2 H), 3.88 (m, 2 H), 4.40 (d, J=7.42 Hz, 2 H), 5.41 (s, 1 H), 7.69 (s, 1 H), 7.84 - 7.90 (m, 1 H), 7.92 - 7.97 (m, 1 H), 8.25 (t, J=0.68 Hz, 1 H), 8.29 (d, J=1.76 Hz, 1 H); MS (ESI) (M+H)⁺ = 430.7; Anal. Calcd for C₂₁H₂₆N₄O₄S+0.80 TFA +0.30 CH₃CN +0.20 H₂O(537.67): C, 51.83; H, 5.27; N, 11.20; Found: C, 51.79; H, 5.20; N, 11.16.

Example 24

1-{{2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-(2-hydroxyethyl)-1*H*-pyrazole-4-carboxamide




Step A: 1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-(2-hydroxyethyl)-1*H*-pyrazole-4-carboxamide



Ethanolamine (29 mg, 0.47 mmol) and DIPEA (122 μ L, 90 mg, 0.70 mmol) were added to a solution of 1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrazole-4-carboxylic acid (4.0 mL, 0.23 mmol) (see following step B for preparation). Stirring for 20 min, HATU (117 mg, 0.47 mmol) was added. The reaction mixture was stirred overnight at room temperature, diluted with H₂O (100 mL), and extracted with EtOAc (3x50 mL). The combined organic phases were washed with NaCl saturated aqueous solution (2x10 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using EtOAc /MeOH (20:1-9:1) on silica gel to give 80 mg (71%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.41 - 1.57 (m, 4 H), 1.60 (s, 9 H), 2.25 - 2.36 (m, 1 H), 3.24 - 3.34 (m, 2 H), 3.40 (t, J=5.66 Hz, 2 H), 3.63 (t, J=5.76 Hz, 2 H), 3.86 - 3.94 (m, 2 H), 4.43 (d, J=7.42 Hz, 2 H), 7.95(d, J = 8.8 Hz, 1 H), 8.02 (dd, J = 8.8, 1.8 Hz, 1 H), 8.06 (d, J=0.78 Hz, 1 H), 8.35 (d, J=1.17 Hz, 1 H), 8.78 (s, 1 H); MS (ESI) (M+H)⁺ = 490.3.


Step B: 1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrazole-4-carboxylic acid



Oxone (344 mg, 0.56 mmol) was added to a solution of 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrazole-4-carbaldehyde (201 mg, 0.47 mmol) (see example 23 for preparation) in DMF (8 mL). The resulting mixture was stirred overnight at room temperature and used directly for step A. MS (ESI) ($M+H$)⁺ = 447.09.

Example 25

1-[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-*N*-isopropyl-1*H*-pyrazole-4-carboxamide




Following the same procedure in Example 24, Step A, using iso-propylamine (9 mg, 0.15 mmol), DIPEA (28 uL, 21 mg, 0.16 mmol), 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrazole-4-carboxylic acid (0.073 mmol) and HATU (44 mg, 0.12 mmol) in DMF (2.5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 25 mg (70%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.17 (d, J=6.45 Hz, 6 H), 1.40 - 1.56 (m, 4 H), 1.59 (s, 9 H), 2.18 - 2.40 (m, 1 H), 3.23 - 3.39 (m, 2 H), 3.81 - 3.96 (m, 2 H), 4.02 - 4.18 (m, 1 H), 4.41 (d, J=7.42 Hz, 2 H), 7.91 (d, J=8.8 Hz, 1 H), 7.98 (dd, J=8.8, 1.8 Hz, 1 H), 8.04 (s, 1 H), 8.33 (d, J=1.76 Hz, 1 H), 8.77 (d, J=0.78 Hz, 1 H); MS (ESI) ($M+H$)⁺ = 488.0; Anal. Calcd for

$C_{24}H_{33}N_5O_4S+0.70$ TFA+0.50 EtOAc+0.40 H_2O (624.71): C, 53.64; H, 6.21; N, 11.21; Found: C, 53.58; H, 6.23; N, 11.28.

Example 26


1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclobutyl-1*H*-pyrazole-4-carboxamide



Following the same procedure in Example 24, Step A, using cyclobutylamine (13 μ L, 10 mg, 0.15 mmol), DIPEA (28 μ L, 21 mg, 0.16 mmol), 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazole-4-carboxylic acid (0.073 mmol) and HATU (44 mg, 0.12 mmol) in DMF (2.5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 17 mg (47%) of a white solid as the title compound. 1H NMR (400 MHz, METHANOL- D_4) δ 1.40 - 1.56 (m, 4 H), 1.58 (s, 9 H), 1.67 - 1.79 (m, 2 H), 1.96 - 2.09 (m, 2 H), 2.22 - 2.34 (m, 3 H), 3.25 - 3.34 (m, 2 H), 3.83 - 3.94 (m, 2 H), 4.34 - 4.39 (m, 1 H), 4.41 (d, $J=7.62$ Hz, 2 H), 7.90 (d, $J=8.6$ Hz, 1 H), 7.97 (dd, $J=8.8$, 1.8 Hz, 1 H), 8.04 (d, $J=0.59$ Hz, 1 H), 8.33 (d, $J=1.37$ Hz, 1 H), 8.77 (d, $J=0.59$ Hz, 1 H); MS (ESI) ($M+H$) $^+$ = 499.8; Anal. Calcd for $C_{25}H_{33}N_5O_4S+0.70$ TFA+0.30 EtOAc+0.20 H_2O (613.09): C, 54.66; H, 6.00; N, 11.42; Found: C, 54.63; H, 5.95; N, 11.51.

Example 27


1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-ethyl-1*H*-pyrazole-4-carboxamide




Following the same procedure in Example 24, Step A, using ethylamine (73 μ L, 2.0 M in THF, 0.15 mmol), DIPEA (28 μ L, 21 mg, 0.16 mmol), 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazole-4-carboxylic acid (0.073 mmol) and HATU (44 mg, 0.12 mmol) in DMF (2.5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 17 mg (48%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.15 (t, $J=7.23$ Hz, 3 H), 1.40 - 1.57 (m, 4 H), 1.59 (s, 9 H), 2.21 - 2.41 (m, 1 H), 2.79 (s, 1 H), 3.29 - 3.35 (m, 4 H), 3.84 - 3.95 (m, 2 H), 4.41 (d, $J=7.42$ Hz, 2 H), 7.91 (d, $J=9.0$ Hz, 1 H), 7.98 (dd, $J=9.0, 1.7$ Hz, 1 H), 8.03 (s, 1 H), 8.33 (d, $J=1.56$ Hz, 1 H), 8.74 (s, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 474.0$; Anal. Calcd for $\text{C}_{23}\text{H}_{31}\text{N}_5\text{O}_4\text{S}+0.70$ TFA+0.30 EtOAc+0.40 H_2O (590.66): C, 52.67; H, 5.96; N, 11.86; Found: C, 52.63; H, 5.99; N, 11.81.

Example 28

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclopropyl-1*H*-pyrazole-4-carboxamide




Method A



Following the same procedure in Example 24, Step A, using cyclopropylamine (10 μ L, 8 mg, 0.15 mmol), DIPEA (28 μ L, 21 mg, 0.16 mmol), 1-([2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)-1*H*-pyrazole-4-carboxylic acid (0.073 mmol) and HATU (44 mg, 0.12 mmol) in DMF (2.5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 27 mg (76%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 0.51 - 0.59 (m, 2 H), 0.69 - 0.79 (m, 2 H), 1.40 - 1.56 (m, 4 H), 1.59 (s, 9 H), 2.22 - 2.35 (m, 1 H), 2.70 - 2.79 (m, 1 H), 3.25 - 3.34 (m, 2 H), 3.85 - 3.93 (m, 2 H), 4.41 (d, $J=7.42$ Hz, 2 H), 7.91 (d, $J=8.7$ Hz, 1 H), 7.98 (dd, $J=8.8, 1.7$ Hz, 1 H), 8.02 (d, $J=0.59$ Hz, 1 H), 8.33 (d, $J=1.76$ Hz, 1 H), 8.74 (d, $J=0.59$ Hz, 1 H); MS (ESI) ($\text{M}+\text{H}$) $^+$ = 486.0; Anal. Calcd for $\text{C}_{24}\text{H}_{31}\text{N}_5\text{O}_4\text{S}+1.0$ TFA (599.63): C, 52.08; H, 5.38; N, 11.68; Found: C, 52.25 H, 5.16; N, 11.92.

METHOD B


Step A: 1-([2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)-*N*-cyclopropyl-1*H*-pyrazole-4-carboxamide



Sodium hydride (0.98 g, 60%, 25 mmol) was added to a solution of *N*-cyclopropyl-1*H*-pyrazole-4-carboxamide (0.49 g, 3.5 mmol) (see following steps B and C for preparation) in 40 mL of THF-DMF (3:1) at 0 $^{\circ}\text{C}$. Stirring for 1 h at 0 $^{\circ}\text{C}$ and 0.5 h at room temperature, 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (1.30 g, 3.5


mmol) was added. The reaction mixture was stirred for 2 h at 0°C, quenched with NaHCO₃ (10 mL) and extracted with EtOAc (3x50 mL). The combined organic phases were washed with NaCl (20 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 0.54 g (33%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.52 - 0.59 (m, 2 H), 0.71 - 0.79 (m, 2 H), 1.39 - 1.57 (m, 4 H), 1.60 (s, 9 H), 2.22 - 2.37 (m, 1 H), 2.71 - 2.79 (m, 1 H), 3.26 - 3.34 (m, 2 H), 3.86 - 3.93 (m, 2 H), 4.43 (d, *J*=7.62 Hz, 2 H), 7.91 - 7.95 (m, 1 H), 7.97 - 8.01 (m, 1 H), 8.03 (d, *J*=0.78 Hz, 1 H), 8.34 (d, *J*=1.37 Hz, 1 H), 8.74 (d, *J*=0.59 Hz, 1 H); MS (ESI) (M+H)⁺ = 485.8.

Step B: 1*H*-pyrazole-4-carbonyl chloride




A mixture of 1*H*-pyrazole-4-carboxylic acid (1.03 g, 9.2 mmol) in thionyl chloride (20 mL) was heated for 18 h at reflux. Upon evaporation, 1.16 g (97%) of a white solid was obtained.

Step C: N-cyclopropyl-1*H*-pyrazole-4-carboxamide




A solution of cyclopropylamine (0.52 mL, 0.43 g, 7.5 mmol) and triethylamine (1.4 mL, 1.01 g, 10.0 mmol) in CH₂Cl₂ (5 mL) was added to a suspension of 1*H*-pyrazole-4-carbonyl chloride (0.69 g, 5.3 mmol) in CH₂Cl₂ (20 mL) at 0 °C. The reaction mixture was stirred overnight at room temperature. After evaporation of the solvent, the crude product was purified by MPLC using EtOAc on silica gel to give 0.79 g (99%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.52 - 0.62 (m, 2 H), 0.72 - 0.82 (m, 2 H), 2.69 - 2.86 (m, 1 H), 7.91 (s, 1 H), 8.09 (s, 1 H).

Example 29**2-*tert*-Butyl-5-(1*H*-pyrrol-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole**


Sodium hydride (139 mg, 60%, 3.5 mmol) was added to a solution of pyrrole (200 μ L, 194 mg, 2.9 mmol) in THF (10 mL). Stirring for 3 h at room temperature, 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (185 mg, 0.5 mmol) was added. The reaction mixture was stirred overnight at room temperature, quenched with NH_4Cl (5 mL), diluted with EtOAc (50 mL), washed with NaCl (2x20 mL) and dried over Na_2SO_4 . The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 70 mg (35%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL-D_4) δ 1.36 - 1.53 (m, 4 H), 1.55 (s, 9 H), 2.18 - 2.38 (m, 1 H), 3.22 - 3.35 (m, 2 H), 3.88 (m, 2 H), 4.33 (d, $J=7.42$ Hz, 2 H), 6.22 - 6.31 (m, 2 H), 7.13 - 7.29 (m, 2 H), 7.71 (d, $J=8.8$ Hz, 1 H), 7.77 (dd, $J=8.6, 1.8$ Hz, 1 H), 8.13 (d, $J=1.37$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 401.8$; Anal. Calcd for $\text{C}_{21}\text{H}_{27}\text{N}_3\text{O}_3\text{S}+0.30 \text{ H}_2\text{O}$ (406.94): C, 61.98; H, 6.84; N, 10.33; Found: C, 62.10; H, 6.90; N, 10.43.

Example 30

Methyl 1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrrole-3-carboxylate




5 Step A: methyl 1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrrole-3-carboxylate



Following the same procedure in Example 29, using methyl 1*H*-pyrrole-3-carboxylate (0.16 g, 1.3 mmol) (see following step B for preparation), sodium hydride (0.18 g, 60%, 4.5 mmol) and 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (0.48 g, 1.3 mmol) in THF (10 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 0.16 g (27%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.46 - 1.54 (m, 4 H), 1.56 (s, 9 H), 2.15 - 2.32 (m, 1 H), 3.25 - 3.37 (m, 2 H), 3.79 (s, 3 H), 3.93 - 4.03 (m, 2 H), 4.22 (d, J=7.42 Hz, 2 H), 6.62 (dd, J=3.32, 1.56 Hz, 1 H), 7.15 (dd, J=3.32, 2.34 Hz, 1 H), 7.42 (d, J=8.79 Hz, 1 H), 7.74 - 7.81 (m, 2 H), 8.33 (d, J=1.37 Hz, 1 H); MS (ESI) (M+H)⁺ = 459.8; Anal. Calcd for C₂₃H₂₉N₃O₅S+0.10 EtOAc+0.30 H₂O (474.98): C, 59.43, H, 6.45; N, 8.85; Found: C, 59.34; H, 6.60; N, 8.84.


20 Step B: methyl 1*H*-pyrrole-3-carboxylate



Potassium carbonate (0.65 g, 5.4 mmol) was added to a solution of 1*H*-pyrrole-3-carboxylic acid (0.50 g, 4.5 mmol) in DMF (10 mL). Stirring for 2 h at room temperature, methyl iodide (0.34 mL, 0.77 g, 5.4 mmol) was added. The mixture was stirred overnight at room temperature, diluted with H₂O (50 mL), and extracted with EtOAc (3x50 mL). The combined organic phases were washed with NaCl (10 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using Hex/EtOAc (7:3) on silica gel to give 0.17 g (30%) of a white solid as the title compound. ¹H NMR (400 MHz, CHLOROFORM-D) δ 3.82 (s, 3 H), 6.56 - 6.72 (m, 1 H), 6.73 - 6.83 (m, 1 H), 7.36 - 7.50 (m, 1 H).


Example 31

1-{{2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-ethyl-1*H*-pyrrole-3-carboxamide




Method A

Step A: 1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-ethyl-1*H*-pyrrole-3-carboxamide



Following the same procedure in Example 29, using *N*-ethyl-1*H*-pyrrole-3-carboxamide (2.7 g, 20 mmol) (see following step B for preparation), sodium hydride (4.0 g, 60%, 100 mmol) and 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (6.1 g, 16 mmol) in THF (250 mL). The crude product was purified by MPLC using Hex/EtOAc (1:4) on silica gel to give 4.0 g (53%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.13 (t, *J*=7.23 Hz, 3 H), 1.41 - 1.58 (m, 4 H), 1.61 (s, 9 H), 2.24 - 2.38 (m, 1 H), 3.24 - 3.35 (m, 4 H), 3.85 - 3.94 (m, 2 H), 4.44 (d, *J*=7.42 Hz, 2 H), 6.65 (dd, *J*=3.32, 1.56 Hz, 1 H), 7.29 (dd, *J*=3.32, 2.34 Hz, 1 H), 7.77 - 7.82 (m, 1 H), 7.95 - 7.98 (m, 2 H), 8.24 - 8.30 (m, 1 H); MS (ESI) (*M*+*H*)⁺ = 472.8; Anal. Calcd for C₂₄H₃₂N₄O₄S+1.20 TFA+0.10 EtOAc+0.30 H₂O (624.86): C, 51.71; H, 5.58; N, 8.97; Found: C, 51.73; H, 5.66; N, 8.91.


Step B: *N*-ethyl-1*H*-pyrrole-3-carboxamide



DIPEA (10.4 mL, 7.8 g, 60 mmol) was added to a solution of 1*H*-pyrrole-3-carboxylic acid (2.2 g, 20 mmol) and ethylamine hydrochloride (2.5 g, 30 mmol) in DMF (50 mL) at 0 °C. Stirring for 20 min, HATU (9.9 g, 26 mmol) was added at 0 °C. The reaction mixture was stirred overnight at room temperature, diluted with EtOAc (300 mL), washed with H₂O (3x30 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using EtOAc on silica gel to give 4.0 mL of a solution of the desired product in DMF. Small amount of the desired product was purified again by MPLC using EtOAc on silica gel for NMR. ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.22 (t, *J*=7.23 Hz, 3 H), 3.39 - 3.51 (m, 2 H), 5.84 (s, 1 H), 6.37 - 6.42 (m, 1 H), 6.77 (dd, *J*=4.98, 2.44 Hz, 1 H), 7.30 - 7.39 (m, 1 H), 8.85 (t, 1 H).


Method B

Step A: 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-ethyl-1*H*-pyrrole-3-carboxamide



Following the same procedure in Example 24, Step A, using DIPEA (105 μ L, 78 mg, 0.60 mmol), 1-[[2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carboxylic acid (0.85 mmol) (see following Steps B and C for preparation) in DMF (15 mL), HATU (582 mg, 1.53 mmol) and ethylamine hydrochloride (154 mg, 1.87 mmol). The crude product was purified by MPLC on silica gel using EtOAc to give 0.32 g (81%) of a white solid as the title compound. ^1H NMR (400 MHz, CHLOROFORM-*D*) δ 1.19 (t, $J=7.23$ Hz, 3 H), 1.45 - 1.54 (m, 4 H), 1.56 (s, 9 H), 2.15 - 2.33 (m, 1 H), 3.26 - 3.35 (m, 2 H), 3.36 - 3.44 (m, 2 H), 3.93 - 4.03 (m, 2 H), 4.22 (d, $J=7.42$ Hz, 2 H), 5.79 (t, $J=5.66$ Hz, 1 H), 6.47 (dd, $J=3.22, 1.66$ Hz, 1 H), 7.17 (dd, $J=3.32, 2.15$ Hz, 1 H), 7.41 (d, $J=8.59$ Hz, 1 H), 7.62 (dd, $J=2.34, 1.76$ Hz, 1 H), 7.76 (dd, $J=8.69, 1.86$ Hz, 1 H), 8.32 (d, $J=1.76$ Hz, 1 H); MS (ESI) ($\text{M}+\text{H}$) $^+$ = 473.3.


Step B: 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carbaldehyde



NaH (0.49 mg, 60%, 12.4 mmol) was added to a solution of 1*H*-Pyrrole-3-carbaldehyde (0.21 mg, 2.47 mmol) in THF (30 mL) at 0 $^{\circ}\text{C}$. The reaction mixture was allowed to warm to room temperature, stirred for 1 hour at room temperature and cooled down to 0 $^{\circ}\text{C}$ again. 2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (1.1g, 2.97 mmol) was added slowly, allowed the reaction to warm to room temperature and stirred for 1 hour. The reaction mixture was quenched with NaHCO_3 (5 mL), diluted with EtOAc (100

mL), washed with brine (2x15 mL) and dried over Na₂SO₄. The crude product was purified by MPLC on silica gel using Hexane/EtOAc (1:1) to give 0.44 g (34%) of a white solid as the title compound. ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.45 - 1.55 (m, 4 H), 1.56 (s, 9 H), 2.16 - 2.31 (m, 1 H), 3.25 - 3.35 (m, 2 H), 3.94 - 4.02 (m, 2 H), 4.22 (d, *J*=7.42 Hz, 2 H), 6.67 (dd, *J*=3.42, 1.66 Hz, 1 H), 7.18 - 7.22 (m, 1 H), 7.44 (d, *J*=8.79 Hz, 1 H), 7.76 - 7.82 (m, 2 H) 8.36 (d, *J*=1.76 Hz, 1 H) 9.79 (s, 1 H); MS (ESI) (M+H)⁺ = 430.00.


Step C: 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carboxylic acid




Oxone (784 mg, 1.28 mmol) was added to a solution of 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carbaldehyde (366 mg, 0.85 mmol) in DMF (15 mL). The reaction mixture was stirred overnight at room temperature and used directly for step A. MS (ESI) (M+H)⁺ = 445.88

Example 32

1-[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-*N*-cyclopropyl-1*H*-pyrrole-3-carboxamide




Step A: 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-*N*-cyclopropyl-1*H*-pyrrole-3-carboxamide



Following the same procedure in Example 29, using *N*-cyclopropyl-1*H*-pyrrole-3-carboxamide (49 mg, 0.33 mmol) (see following step B for preparation), sodium hydride (100 mg, 60%, 2.5 mmol) and 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (122 mg, 0.33 mmol) in THF (6 mL) and DMF (0.5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:4) on silica gel to give 82 mg (51%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.50 - 0.56 (m, 2 H), 0.69 - 0.76 (m, 2 H), 1.40 - 1.57 (m, 4 H), 1.59 (s, 9 H), 2.29 (m, 1 H), 2.67 - 2.76 (m, 1 H), 3.24 - 3.34 (m, 2 H), 3.84 - 3.93 (m, 2 H), 4.41 (d, *J*=7.42 Hz, 2 H), 6.64 (dd, *J*=3.32, 1.56 Hz, 1 H), 7.27 (dd, *J*=3.32, 2.34 Hz, 1 H), 7.78 - 7.82 (m, 1 H), 7.90 (d, *J*= 9.0 Hz, 1 H), 7.94 (dd, *J* = 8.6, 1.5 Hz, 1 H), 8.25 (d, *J*=1.56 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 484.7; Anal. Calcd for C₂₅H₃₂N₄O₄S+1.10 TFA+0.10 H₂O (611.88): C, 53.40; H, 5.49; N, 9.16; Found: C, 53.44; H, 5.53; N, 9.18.


Step B: *N*-cyclopropyl-1*H*-pyrrole-3-carboxamide




Following the same procedure in Example 31, step B, using DIPEA (0.87 mL, 0.65 g, 5.0 mmol), 1*H*-pyrrole-3-carboxylic acid (0.25 g, 2.3 mmol), cyclopropylamine (0.14 g, 2.5 mmol) and HATU (1.0 g, 2.7 mmol) in DMF (10 mL). The crude product was purified by MPLC using EtOAc on silica gel to 52 mg (15%) of the title product. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.42 - 0.63 (m, 2 H), 0.66 - 0.83 (m, 2 H), 2.60 - 2.80 (m, 1 H), 6.49 (dd, *J*=2.93, 1.56 Hz, 1 H), 6.69 (dd, *J*=2.73, 1.95 Hz, 1 H), 7.30 (t, *J*=1.76 Hz, 1 H).

Example 33

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclobutyl-1*H*-pyrrole-3-carboxamide



Step A: 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclobutyl-1*H*-pyrrole-3-carboxamide




DIPEA (0.1 mL, 74 mg, 0.57 mmol) was added to a solution of 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxylic acid (0.078 mmol) (see following step B for preparation) and cyclobutylamine (0.1 mL, 83 mg, 1.17 mmol) in DMF (5 mL) at 0 °C. Stirring for 20 min, HATU (100 mg, 0.31 mmol) was added at 0 °C.

The reaction mixture was stirred overnight at room temperature, diluted with H₂O (50 mL) and extracted with EtOAc (3x25 mL). The combined organic phases were washed with H₂O (2x10 mL), NaCl (10 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using

Hex/EtOAc (3:7) on silica gel to 30 mg (78%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.41 - 1.57 (m, 4 H), 1.60 (s, 9 H), 1.66 - 1.78 (m, 2 H), 1.95 - 2.09 (m, 2 H), 2.20 - 2.35 (m, 3 H), 3.25 - 3.34 (m, 2 H), 3.85 - 3.93 (m, 2 H), 4.33 - 4.41 (m, 1 H), 4.43 (d, J=7.62 Hz, 2 H), 6.67 (dd, J=3.32, 1.56 Hz, 1 H), 7.28 (dd, J=3.32, 2.34 Hz, 1 H), 7.81 - 7.84 (m, 1 H), 7.91 - 7.95 (m, 1 H), 7.95 - 7.99 (m, 1 H), 8.26 (dd, J=1.66, 0.68 Hz, 1 H);

MS (ESI) $(M+H)^+ = 498.8$; Anal. Calcd for $C_{26}H_{34}N_4O_4S + 0.90 \text{ TFA} + 0.80 \text{ H}_2\text{O}$ (615.68): C, 54.23; H, 5.98; N, 9.10; Found: C, 54.25; H, 6.02; N, 9.12.


Step B: 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carboxylic acid



Lithium hydroxide (25 mg, 1.0 mmol) was added to mixture of methyl 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carboxylate (90 mg, 0.2 mmol) in 10 mL of THF-H₂O (7:3) at 0 °C. The reaction mixture was stirred overnight at room temperature and acidified to pH=1. Upon evaporation and dried in vacuo, the residue was dissolved in DMF (10 mL) and then used directly for step A. Purity: >80% (checked by LCMS). MS (ESI) $(M+H)^+ = 445.99$.

Example 34

***N*-Allyl-1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carboxamide**




Following the same procedure in Example 33, step A, using DIPEA (0.1 mL, 74 mg, 0.57 mmol), 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carboxylic acid (0.078 mmol) (see the step B in example 33 for preparation),

allylamine (0.1 mL, 76 mg, 1.33 mmol) and HATU (100 mg, 0.31 mmol) in DMF (5 mL). The crude product was purified by MPLC using Hex/EtOAc (3:7) on silica gel to 32 mg (85%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.41 - 1.57 (m, 4 H), 1.60 (s, 9 H), 2.20 - 2.41 (m, 1 H), 3.24 - 3.38 (m, 2 H), 3.84 - 3.97 (m, 4 H), 4.43 (d, $J=7.42$ Hz, 2 H), 5.03 - 5.10 (m, 1 H), 5.10 - 5.19 (m, 1 H), 5.75 - 5.94 (m, 1 H), 6.67 (dd, $J=3.32, 1.76$ Hz, 1 H), 7.30 (dd, $J=3.42, 2.25$ Hz, 1 H), 7.79 - 7.85 (m, 1 H), 7.93 (d, $J=9.0$ Hz, 1 H), 7.970 (dd, $J=9.0, 1.8$ Hz, 1 H), 8.27 (d, $J=1.76$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 484.7$; Anal. Calcd for $\text{C}_{25}\text{H}_{32}\text{N}_4\text{O}_4\text{S}+0.90$ TFA+0.20 H_2O (590.85): C, 54.48; H, 5.68; N, 9.48; Found: C, 54.53; H, 5.69; N, 9.57.

Example 35


1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-methyl-1*H*-pyrrole-3-carboxamide




Following the same procedure in Example 33, step A, using DIPEA (0.37 mL, 274 mg, 2.2 mmol), 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxylic acid (0.12 mmol) (see the step B in example 33 for preparation), methylamine hydrochloride (100 mg, 1.45 mmol) and HATU (150 mg, 0.40 mmol) in DMF (5 mL). The crude product was purified by MPLC using Hex/EtOAc (3:7) on silica gel to 25 mg (45%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.41 - 1.58 (m, 4 H), 1.61 (s, 9 H), 2.21 - 2.41 (m, 1 H), 2.79 (s, 3 H), 3.23 - 3.35 (m, 2 H), 3.83 - 3.96 (m, 2 H), 4.44 (d, $J=7.62$ Hz, 2 H), 6.63 (dd, $J=3.32, 1.76$ Hz, 1 H), 7.30 (dd, $J=3.32, 2.34$ Hz, 1 H), 7.75 - 7.80 (m, 1 H), 7.95 (d, $J=8.7$ Hz, 1 H), 7.98 (dd, $J=8.7, 1.5$ Hz, 1 H), 8.27 (d, $J=0.98$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 458.8$; Anal. Calcd for $\text{C}_{23}\text{H}_{30}\text{N}_4\text{O}_4\text{S}+1.50$ TFA (629.62): C, 49.60; H, 5.04; N, 8.90; Found: C, 49.53; H, 5.00; N, 9.10.

Example 36

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-(2-hydroxyethyl)-1*H*-pyrrole-3-carboxamide




Step A: 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-(2-hydroxyethyl)-1*H*-pyrrole-3-carboxamide



Following the same procedure in Example 33, step A, using DIPEA (47 μ L, 35 mg, 0.27 mmol), 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxylic acid (60 mg, 0.14 mmol) (see following step B for preparation), ethanolamine (17 mg, 0.27 mmol) and HATU (103 mg, 0.27 mmol) in DMF (5 mL). The crude product was purified by MPLC using EtOAc/MeOH (9:1) on silica gel to give 48 mg (72%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.42 - 1.58 (m, 4 H), 1.61 (s, 9 H), 2.23 - 2.36 (m, 1 H), 3.25 - 3.34 (m, 2 H), 3.38 (t, $J=5.76$ Hz, 2 H), 3.61 (t, $J=5.76$ Hz, 2 H), 3.86 - 3.94 (m, 2 H), 4.44 (d, $J=7.42$ Hz, 2 H), 6.67 (dd, $J=3.32$, 1.76 Hz, 1 H), 7.30 (dd, $J=3.32$, 2.34 Hz, 1 H), 7.82 - 7.85 (m, 1 H), 7.94 (d, $J=8.8$ Hz, 1 H), 7.98 (d, dd, $J=8.7$, 1.5 Hz, 1 H), 8.28 (d, $J=1.17$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 489.3$.


Step B: 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrrole-3-carboxylic acid




5 Butyllithium (7.0 mL, 2.0 M, 14 mmol) was added to a solution of 1*H*-pyrrole-3-carboxylic acid (0.67 g, 6.0 mmol) in THF (35 mL) at -78°C . Stirring for 45 min at -78°C and 30 min at 0°C , 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (1.86 g, 5.0 mmol) was added. The reaction mixture was stirred overnight at room temperature, diluted with EtOAc (200 mL), washed with 2*N* HCl (2x20 mL), NaCl (20 mL) and dried over
10 Na_2SO_4 . The crude product was purified by MPLC using $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (20:1) on silica gel to 0.40 g (18%) of a white solid as the title compound. MS (ESI) $(\text{M}+\text{H})^+ = 445.98$.

Example 37

1-[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]azetidin-3-amine
15




Step A: 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]azetidin-3-amine



$tert$ -butyl (1-([2- $tert$ -butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)azetidin-3-yl)carbamate (0.84 g, 1.66 mmol)(see following step B for preparation) in CH_2Cl_2 (10 mL) was treated with TFA (5 mL) for 1 h at room temperature. Upon evaporation, the residue was dissolved in H_2O (20 mL), neutralized with 2 *N* NaOH to pH=10, and extracted with CH_2Cl_2 (5x30 mL). The combined organic phases were washed with NaCl (10 mL) and dried over Na_2SO_4 . After concentration, 0.58 g (86%) of a white solid was obtained as the title compound. ^1H NMR (400 MHz, METHANOL-D_4) δ 1.45 - 1.62 (m, 4 H), 1.63 (s, 9 H), 2.28 - 2.44 (m, 1 H), 3.30 - 3.39 (m, 2 H), 3.82 - 3.89 (m, 3 H), 3.89 - 3.97 (m, 2 H), 3.99 - 4.10 (m, 2 H), 4.48 (d, $J=7.62$ Hz, 2 H), 7.85 (dd, $J=8.69$, 1.66 Hz, 1 H), 7.98 (d, $J=8.79$ Hz, 1 H), 8.15 (d, $J=1.76$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 407.0$; Anal. Calcd for $\text{C}_{20}\text{H}_{30}\text{N}_4\text{O}_3\text{S}+2.10 \text{ TFA}+0.20 \text{ CH}_3\text{OH}+0.20 \text{ H}_2\text{O}$ (656.01): C, 44.67; H, 5.12; N, 8.54 Found: C, 44.68; H, 5.15; N, 8.56.

Step B: $tert$ -butyl (1-([2- $tert$ -butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)azetidin-3-yl)carbamate




Following the same procedure in Example 1, Step A, using 2- $tert$ -butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (0.74 g, 2.0 mmol), $tert$ -butyl azetidin-3-ylcarbamate (0.35 g, 2.0 mmol) and DMAP (0.75 g, 6.1 mmol) in MeCN (60 mL).

The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 0.84 g (83%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.32 (s, 9 H), 1.49 - 1.64 (m, 4 H), 1.66 (s, 9 H), 2.29 - 2.45 (m, 1 H), 3.30 - 3.41 (m, 2 H), 3.63 (m, 2 H), 3.88 - 4.01 (m, 4 H), 4.03 - 4.14 (m, 1 H), 4.52 (d, $J=7.62$ Hz, 2 H), 7.90 (dd, $J=8.59$, 1.37 Hz, 1 H), 8.05 (d, $J=8.79$ Hz, 1 H), 8.15 (d, $J=1.17$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 506.8$; Anal. Calcd for $\text{C}_{25}\text{H}_{38}\text{N}_4\text{O}_5\text{S}+0.90$ TFA+0.10 EtOAc+0.50 H_2O (628.31): C, 52.19; H, 6.53; N, 8.92; Found: C, 52.13; H, 6.53; N, 8.84.

Example 39


2-*tert*-Butyl-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole




Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (90 mg, 0.24 mmol), 3,3-difluoroazetidine (45 mg, 0.49 mmol) and DMAP (59 mg, 0.49 mmol) in MeCN (10 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 68 mg (66%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.46 - 1.63 (m, 4 H), 1.65 (s, 9 H), 2.27 - 2.44 (m, 1 H), 3.30 - 3.39 (m, 2 H), 3.89 - 3.98 (m, 2 H), 4.20 (t, $J=12.30$ Hz, 4 H), 4.51 (d, $J=7.62$ Hz, 2 H), 7.93 (dd, $J=8.69$, 1.66 Hz, 1 H), 8.05 (d, $J=8.79$ Hz, 1 H), 8.19 (d, $J=1.17$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 427.8$; Anal. Calcd for $\text{C}_{20}\text{H}_{27}\text{F}_2\text{N}_3\text{O}_3\text{S}+1.10$ TFA+ 0.3 CH_3CN (565.26): C, 48.45; H, 5.17; N, 8.18; Found: C, 48.42; H, 4.86; N, 8.20.

Example 40

2-(1,1-Dimethylpropyl)-5-(1*H*-pyrazol-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole




Step A: 2-(1,1-dimethylpropyl)-5-(1*H*-pyrazol-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole




Following the same procedure in Example 1, Step A, using 2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride **e** (287 mg, 0.746 mmol) (see following Steps B, C, D and E for preparation), pyrazol (152 mg, 2.24 mmol) and DMAP (182 mg, 1.49 mmol) in MeCN (15 mL). The crude product was purified by MPLC using Hex/EtOAc (3:7) on silica gel to give 305 mg (98%) of a white solid as the title compound. ¹H NMR (400 MHz, CHLOROFORM-*D*) δ 0.73 (t, *J*=7.52 Hz, 3 H), 1.37 - 1.52 (m, 4 H), 1.54 (s, 6 H), 1.90 (q, *J*=7.49 Hz, 2 H), 2.20 - 2.34 (m, 1 H), 3.24 - 3.34 (m, 2 H), 3.87-3.90 (m, 2 H), 4.34 (d, *J*=7.62 Hz, 2 H), 6.47 (dd, *J*=2.73, 1.56 Hz, 1 H), 7.73 (dd, *J*=1.56, 0.59 Hz, 1 H), 7.76 (dd, *J*=8.79, 0.39 Hz, 1 H), 7.86 (dd, *J*=8.8, 1.8 Hz, 1 H), 8.22 - 8.27 (m, 1 H), 8.31 (dd, *J*=2.73, 0.59 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 417.3; Anal. Calcd for C₂₁H₂₈N₄O₃S+0.1 H₂O (418.35): C, 60.29; H, 6.79; N, 13.39; Found: C, 60.32; H, 6.58; N, 13.77.

Step B: *N*-{5-(acetylamino)-2-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}-2,2-dimethylbutanamide



Following the same procedure in Example 1, Step E, using *N*-{3-Amino-4-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}acetamide (10.5 g, 40 mmol), DMAP (2.4 g, 20 mmol) and
 5 2,2-dimethylbutyryl chloride (5.9 g, 44 mmol) in 350 mL of DCM. Yield: 14.2 g (98%); ¹H NMR (400 MHz, CHLOROFORM-*D*) δ 0.94 (t, *J*=7.52 Hz, 3 H), 1.29 (s, 6 H), 1.32 - 1.46 (m, 2 H), 1.66 (q, *J*=7.42 Hz, 2 H), 1.68 - 1.75 (m, 2 H), 1.78 - 1.90 (m, 1 H), 2.13 (s, 3 H), 2.97 (d, *J*=7.03 Hz, 2 H), 3.34 - 3.45 (m, 2 H), 3.77 - 3.86 (m, 1 H), 3.94 - 4.06 (m, 2 H), 6.75 (d, *J*=8.79 Hz, 1 H), 7.05 (s, 1 H), 7.21 (dd, *J*=8.59, 2.54 Hz, 1 H), 7.49 (s, 1 H), 7.55 (d, *J*=2.34
 10 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 362.06.


Step C: *N*-[2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]acetamide



15


Following the same procedure in Example 1, Step F, using *N*-{5-(acetylamino)-2-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}-2,2-dimethylbutanamide (5.12 g, 14.2 mmol) in AcOH (60 mL). Yield: 2.30 g (47%). ¹H NMR (400 MHz, CHLOROFORM-*D*): δ 0.78 (t, *J*=7.42 Hz, 3 H), 1.45 - 1.60 (m, 10 H), 1.86 (q, *J*=7.42 Hz, 2 H), 2.19 (s, 3 H), 2.22 - 2.37 (m, 1 H), 3.24 -
 20 3.38 (m, 2 H), 3.91 - 4.02 (m, 2 H), 4.17 (d, *J*=7.42 Hz, 2 H), 7.26 (d, *J*=8.5 Hz, 1 H), 7.39 (s, 1 H), 7.53 (dd, *J*=8.69, 2.05 Hz, 1 H), 7.67 (d, *J*=1.95 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 344.05.

Step D: 2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-amine



Following the same procedure in Example 1, Step G, using *N*-[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]acetamide (2.08 g, 6.06 mmol) in 37% HCl (20 mL). Yield: 1.81 g (99%). ¹H NMR (400 MHz, CHLOROFORM-D): δ 0.79 (t, $J=7.52$ Hz, 3 H), 1.42 - 1.51 (m, 4 H), 1.52 (s, 6 H), 1.84 (q, $J=7.42$ Hz, 2 H), 2.15 - 2.37 (m, 1 H), 3.25 - 3.38 (m, 2 H), 3.59 (s, 2 H), 3.92 - 4.03 (m, 2 H), 4.12 (d, $J=7.42$ Hz, 2 H), 6.65 (dd, $J=8.50, 2.25$ Hz, 1 H), 7.06 (d, $J=2.15$ Hz, 1 H), 7.10 (d, $J=8.01$ Hz, 1 H); MS (ESI) (M+H)⁺ = 301.98.

Step E: 2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride




Following the same procedure in Example 1, Step H, using 2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-amine (7.44 g, 24.7 mmol) in concentrated hydrochloric acid (50 mL), NaNO₂ (2.04 g, 29.6 mmol), CuCl₂ (2.00 g, 14.9 mmol) and saturated SO₂ in AcOH (100 mL). Yield: 9.04 g (95%) of a yellow solid was obtained. ¹H NMR (400 MHz, CHLOROFORM-D) δ 0.92 (t, $J=7.03$ Hz, 3 H), 1.51 - 1.69 (m,


4 H), 1.82 (s, 6 H), 2.05 - 2.16 (m, 2 H), 2.27 - 2.44 (m, 1 H), 3.37 (t, $J=11.03$ Hz, 2 H), 4.04 (dd, $J=11.23, 2.64$ Hz, 2 H), 4.51 (dd, $J=3.32$ Hz, 2 H), 7.86 - 7.97 (m, $J=7.62$ Hz, 1 H), 8.12 (d, $J=7.03$ Hz, 1 H), 8.99 (s, 1 H); MS (ESI) $(M+H)^+ = 384.94$.

5 Example 41

1-{[2-(1,1-Dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-methyl-1H-pyrazole-4-carboxamide




Step A: 1-{[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-methyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 24, Step A, using methylamine hydrochloride (24 mg, 0.36 mmol), DIPEA (104 μ L, 77 mg, 0.59 mmol), 1-{[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrazole-4-carboxylic acid (0.18 mmol) (see following Steps B and C for preparation) and HATU (109 mg, 0.29 mmol) in DMF (3 mL). The crude product was purified by MPLC using Hex/EtOAc (1:9) on silica gel to give 78 mg (92%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 0.78 (t, $J=7.52$ Hz, 3 H), 1.40 - 1.57 (m, 4 H), 1.59 (s, 6 H), 1.95 (q, $J=7.29$ Hz, 2 H), 2.21 - 2.37 (m, 1 H), 2.82 (s, 3 H), 3.25 - 3.35 (m, 2 H), 3.85 - 3.94 (m, 2 H), 4.42 (d, $J=7.42$ Hz, 2 H), 7.94 (d, $J=9.0$ Hz, 1 H), 8.00 (dd, $J=8.8, 1.7$ Hz, 1 H), 8.02 (d, $J=0.59$ Hz, 1 H), 8.35 (d, $J=1.56$ Hz, 1 H), 8.72 (d, $J=0.59$ Hz, 1 H); MS (ESI) $(M+H)^+ = 474.0$; Anal.


Calcd for $C_{23}H_{31}N_5O_4S + 1.10 \text{ TFA} + 0.4 \text{ H}_2\text{O}$ (606.23): C, 49.93; H, 5.47; N, 11.55; Found: C, 49.95; H, 5.44; N, 11.48.

Step B: 1-[[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl]-1H-pyrazole-4-carbaldehyde



Following the same procedure in Example 1, Step A, using 2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (2.12 g, 5.5 mmol), 1H-pyrazole-4-carbaldehyde (0.48 g, 5.0 mmol) and DMAP (0.73 g, 6.0 mmol) in MeCN (20 mL). The crude product was purified by MPLC using $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:1) on silica gel to give 0.53 g (24%) of a white solid as the title compound. MS (ESI) $(M+H)^+ = 444.92$.


Step C: 1-[[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl]-1H-pyrazole-4-carboxylic acid



Oxone (534 mg, 0.869 mmol) was added to a solution of 1-[[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl]-1H-pyrazole-4-carbaldehyde (322 mg, 0.724 mmol) in DMF (8 mL). The resulting mixture was stirred overnight at room temperature and used directly for step A. MS (ESI) $(M+H)^+ = 460.92$.

Example 42


1-{[2-(1,1-Dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-ethyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 24, Step A, using ethylamine hydrochloride (29 mg, 0.36 mmol), DIPEA (104 μ L, 77 mg, 0.59 mmol), 1-{[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrazole-4-carboxylic acid (0.18 mmol) and HATU (109 mg, 0.29 mmol) in DMF (3 mL). The crude product was purified by MPLC using Hex/EtOAc (1:4) on silica gel to give 53 mg (61%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 0.77 (t, $J=7.42$ Hz, 3 H), 1.15 (t, $J=7.32$ Hz, 3 H), 1.39 - 1.57 (m, 4 H), 1.58 (s, 6 H), 1.94 (q, $J=7.68$ Hz, 2 H), 2.19 - 2.37 (m, 1 H), 3.24 - 3.40 (m, 4 H), 3.83 - 3.94 (m, 2 H), 4.41 (d, $J=7.23$ Hz, 2 H), 7.92 (d, $J=8.8$ Hz, 1 H), 7.99 (dd, $J=8.8, 1.4$ Hz, 1 H), 8.04 (s, 1 H), 8.34 (d, $J=1.17$ Hz, 1 H), 8.74 (s, 1 H).; MS (ESI) $(\text{M}+\text{H})^+ = 488.0$; Anal. Calcd for $\text{C}_{24}\text{H}_{33}\text{N}_5\text{O}_4\text{S}+0.9 \text{ TFA}+0.3 \text{ H}_2\text{O}$ (595.65): C, 52.02; H, 5.84; N, 11.76; Found: C, 52.01; H, 5.66; N, 11.91.

Example 43

N-Cyclopropyl-1-{[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrazole-4-carboxamide




Following the same procedure in Example 24, Step A, using cyclopropylamine (21 mg, 25 μ L, 0.36 mmol), DIPEA (104 μ L, 77 mg, 0.59 mmol), 1-{[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrazole-4-carboxylic acid (0.18

mmol) and HATU (109 mg, 0.29 mmol) in DMF (3 mL). The crude product was purified by MPLC using Hex/EtOAc (1:4) on silica gel to give 38 mg (42%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.54 - 0.61 (m, 2 H), 0.74 - 0.82 (m, 5 H), 1.42 - 1.58 (m, 4 H), 1.60 (s, 6 H), 1.96 (q, J=7.55 Hz, 2 H), 2.22 - 2.36 (m, 1 H), 2.73 - 2.80 (m, 1 H), 3.26 - 3.36 (m, 2 H), 3.86 - 3.95 (m, 2 H), 4.42 (d, J=7.42 Hz, 2 H), 7.92 (d, J=8.8 Hz, 1 H), 7.98 (dd, J=8.8, 1.8 Hz, 1 H), 8.05 (s, 1 H), 8.34 (d, J=1.76 Hz, 1 H), 8.76 (s, 1 H); MS (ESI) (M+H)⁺ = 500.0; Anal. Calcd for C₂₅H₃₃N₅O₄S+0.6 TFA+ 1.0 H₂O (586.07): C, 53.70; H, 6.12; N, 11.95; Found: C, 53.65; H, 5.98; N, 12.02.

Example 44


1-{[2-(1,1-Dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-isopropyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 24, Step A, using isopropylamine (21 mg, 31 uL, 0.36 mmol), DIPEA (104 uL, 77 mg, 0.59 mmol), 1-{[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrazole-4-carboxylic acid (0.18 mmol) and HATU (109 mg, 0.29 mmol) in DMF (3 mL). The crude product was purified by MPLC using Hex/EtOAc (1:2) on silica gel to give 67 mg (74%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.79 (t, J=7.42 Hz, 3 H), 1.20 (d, J=6.64 Hz, 6 H), 1.42 - 1.58 (m, 4 H), 1.61 (s, 6 H), 1.97 (q, J=7.42 Hz, 2 H), 2.22 - 2.41 (m, 1 H), 3.26 - 3.37 (m, 2 H), 3.87 - 3.96 (m, 2 H), 4.06 - 4.19 (m, 1 H), 4.43 (d, J=7.62 Hz, 2 H), 7.95 (d, J=8.8 Hz, 1 H), 7.98 - 8.03 (dd, J=9.0, 2.0 Hz, 1 H), 8.07 (s, 1 H), 8.36 (d, J=1.76 Hz, 1 H), 8.79 (s, 1 H); MS (ESI) (M+H)⁺ = 502.0; Anal. Calcd for C₂₅H₃₅N₅O₄S+1.0 TFA+ 0.6 H₂O (626.48): C, 51.76; H, 5.99; N, 11.18; Found: C, 51.77; H, 5.96; N, 11.27.

Example 45

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-1H-pyrazole-4-carboxamide




Following the same procedure in Example 24, Step A, using DIPEA (105 μ L, 78 mg, 0.60 mmol), 1-{{2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-1H-pyrazole-4-carboxylic acid (0.20 mmol), HATU (114 mg, 0.30 mmol) and saturated ammonia in DMF (5 mL). The crude product was purified by MPLC using $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (20:1) on silica gel to give 17 mg (18%) of a white solid as the title compound.

^1H NMR (400 MHz, METHANOL- D_4) δ 0.78 (t, $J=7.52$ Hz, 3 H), 1.41 - 1.57 (m, 4 H), 1.59 (s, 6 H), 1.95 (q, $J=7.42$ Hz, 2 H), 2.20 - 2.37 (m, 1 H), 3.22 - 3.38 (m, 2 H), 3.90 (dd, $J=11.82$, 3.22 Hz, 2 H), 4.42 (d, $J=7.42$ Hz, 2 H), 7.94 (d, $J=8.8$ Hz, 1 H), 8.01 (dd, $J=8.8$, 1.8 Hz, 1 H), 8.05 (s, 1 H), 8.36 (d, $J=1.56$ Hz, 1 H), 8.79 (d, $J=0.59$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 460.3$.

Example 46

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-(2-fluoroethyl)-1H-pyrazole-4-carboxamide




Following the procedure of example 24, step A, using DIPEA (118 μ L, 88 mg, 0.68 mmol), 1-{{2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-1H-pyrazole-4-carboxylic acid (0.22 mmol), HATU (94 mg, 0.25 mmol) and 2-


fluoroethylamine hydrochloride (48 mg, 0.45 mmol) in DMF (5 mL). The crude product was purified by reversed-phase HPLC using 10-90% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 73 mg (52%); ¹H NMR (400 MHz, CDCl₃) δ 0.82 (t, *J*=7.52 Hz, 3 H), 1.40 - 1.70 (m, 10 H), 1.84 - 2.01 (m, 2 H), 2.15 - 2.34 (m, 1 H), 3.31 (td, *J*=11.18, 2.44 Hz, 2 H), 3.65 (q, *J*=4.95 Hz, 1 H), 3.72 (q, *J*=5.01 Hz, 1 H), 4.00 (d, *J*=11.13 Hz, 2 H), 4.22 - 4.38 (m, 2 H), 4.54 (dt, *J*=47.31, 4.76 Hz, 2 H), 7.13 (t, *J*=5.57 Hz, 1 H), 7.49 - 7.64 (m, 1 H), 7.92 - 8.05 (m, 2 H), 8.50 - 8.61 (m, 2 H); MS (ESI) (*M*+H)⁺ 506.2.

Example 47

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrrole-3-carboxamide



Step A: 1-{{2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrrole-3-carboxylic acid




Following the same procedure in Example 24, Step A, using DIPEA (105 uL, 78 mg, 0.60 mmol), 1-{{2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrrole-3-carboxylic acid (0.20 mmol) (see following Steps B and C for preparation), HATU (114 mg, 0.30 mmol) and saturated ammonia in DMF (5 mL). The crude product was purified by reversed HPLC using CH₃CN/H₂O (30-60%) to give 52 mg (45%) of a white solid as the title compound. ¹H NMR (400 MHz, CD₃OD) δ 0.78 (t, *J*=7.52 Hz, 3 H),

1.41 - 1.57 (m, 4 H), 1.59 (s, 6 H), 1.95 (q, $J=7.42$ Hz, 2 H), 2.20 - 2.37 (m, 1 H), 3.22 - 3.38 (m, 2 H), 3.90 (dd, $J=11.82, 3.22$ Hz, 2 H), 4.42 (d, $J=7.42$ Hz, 2 H), 7.94 (d, $J=8.8$ Hz, 1 H), 8.01 (dd, $J=8.8, 1.8$ Hz, 1 H), 8.05 (s, 1 H), 8.36 (d, $J=1.56$ Hz, 1 H), 8.79 (d, $J=0.59$ Hz, 1 H); MS (ESI) $(M+H)^+ = 460.3$.


5

Step B: 1-[[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl]-1H-pyrrole-3-carbaldehyde



Following the same procedure in Example 29, using 2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (0.66 g, 1.7 mmol), 1H-pyrrole-3-carbaldehyde (0.14 g, 1.4 mmol) and sodium hydride (0.29 g, 60%, 7.2 mmol) in THF (15 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 0.45 g (71%) of a white solid as the title compound. MS (ESI) $(M+H)^+ = 443.93$


Step C: 1-[[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl]-1H-pyrrole-3-carboxylic acid




Oxone (148 mg, 0.24 mmol) was added to a solution of 1-[[2-(1,1-dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl]-1H-pyrrole-3-carbaldehyde (89 mg, 0.20 mmol) in DMF (8 mL). The resulting mixture was stirred overnight at room temperature and used directly for step A. MS (ESI) $(M+H)^+ = 460.06$.

Example 48

1-{[2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-methyl-1*H*-pyrrole-3-carboxamide




Step A: 1-{[2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-methyl-1*H*-pyrrole-3-carboxamide



Following the same procedure in Example 29, using *N*-methyl-1*H*-pyrrole-3-carboxamide (57 mg, 0.46 mmol) (see following step B for preparation), sodium hydride (110 mg, 60%, 2.76 mmol), 2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (352 mg, 0.92 mmol) in THF (10 mL). The crude product was purified by MPLC using EtOAc on silica gel to give 134 mg (62%) of a white solid as the title compound.

¹H NMR (400 MHz, METHANOL-D₄) δ 0.77 (t, J=7.42 Hz, 3 H), 1.40 - 1.56 (m, 4 H), 1.59 (s, 6 H), 1.94 (q, J=7.42 Hz, 2 H), 2.19 - 2.37 (m, 1 H), 2.79 (s, 3 H), 3.24 - 3.36 (m, 2 H), 3.84 - 3.94 (m, 2 H), 4.41 (d, J=7.62 Hz, 2 H), 6.63 (dd, J=3.32, 1.56 Hz, 1 H), 7.29 (dd, J=3.32, 2.34 Hz, 1 H), 7.78 (dd, J=2.15, 1.76 Hz, 1 H), 7.88 - 7.92 (m, 1 H), 7.92 - 7.98 (m, 1 H), 8.26 (dd, J=1.56, 0.59 Hz, 1 H); MS (ESI) (M+H)⁺ = 473.0; Anal. Calcd for C₂₄H₃₂N₄O₄S+1.0 TFA (586.63): C, 53.23; H, 5.67; N, 9.55; Found: C, 53.28; H, 5.77; N, 9.42.


Step B: *N*-methyl-1*H*-pyrrole-3-carboxamide



DIPEA (284 mg, 381 μ L, 2.2 mmol) was added to a solution of 1*H*-pyrrole-3-carboxylic acid (111 g, 1.0 mmol) and methylamine hydrochloride (222 mg, 3.3 mmol) in DMF (10 mL) at 0 °C. Stirring for 20 min, HATU (570 g, 1.5 mmol) was added at 0 °C. The reaction mixture was stirred overnight at room temperature, diluted with EtOAc (100 mL), washed with H₂O (3x10 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using EtOAc on silica gel. Yield: 57 mg (46%). ¹H NMR (400 MHz, CHLOROFORM-D) δ 2.89 (s, 3 H), 5.89 (s, 1 H), 6.36 - 6.44 (m, 1 H), 6.75 - 6.79 (m, 1 H), 7.34 - 7.40 (m, 1 H).

Example 49

1-[[2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-*N*-ethyl-1*H*-pyrrole-3-carboxamide




Following the same procedure in Example 29, using *N*-ethyl-1*H*-pyrrole-3-carboxamide (166 mg, 1.2 mmol) (see the step B in example 31 for preparation), sodium hydride (240 mg, 60%, 6.0 mmol) and 2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (385 mg, 1.0 mmol) in THF (20 mL). The crude product was purified by MPLC using EtOAc on silica gel to give 195 mg (40%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.78 (t, *J*=7.42 Hz, 3 H), 1.13 (t, *J*=7.23 Hz, 3 H), 1.41 - 1.56 (m, 4 H), 1.59 (s, 6 H), 1.95 (q, *J*=7.49 Hz, 2 H), 2.21 - 2.35 (m, 1 H), 3.24 - 3.34 (m, 4 H), 3.85 - 3.94 (m, 2 H), 4.42 (d, *J*=7.62 Hz, 2 H), 6.65 (dd, *J*=3.32, 1.76 Hz, 1 H), 7.29 (dd, *J*=3.32, 2.34 Hz, 1 H), 7.78 - 7.82 (m, 1 H), 7.92 (d, *J*=8.8 Hz, 1 H), 7.96 (dd, *J*=8.8, 1.8 Hz, 1 H), 8.27 (d, *J*=1.56 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 487.0; Anal. Calcd for

$C_{25}H_{34}N_4O_4S + 1.0 \text{ TFA} + 0.1 \text{ H}_2\text{O}$ (602.46): C, 53.83; H, 5.89; N, 9.30; Found: C, 53.79; H, 6.00; N, 9.19.

Example 50


5 ***N*-Cyclopropyl-1-{[2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxamide**




Following the same procedure in Example 29, using *N*-cyclopropyl-1*H*-pyrrole-3-carboxamide
 10 (49 mg, 0.33 mmol) (see the step B in example 32 for preparation), sodium hydride (110 mg, 60%, 2.75 mmol) and 2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (354 mg, 0.92 mmol) in THF (10 mL). The crude product was purified by MPLC using Hex/EtOAc (3:7) on silica gel to give 137 mg (83%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 0.50 - 0.57 (m, 2 H),
 15 0.69 - 0.75 (m, 2 H), 0.78 (t, $J=7.42$ Hz, 3 H), 1.42 - 1.56 (m, 4 H), 1.60 (s, 6 H), 1.95 (q, $J=7.62$ Hz, 2 H), 2.21 - 2.37 (m, 1 H), 2.67 - 2.75 (m, 1 H), 3.23 - 3.35 (m, 2 H), 3.84 - 3.93 (m, 2 H), 4.43 (d, $J=7.42$ Hz, 2 H), 6.65 (dd, $J=3.32, 1.76$ Hz, 1 H), 7.28 (dd, $J=3.32, 2.15$ Hz, 1 H), 7.77 - 7.84 (m, 1 H), 7.90 - 8.01 (m, 2 H), 8.26 (d, $J=0.78$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ =$
 20 499.0; Anal. Calcd for $C_{26}H_{34}N_4O_4S + 1.2 \text{ TFA}$ (635.48): C, 53.68; H, 5.58; N, 8.82; Found: C, 53.65; H, 5.61; N, 8.56.

Example 51

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-isopropyl-1*H*-pyrrole-3-carboxamide




Step A: 1-{{2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-isopropyl-1*H*-pyrrole-3-carboxamide



Following the same procedure in Example 29, using *N*-isopropyl-1*H*-pyrrole-3-carboxamide (76 mg, 0.50 mmol) (see following step B for preparation), sodium hydride (159 mg, 60%, 3.97 mmol) and 2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (535 mg, 1.39 mmol) in THF (15 mL). The crude product was purified by MPLC using Hex/EtOAc (3:7) on silica gel to give 158 mg (64%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.77 (t, J=7.42 Hz, 3 H), 1.15 (d, J=6.64 Hz, 6 H), 1.39 - 1.56 (m, 4 H), 1.59 (s, 6 H), 1.94 (q, J=7.42 Hz, 2 H), 2.19 - 2.38 (m, 1 H), 3.23 - 3.35 (m, 2 H), 3.83 - 3.96 (m, 2 H), 4.01 - 4.15 (m, 1 H), 4.41 (d, J=7.62 Hz, 2 H), 6.67 (dd, J=3.32, 1.56 Hz, 1 H), 7.28 (dd, J=3.12, 2.34 Hz, 1 H), 7.79 - 7.86 (m, 1 H), 7.88 - 7.99 (m, 2 H) 8.26 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 501.3; Anal. Calcd for C₂₆H₃₆N₄O₄S+1.2 TFA+0.1 H₂O (615.50): C, 55.33; H, 6.11; N, 9.09; Found: C, 55.38; H, 6.16; N, 9.04.

Step B: *N*-isopropyl-1*H*-pyrrole-3-carboxamide




DIPEA (284 mg, 381 μ L, 2.2 mmol) was added to a solution of 1*H*-pyrrole-3-carboxylic acid (111 g, 1.0 mmol) and isopropylamine (118 mg, 170 μ L, 2.0 mmol) in DMF (10 mL) at 0 °C.

5 Stirring for 20 min, HATU (570 g, 1.5 mmol) was added at 0 °C. The reaction mixture was stirred overnight at room temperature, diluted with EtOAc (100 mL), washed with H₂O (3x10 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using EtOAc on silica gel. Yield: 80 mg (52%). ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.19 (d, *J*=6.64 Hz, 6 H), 3.95 - 4.31 (m, 1 H), 6.52 (dd, *J*=2.93, 1.56 Hz, 1 H), 6.70 (dd, *J*=2.93, 2.15 Hz, 1 H), 7.31 (t, *J*=1.76 Hz, 1 H), 7.58 (s, 1 H).

Example 52

1-([2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)-*N*-(2-fluoroethyl)-1*H*-pyrrole-3-carboxamide




Following the procedure of example 24, step A, using 1-([2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)-1*H*-pyrrole-3-carboxylic acid (0.22 mmol), 2-fluoroethylamine hydrochloride (48 mg, 0.45 mmol), DIPEA (118 μ L, 88 mg, 0.68 mmol) and HATU (94 mg, 0.25 mmol) in DMF (5 mL). The crude product was purified by reversed-phase HPLC using 10-90% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 63 mg (45%); ¹H NMR (400 MHz, CDCl₃) δ 0.84 (t, *J*=7.52 Hz, 3 H), 1.44 - 1.60 (m, 4 H), 1.64 (s, 6 H), 1.95 (q, *J*=7.49 Hz, 2


H), 2.15 - 2.35 (m, 1 H), 3.24 - 3.42 (m, 2 H), 3.64 (q, $J=5.14$ Hz, 1 H), 3.70 (q, $J=5.01$ Hz, 1 H), 3.94 - 4.09 (m, 2 H), 4.32 (d, $J=7.23$ Hz, 2 H), 4.52 (dt, $J=47.21, 4.91$ Hz, 2 H), 6.57 (dd, $J=3.32, 1.56$ Hz, 1 H), 7.01 (t, $J=5.47$ Hz, 1 H), 7.13 (dd, $J=3.22, 2.25$ Hz, 1 H), 7.57 (d, $J=8.79$ Hz, 1 H), 7.73 (t, $J=1.86$ Hz, 1 H), 7.92 (dd, $J=8.69, 1.66$ Hz, 1 H), 8.58 (d, $J=1.37$ Hz, 1 H).; MS (ESI) $(M+H)^+ = 505.3$.

Example 53

1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-methyl-1H-pyrazole-4-carboxamide




Step A. 1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-methyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 24, Step A, using HATU (37 mg, 0.09 mmol), methylamine in THF (0.07 mL, 2M, 0.14 mmol), DIPEA (0.02 mL, 0.10 mmol) and 1-{{2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-1H-pyrazole-4-carboxylic acid (40 mg, 0.09 mmol) (see following step B for preparation) in DMF (5mL). The crude product was purified by MPLC on silica gel using EtOAc/DCM (1:1) to provide the title

compound as a white solid. The product was converted to its TFA salt. Yield: 15 mg (29%); ^1H NMR (400 MHz, CD_3OD) δ 1.38 - 1.46 (m, 2 H), 1.46 - 1.54 (m, 2 H), 1.54 - 1.59 (s, 9 H), 2.22 - 2.36 (m, 1 H), 2.83 (s, 3 H), 3.25 - 3.35 (m, 2 H), 3.89 (dd, $J=11.43, 3.61$ Hz, 2 H), 4.36 (d, $J=7.42$ Hz, 2 H), 7.79 (d, $J=8.59$ Hz, 1 H), 7.90 (dd, $J=8.69, 1.86$ Hz, 1 H), 8.01 (s, 1 H), 8.29 (d, $J=1.95$ Hz, 1 H), 8.72 (s, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 459.8$; Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{N}_5\text{O}_4\text{S} + 0.1 \text{ H}_2\text{O}$: C, 57.27; H, 6.38; N, 15.18. Found: C, 57.49; H, 6.55; N, 14.34.


Step B: 1- $\{[2\text{-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}\}$ -1H-pyrazole-4-carboxylic acid



Oxone (596 mg, 0.97 mmol) was added to a solution of 1- $\{[2\text{-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}\}$ -1H-pyrazole-4-carbaldehyde (380 mg, 0.88 mmol) (see example 23 for preparation) in DMF (15 mL). The resulting mixture was stirred overnight at room temperature and the solvent was concentrated. The residue was dissolved in DCM, washed with 10% HCl solution and dried over anhydrous Na_2SO_4 . The solvent was concentrated to provide the title compound as white solid Yield: 330 mg (74%); MS (ESI) $(\text{M}+\text{H})^+ = 447.09$.

Example 54


1- $\{[2\text{-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}\}$ -N-propyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 53, Step A, using n-propylamine (8 mg, 0.13 mmol), HATU (37 mg, 0.09 mmol), DIPEA (0.02 mL, 0.10 mmol) and 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrazole-4-carboxylic acid (40 mg, 0.09 mmol) in DMF (5mL). The crude product was purified by MPLC on silica gel using EtOAc/DCM (1:1) to provide the title compound as a white solid. The product was converted to its TFA salt. Yield: 32 mg (59%); ¹H NMR (400 MHz, CD₃OD) δ 0.93 (t, J=7.52 Hz, 3 H), 1.43 - 1.52 (m, 2 H), 1.52 - 1.62 (m, 4 H), 1.64 (s, 9 H), 2.25 - 2.37 (m, 1 H), 3.28 - 3.36 (m, 4 H), 3.91 (dd, J=11.43, 3.22 Hz, 2 H), 4.48 (d, J=7.62 Hz, 2 H), 7.99 - 8.11 (m, 3 H), 8.39 (d, J=1.37 Hz, 1 H), 8.77 (s, 1 H); MS (ESI) (M+H)⁺ = 487.8; Anal. Calcd for C₂₄H₃₃N₅O₄S + 1.7 TFA + 1.8 H₂O: C, 46.10; H, 5.41; N, 9.81. Found: C, 46.15; H, 5.56; N, 9.48.

Example 55

1-[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-N-(cyclopropylmethyl)-1*H*-pyrazole-4-carboxamide




Following the same procedure in Example 53, Step A, step A, using (cyclopropylmethyl)amine (10 mg, 0.13 mmol), HATU (37 mg, 0.09 mmol), DIPEA (0.02 mL, 0.10 mmol) and 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-1*H*-pyrazole-4-

carboxylic acid (40 mg, 0.09 mmol) in DMF (5mL). The crude product was purified by MPLC on silica gel using EtOAc/DCM (1:1) to provide the title compound as a white solid. The product was converted to its TFA salt. Yield: 28 mg (50%); ^1H NMR (400 MHz, CD_3OD) δ 0.17 - 0.27 (m, 2 H), 0.45 - 0.54 (m, 2 H), 0.98 - 1.07 (m, 1 H), 1.43 - 1.52 (m, 3 H), 1.55 (dd, $J=12.60, 3.81$ Hz, 1 H), 1.62 (s, 9 H), 2.26 - 2.38 (m, 1 H), 3.15 (d, $J=7.03$ Hz, 2 H), 3.27 - 3.36 (m, 2 H), 3.90 (dd, $J=11.03, 3.61$ Hz, 2 H), 4.45 (d, $J=7.62$ Hz, 2 H), 7.93 - 8.04 (m, 2 H), 8.07 (s, 1 H), 8.36 (d, $J=1.37$ Hz, 1 H), 8.78 (s, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 499.8$; Anal. Calcd for $\text{C}_{25}\text{H}_{33}\text{N}_5\text{O}_4\text{S} + 1.6 \text{ TFA} + 4.5 \text{ H}_2\text{O}$: C, 44.38; H, 5.76; N, 9.18. Found: C, 44.45; H, 5.88; N, 8.93.

Example 56

1-{[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-(cyclobutylmethyl)-1H-pyrazole-4-carboxamide




Following the same procedure in example 53, step A, using (cyclobutylmethyl)amine (12 mg, 0.13 mmol), HATU (37 mg, 0.09 mmol), DIPEA (0.02 mL, 0.10 mmol) and 1-{[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrazole-4-carboxylic acid (40 mg, 0.09 mmol) in DMF (5mL). The crude product was purified by MPLC on silica gel using EtOAc/DCM (1:1) to provide the title compound as a white solid. The product was converted to its TFA salt. Yield: 27 mg (48%); ^1H NMR (400 MHz, CD_3OD) δ 1.43 - 1.51 (m, 3 H), 1.55 (dd, $J=12.30, 3.91$ Hz, 1 H), 1.61 (s, 9 H), 1.66 - 1.78 (m, 2 H), 1.81 - 1.93 (m, 2 H), 1.99 - 2.10 (m, 2 H), 2.26 - 2.37 (m, 1 H), 2.48 - 2.59 (m, 1 H), 3.26 - 3.36 (m, 4 H), 3.90 (dd, $J=11.13, 3.71$ Hz, 2 H), 4.45 (d, $J=7.42$ Hz, 2 H), 7.94 - 8.04 (m, 2 H), 8.05 (d, $J=0.78$ Hz, 1 H), 8.36 (d, $J=1.37$ Hz, 1 H), 8.76 (s, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 513.7$; Anal. Calcd for

$C_{26}H_{35}N_5O_4S + 1.8 \text{ TFA} + 2.4 \text{ H}_2\text{O}$: C, 46.65; H, 5.50; N, 9.19. Found: C, 46.74; H, 5.61; N, 8.97.

Example 57

5 **2-tert-Butyl-5-[(3-methylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole**




Following the same procedure in Example 1, Step A, using 2-tert-Butyl-1-(tetrahydro-2H-
 10 pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol), 3-methylpiperidine (146 mg, 1.47 mmol), DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 41 mg (25%);
¹H NMR (400 MHz, CD₃OD) δ 0.88 (d, *J*=6.45 Hz, 3 H), 1.50 - 1.65 (m, 4 H), 1.64 - 1.78 (m,
 15 14 H), 1.90 - 2.00 (m, 1 H), 2.24 - 2.33 (m, 1 H), 2.33 - 2.44 (m, 1 H), 3.31 - 3.40 (m, 2.64 Hz, 2 H), 3.57 - 3.69 (m, 2 H), 3.90 - 4.00 (m, 2 H), 4.53 (d, *J*=7.42 Hz, 2 H), 7.85 (dd, *J*=8.79, 1.76 Hz, 1 H), 8.04 (d, *J*=8.79 Hz, 1 H), 8.08 (d, *J*=1.17 Hz, 1 H); MS (ESI) (*M*+H)⁺=434.0; Anal. Calcd for C₂₃H₃₅N₃O₃S + 1.3 TFA + 0.1 H₂O: C, 52.68; H, 6.30; N, 7.20. Found: C, 52.65; H, 6.20; N, 7.23

20

Example 58


2-tert-Butyl-5-[(3-phenylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole



Following the same procedure in Example 1, step A, using 3-phenylpiperidine (238 mg, 1.47 mmol), 2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol), DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 22 mg (12%);
¹H NMR (400 MHz, CD₃OD) δ 1.41 - 1.64 (m, 5 H), 1.66 (s, 9 H), 1.68 - 1.80 (m, 1 H), 1.80 - 1.93 (m, 2 H), 2.25 - 2.44 (m, 3 H), 2.77 - 2.89 (m, 1 H), 3.35 (t, *J*=11.23 Hz, 2 H), 3.75 - 3.89 (m, 2 H), 3.94 (dd, *J*=10.94, 3.52 Hz, 2 H), 4.52 (d, *J*=7.62 Hz, 2 H), 7.13 - 7.22 (m, 3 H), 7.27 (t, *J*=7.13 Hz, 2 H), 7.84 (dd, *J*=8.79, 1.56 Hz, 1 H), 8.03 (d, *J*=8.79 Hz, 1 H), 8.07 (d, *J*=1.17 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 496.0; Anal. Calcd for C₂₈H₃₇N₃O₃S + 1.3 TFA + 0.2 H₂O: C, 56.76; H, 6.02; N, 6.49. Found: C, 56.85; H, 5.82; N, 6.08.

Example 59

2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-5-[[4-(trifluoromethyl)piperidin-1-yl]sulfonyl]-1*H*-benzimidazole




Following the same procedure in Example 1, step A, using 4-(trifluoromethyl)piperidine (225 mg, 1.47 mmol), 2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-

sulfonyl chloride (120 mg, 0.29 mmol), DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 98 mg (55%);
¹H NMR (400 MHz, CD₃OD) δ 1.49 - 1.57 (m, 4 H), 1.57 - 1.64 (m, 2 H), 1.67 (s, 9 H), 1.92
 5 (d, J=11.33 Hz, 2 H), 2.08 - 2.21 (m, 1 H), 2.38 (td, J=12.30, 2.34 Hz, 2 H), 3.35 (td, J=11.67, 2.44 Hz, 2 H), 3.85 - 3.99 (m, 4 H), 4.53 (d, J=7.42 Hz, 2 H), 7.87 (dd, J=8.79, 1.76 Hz, 1 H), 8.05 (d, J=8.79 Hz, 1 H), 8.11 (d, J=2.15 Hz, 1 H); MS (ESI) (M+H)⁺ = 487.8; Anal. Calcd for C₂₃H₃₂F₃N₃O₃S + 1.5 TFA: C, 47.42; H, 5.13; N, 6.38. Found: C, 47.42; H, 5.14; N, 6.26.

10 Example 60


2-tert-Butyl-5-[(4-methoxypiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole



15 Following the same procedure in Example 1, step A, using 4-methoxypiperidine hydrochloride (223 mg, 1.47 mmol), 2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol), DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 42 mg (25%);
 20 ¹H NMR (400 MHz, CD₃OD) δ 1.50 - 1.59 (m, 2 H), 1.59 - 1.66 (m, 3 H), 1.68 (s, 9 H), 1.82 - 1.92 (m, 2 H), 2.32 - 2.44 (m, 1 H), 2.96 - 3.06 (m, 2 H), 3.07 - 3.16 (m, 2 H), 3.18 - 3.23 (m, 3 H), 3.25 - 3.29 (m, 1 H), 3.36 (td, J=11.52, 2.73 Hz, 2 H), 3.95 (dd, J=12.01, 2.83 Hz, 2 H), 4.55 (d, J=7.42 Hz, 2 H), 7.88 (dd, J=8.79, 1.76 Hz, 1 H), 8.05 - 8.12 (m, 2 H); MS (ESI) (M+H)⁺ = 450.0; Anal. Calcd for C₂₃H₃₅N₃O₄S + 1.4 TFA + 0.2 H₂O: C, 50.56; H, 6.05; N,
 25 6.86. Found: C, 50.71; H, 6.13; N, 6.31.

Example 61


2-tert-Butyl-5-[(4,4-difluoropiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole



Following the same procedure in Example 1, step A, using 4,4-difluoropiperidine hydrochloride (231 mg, 1.47 mmol), 2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol), DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 53 mg (31%); ¹H NMR (400 MHz, CD₃OD) δ 1.49 - 1.65 (m, 4 H), 1.67 (s, 9 H), 1.99 - 2.14 (m, 4 H), 2.30 - 2.43 (m, 1 H), 3.16 - 3.26 (m, 4 H), 3.35 (td, J=11.57, 2.44 Hz, 2 H), 3.94 (dd, J=11.62, 3.03 Hz, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.89 (dd, J=8.79, 1.56 Hz, 1 H), 8.05 (d, J=8.79 Hz, 1 H), 8.12 (d, J=1.37 Hz, 1 H); MS (ESI) (M+H)⁺ = 456.0; Anal. Calcd for C₂₂H₃₁F₂N₃O₃S + 1.2 TFA + 0.8 H₂O: C, 48.30; H, 5.61; N, 6.92. Found: C, 48.33; H, 5.60; N, 6.87.

Example 62


2-tert-Butyl-5-[(3,3-difluoropiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole



Following the same procedure in Example 1, step A, using 3,3-difluoropiperidine hydrochloride (231 mg, 1.47 mmol), 2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol), DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 73 mg (43%); ¹H NMR (400 MHz, CD₃OD) δ 1.49 - 1.64 (m, 4 H), 1.67 (s, 9 H), 1.72 - 1.82 (m, 2 H), 1.82 - 1.96 (m, 2 H), 2.30 - 2.45 (m, 1 H), 3.10 - 3.17 (m, 2 H), 3.31 - 3.40 (m, 4 H), 3.94 (dd, J=11.33, 3.32 Hz, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.88 (dd, J=8.79, 1.56 Hz, 1 H), 8.05 (d, J=8.79 Hz, 1 H), 8.12 (d, J=1.56 Hz, 1 H); MS (ESI) (M+H)⁺ = 456.0; Anal. Calcd for C₂₂H₃₁F₂N₃O₃S + 1.5 TFA: C, 47.92; H, 5.23; N, 6.71. Found: C, 48.14; H, 5.37; N, 6.23.

EXAMPLE 63

2-*tert*-Butyl-5-[(2-ethylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole




Following the same procedure in Example 1, step A, using 2-ethylpiperidine (167 mg, 1.47 mmol), 2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl

chloride (120 mg, 0.29 mmol), DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 40 mg (24%);
¹H NMR (400 MHz, CD₃OD) δ 0.86 (t, J=7.42 Hz, 3 H), 1.07 - 1.21 (m, 1 H), 1.29 - 1.46 (m, 2 H), 1.46 - 1.64 (m, 6 H), 1.66 - 1.70 (m, 11 H), 2.30 - 2.44 (m, 1 H), 3.1 (m, 1 H), 3.31 - 3.40 (m, 3 H), 3.8 (m, 1 H), 3.89 - 4.02 (m, 3 H), 4.53 (d, J=7.42 Hz, 2 H), 7.92 - 7.99 (m, 1 H), 8.01 - 8.07 (m, 1 H), 8.17 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 448.0; Anal. Calcd for C₂₄H₃₇N₃O₃S + 1.6 TFA: C, 51.85; H, 6.18; N, 6.67. Found: C, 51.91; H, 5.93; N, 6.50.

Example 64

2-tert-Butyl-5-[(3-phenylpyrrolidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole




Following the same procedure in Example 1, step A, using 3-phenylpyrrolidine (217 mg, 1.47 mmol), 2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol) and DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 50 mg (28%);
¹H NMR (400 MHz, CD₃OD) δ 1.50 - 1.58 (m, 2 H), 1.61 (dd, J=12.30, 3.91 Hz, 1 H), 1.68 (s, 9 H), 1.79 - 1.91 (m, 1 H), 2.12 - 2.23 (m, 1 H), 2.33 - 2.42 (m, 1 H), 3.15 - 3.25 (m, 2 H), 3.31 - 3.43 (m, 4 H), 3.51 - 3.61 (m, 1 H), 3.70 - 3.79 (m, 1 H), 3.94 (dd, J=10.84, 3.81 Hz, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.05 - 7.11 (m, 2 H), 7.12 - 7.24 (m, 3 H), 7.91 - 7.97 (m, 1 H), 8.00 - 8.06 (m, 1 H), 8.17 (d, J=1.56 Hz, 1 H); MS (ESI) (M+H)⁺ = 482.0; Anal. Calcd for C₂₇H₃₅N₃O₃S + 1.1 TFA: C, 57.77; H, 5.99; N, 6.92. Found: C, 58.04; H, 5.81; N, 6.48.

Example 65

2-tert-Butyl-5-[[2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole

5




Following the same procedure in Example 1, step A, using 2-(methoxymethyl)pyrrolidine (170 mg, 1.47 mmol), 2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol) and DMAP (180 mg, 1.47 mmol) in MeCN (10 mL).

10 The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 53 mg (31%); ¹H NMR (400 MHz, CD₃OD) δ 1.47 - 1.58 (m, 4 H), 1.58 - 1.67 (m, 2 H), 1.68 (s, 9 H), 1.78 - 1.92 (m, 2 H), 2.29 - 2.42 (m, 1 H), 3.12 - 3.22 (m, 1 H), 3.3 (m, 1 H), 3.35 (s, 3 H), 3.37 - 3.46 (m, 3 H), 3.58 (dd, J=9.47, 3.81 Hz, 1 H), 3.71 - 3.81 (m, 1 H), 3.95 (dd, J=11.23, 3.42
15 Hz, 2 H), 4.48 - 4.57 (m, 2 H), 7.93 - 7.99 (m, 1 H), 8.01 - 8.07 (m, 1 H), 8.17 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 450.0; Anal. Calcd for C₂₃H₃₅N₃O₄S + 1.8 TFA: C, 48.65; H, 5.68; N, 6.40. Found: C, 48.61; H, 5.70; N, 6.42.

Example 66


20 **2-tert-Butyl-5-[(3,3-difluoropyrrolidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole**



Following the same procedure in Example 1, step A, using 3,3-difluoropyrrolidine hydrochloride (210 mg, 1.47 mmol), 2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol) and DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 108 mg (65%); ¹H NMR (400 MHz, CD₃OD) δ 1.46 - 1.54 (m, 2 H), 1.55 - 1.63 (m, 2 H), 1.65 (s, 9 H), 2.21 - 2.42 (m, 3 H), 3.34 (td, J=11.77, 2.44 Hz, 2 H), 3.45 (t, J=7.32 Hz, 2 H), 3.58 (t, J=12.89 Hz, 2 H), 3.94 (dd, J=10.84, 4.00 Hz, 2 H), 4.48 (d, J=7.62 Hz, 2 H), 7.87 (dd, J=8.69, 1.66 Hz, 1 H), 7.94 - 8.00 (m, 1 H), 8.15 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 442.0; Anal. Calcd for C₂₁H₂₉F₂N₃O₃S + 0.8 TFA + 0.1 H₂O: C, 50.78; H, 5.66; N, 7.86. Found: C, 50.75; H, 5.55; N, 7.42.

Example 67

2-*tert*-Butyl-5-(pyrrolidin-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole




Following the same procedure in Example 1, step A, using pyrrolidine (105 mg, 1.47 mmol), 2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (120 mg,

0.29 mmol) and DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 54 mg (35%); ¹H NMR (400 MHz, CD₃OD) δ 1.51 - 1.58 (m, 2 H), 1.58 - 1.67 (m, 2 H), 1.69 (s, 9 H), 1.71 - 1.78 (m, 4 H), 2.31 - 2.44 (m, 1 H), 3.22 - 3.28 (m, 4 H), 3.35 (td, J=11.57, 2.64 Hz, 2 H), 3.90 - 3.99 (m, 2 H), 4.54 (d, J=7.42 Hz, 2 H), 7.95 (dd, J=8.79, 1.76 Hz, 1 H), 8.07 (d, J=8.79 Hz, 1 H), 8.15 (d, J=1.76 Hz, 1 H); MS (ESI) (M+H)⁺ = 406.0; Anal. Calcd for C₂₁H₃₁N₃O₃S + 0.1 MeCN: C, 48.96; H, 5.51; N, 7.49. Found: C, 49.17; H, 5.34; N, 7.13.

Example 68

5-[(3-Benzylpyrrolidin-1-yl)sulfonyl]-2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole




Following the same procedure in Example 1, step A, using 3-benzylpyrrolidine (238 mg, 1.47 mmol), 2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (120 mg, 0.29 mmol) and DMAP (180 mg, 1.47 mmol) in MeCN (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 49 mg (27%); ¹H NMR (400 MHz, CD₃OD) δ 1.40 - 1.53 (m, 3 H), 1.52 - 1.62 (m, 3 H), 1.65 (s, 9 H), 1.76 - 1.91 (m, 1 H), 2.20 - 2.40 (m, 2 H), 2.40 - 2.48 (m, 2 H), 2.66 - 2.80 (m, 1 H), 2.92 (dd, J=9.96, 7.23 Hz, 1 H), 3.19 - 3.34 (m, 2 H), 3.35 - 3.44 (m, 1 H), 3.90 (dd, J=11.43, 3.81 Hz, 2 H), 4.48 (d, J=7.42 Hz, 2 H), 6.94 - 7.05 (m, 1 H), 7.08 - 7.16 (m, 1 H), 7.16 - 7.23 (m, 2 H), 7.24 - 7.33 (m, 1 H), 7.85 (dd, J=8.79, 1.76 Hz, 1 H), 7.96 (d, J=8.79 Hz, 1 H), 8.11 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 496.0; Anal. Calcd for C₂₈H₃₇N₃O₃S + 0.9 TFA: C, 59.82; H, 6.38; N, 7.02. Found: C, 59.82; H, 6.25; N, 6.93.

Example 69


1-{[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropylpiperidine-4-carboxamide

5



Step A. 1-{[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropylpiperidine-4-carboxamide

10




HATU (45 mg, 0.11 mmol) and cyclopropylamine (10 mg, 0.16 mmol) were added to a solution of 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}piperidine-4-carboxylic acid (50 mg, 0.10 mmol) (see following steps B and C for preparation) and DIPEA (20 μ L, 0.11 mmol) in DMF (5 mL) at 0°C. The reaction mixture was stirred for 1 hr. and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-50% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 30 mg (45%); ¹H NMR (400 MHz, CD₃OD) δ 0.36 - 0.44 (m, 2 H), 0.62 - 0.70 (m, 2 H), 1.51 - 1.61 (m, 4 H), 1.61 - 1.67 (m, 2 H), 1.69 (s, 9 H), 1.71 - 1.80 (m, 3 H), 2.01 - 2.11 (m, 1 H), 2.32 - 2.39 (m, 1 H), 2.43 (td, J=11.77, 3.03 Hz, 2 H), 2.53 - 2.61 (m, 1 H), 3.35 (td, J=11.52, 2.73 Hz, 2 H), 3.73 - 3.81 (m, 2 H), 3.94 (dd,

20


$J=10.84, 3.22$ Hz, 2 H), 4.55 (d, $J=7.62$ Hz, 2 H), 7.88 (dd, $J=8.79, 1.76$ Hz, 1 H), 8.05 - 8.12 (m, 2 H); MS (ESI) $(M+H)^+ = 502.8$; Anal. Calcd for $C_{26}H_{38}N_4O_4S + 2.0$ TFA + 0.8 H_2O : C, 48.36; H, 5.63; N, 7.52. Found: C, 48.37; H, 5.65; N, 7.32.

5 **Step B. methyl 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}piperidine-4-carboxylate**



2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (400
 10 mg, 0.98 mmol) was added to a solution of methyl piperidine-4-carboxylate (703 mg, 4.90 mmol) and DMAP (600 mg, 4.90 mmol) in MeCN (50 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The product was purified by MPLC using 50-90% EtOAc/Heptane on silica gel to provide the title compound as colorless oil. Yield: 182 mg (38%); 1H NMR (400 MHz, $CDCl_3$) δ 1.48 - 1.57 (m, 4 H), 1.59 (s, 9 H), 1.76 - 1.89 (m, 2 H), 1.91 - 2.00 (m, 2 H), 2.17 - 2.34 (m, 2 H), 2.48 (td, $J=11.28, 2.83$
 15 Hz, 2 H), 3.27 - 3.39 (m, 2 H), 3.64 (s, 3 H), 3.65 - 3.70 (m, 1 H), 3.95 - 4.04 (m, 2 H), 4.25 (d, $J=7.42$ Hz, 2 H), 7.42 (dd, $J=8.59, 0.59$ Hz, 1 H), 7.64 (dd, $J=8.40, 1.76$ Hz, 1 H), 8.17 (dd, $J=1.66, 0.49$ Hz, 1 H); MS (ESI) $(M+H)^+ = 478.0$.


20 **Step C. 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}piperidine-4-carboxylic acid**



NaOH (0.75 mL, 2M, 1.5 mmol) was added to a solution of methyl 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]piperidine-4-carboxylate (173 mg, 0.36 mmol) in 10 mL MeOH-H₂O (1:1) at ambient temperature. The reaction mixture was stirred overnight and diluted with water (40 mL). The solvent was concentrated to 40 mL. The resulting solution was neutralized with HCl solution and the product was extracted with EtOAc and dried over anhydrous Na₂SO₄. The solvent was concentrated to provide the title compound as white solid. Yield: 60 mg (95%); MS (ESI) (M+H)⁺ = 464.0.


10 Example 70

1-[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-*N*-ethylpiperidine-3-carboxamide




15

Step A. 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]-*N*-ethylpiperidine-3-carboxamide




HATU (45 mg, 0.11 mmol) and ethylamine 2M solution in THF (80 mg, 0.16 mmol) were added to a solution of 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]piperidine-3-carboxylic acid (50 mg, 0.10 mmol) (see following steps Band C for preparation) and DIPEA (20 μ L, 0.11 mmol) in DMF (5 mL) at 0 °C. The reaction mixture was stirred for 1 h and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-50% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 46 mg (70%); ¹H NMR (400 MHz, CD₃OD) δ 1.09 (t, *J*=7.23 Hz, 3 H), 1.26 - 1.39 (m, 1 H), 1.50 - 1.58 (m, 2 H), 1.58 - 1.66 (m, 2 H), 1.68 (s, 9 H), 1.76 - 1.87 (m, 2 H), 2.23 (td, *J*=11.77, 2.83 Hz, 1 H), 2.30 - 2.42 (m, 2 H), 2.43 - 2.52 (m, 1 H), 3.16 (q, *J*=7.36 Hz, 2 H), 3.36 (td, *J*=11.57, 2.64 Hz, 2 H), 3.71 - 3.82 (m, 2 H), 3.94 (dd, *J*=11.13, 3.32 Hz, 2 H), 4.54 (d, *J*=7.42 Hz, 2 H), 7.85 (dd, *J*=8.79, 1.76 Hz, 1 H), 8.06 (d, *J*=8.79 Hz, 1 H), 8.09 (d, *J*=1.56 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 490.8; Anal. Calcd for C₂₅H₃₈N₄O₄S + 1.3 TFA + 0.3 H₂O: C, 51.45; H, 6.24; N, 8.70. Found: C, 51.41; H, 6.27; N, 8.64.

Step B. ethyl 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]piperidine-3-carboxylate



2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (400 mg, 0.98 mmol) was added to a solution of ethyl piperidine-3-carboxylate (771 mg, 4.90 mmol) and DMAP (600 mg, 4.90 mmol) in MeCN (50 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The product was purified by MPLC using 50-90% EtOAc/Heptane on silica gel to provide the title compound as colorless oil. Yield: 182 mg (38%); ¹H NMR (400 MHz, CDCl₃) δ 1.26 (t, *J*=7.13 Hz, 3 H), 1.29 - 1.38 (m, 1 H), 1.49 - 1.57 (m, 4 H), 1.59 (s, 9 H), 1.63 - 1.83 (m, 2 H), 1.91 - 2.02 (m, 1 H), 2.30 (td, *J*=11.43, 2.93 Hz, 2 H), 2.44 (t, *J*=11.13 Hz, 1 H), 2.57 - 2.69 (m, 1 H), 3.28 - 3.40 (m, 2 H), 3.65 - 3.75 (m, 1 H), 3.91 (dd, *J*=11.82, 3.81 Hz, 1 H), 3.96 - 4.05 (m, 2 H), 4.13 (q, *J*=7.03 Hz, 2 H), 4.25 (d, *J*=7.23 Hz, 2 H), 7.43 (d, *J*=8.20 Hz, 1 H), 7.64 (dd, *J*=8.59, 1.76 Hz, 1 H), 8.19 (d, *J*=1.56 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ 491.9.


Step C. 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]piperidine-3-carboxylic acid



NaOH (0.75 mL, 2*M*, 1.5 mmol) was added to a solution of ethyl 1-[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]piperidine-3-carboxylate (158 mg, 0.36 mmol) in 10 mL of MeOH-H₂O (1:1) at ambient temperature. The reaction mixture was stirred overnight and diluted with water (40 mL). The solvent was concentrated to 40 mL. The resulting solution was neutralized with HCl solution and the product was extracted with EtOAc and dried over anhydrous Na₂SO₄. The solvent was concentrated to provide the title compound as white solid. Yield: 108 mg (72%); MS (ESI) (*M*+*H*)⁺ = 464.0.

Example 71


1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-cyclopropylpiperidine-3-carboxamide




- 5 Following the same procedure in example 70 step A, using cyclopropylamine (9 mg, 0.16 mmol), HATU (45 mg, 0.11 mmol), 1-{{2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}piperidine-3-carboxylic acid (50 mg, 0.10 mmol) and DIPEA (20 μ L, 0.11 mmol) in DMF (5 mL). The crude product was purified by reverse-phase preparative HPLC using 10-50% MeCN/H₂O and lyophilized affording the title compound as the
- 10 corresponding TFA salt. Yield: 40 mg (60%); ¹H NMR (400 MHz, CD₃OD) δ 0.39 - 0.52 (m, 2 H), 0.63 - 0.74 (m, 2 H), 1.26 - 1.39 (m, 1 H), 1.50 - 1.59 (m, 3 H), 1.61 (dd, J=12.01, 4.20 Hz, 2 H), 1.68 (s, 9 H), 1.75 - 1.85 (m, 2 H), 2.22 (td, J=11.82, 2.15 Hz, 1 H), 2.34 (t, J=11.13 Hz, 1 H), 2.37 - 2.48 (m, 2 H), 2.57 - 2.65 (m, 1 H), 3.36 (td, J=11.52, 2.54 Hz, 2 H), 3.69 - 3.80 (m, 2 H), 3.95 (dd, J=11.52, 3.52 Hz, 2 H), 4.54 (d, J=7.42 Hz, 2 H), 7.86 (dd, J=8.79,
- 15 1.76 Hz, 1 H), 8.07 (d, J=8.79 Hz, 1 H), 8.09 (d, J=1.76 Hz, 1 H); MS (ESI) (M+H)⁺ = 502.8; Anal. Calcd for C₂₆H₃₈N₄O₄S + 1.6 TFA + 0.1 H₂O: C, 51.06; H, 5.84; N, 8.16. Found: C, 51.17; H, 5.97; N, 7.63.

Example 72


- 20 **1-{{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl}-N-methyl-1H-pyrazole-4-carboxamide**




Step A. 1-((2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl)sulfonyl)-N-methyl-1H-pyrazole-4-carboxamide



HATU (39 mg, 0.10 mmol) and methylamine (50 μ L, 2M in THF, 0.10 mmol) were added to a solution of 1-((2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl)sulfonyl)-1H-pyrazole-4-carboxylic acid (45 mg, 0.09 mmol) (see following steps B, C, D, E, F, G, H, I and J for preparation) and DIPEA (20 μ L, 0.11 mmol) in DMF (10 mL). The reaction mixture was stirred for 4 hrs. and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 15 mg (26%); ¹H NMR (400 MHz, CDCl₃) δ 1.44 - 1.60 (m, 3 H), 1.62 (s, 9 H), 1.64 - 1.78 (m, 3 H), 2.03 - 2.20 (m, 3 H), 2.93 (d, J=4.69 Hz, 3 H), 4.32 (d, J=7.42 Hz, 2 H), 6.73 - 6.80 (m, 1 H), 7.51 - 7.58 (m, 1 H), 7.93 (s, 1 H), 8.01 (dd, J=8.79, 1.76 Hz, 1 H), 8.49 (s, 1 H), 8.57 (d, J=1.56 Hz, 1 H); MS (ESI) (M+H)⁺ = 494.3; Anal. Calcd for C₂₃H₂₉F₂N₅O₃S + 1.0 TFA + 0.2 H₂O: C, 49.13; H, 5.01; N, 11.46. Found: C, 49.22; H, 5.00; N, 11.32.


Step B. *tert*-Butyl [(4,4-difluorocyclohexyl)methyl]carbamate

5 4-N-Boc-aminomethyl cyclohexanone (1.00 g, 4.4 mmol) was dissolved in 30 mL of DCM at 0°C. DAST (1.45 mL, 11.0 mmol) was added dropwise and the solution was stirred at rt overnight. The solution was washed with aqueous 5% KHSO₄ solution, saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash chromatography using hexane/EtOAc (3:1) on silica gel. Yield: 508 mg (46%); ¹H NMR (400 MHz, CDCl₃) δ 1.19 - 1.36 (m, 2 H), 1.44 (s, 9 H), 1.51 - 1.56 (m, 1 H), 1.59 - 1.75 (m, 2 H), 1.75 - 1.84 (m, 2 H), 2.01 - 2.16 (m, 2 H), 3.03 (t, *J*=6.54 Hz, 2 H), 4.62 (br.s, 1 H).

Step C. [(4,4-Difluorocyclohexyl)methyl]amine hydrochloride

15 *tert*-Butyl [(4,4-difluorocyclohexyl)methyl]carbamate (505 mg, 2.03 mmol) was stirred in 5 mL of 1M HCl/AcOH at rt for 2 h. The solvent was evaporated. The residue was washed with ether, filtered and dried. Yield: 330 mg (88%); ¹H NMR (400 MHz, CD₃OD) δ 1.28 - 1.40 (m, 2 H), 1.71 - 1.82 (m, 2 H), 1.84 (d, *J*=3.12 Hz, 2 H), 1.86 - 1.89 (m, 1 H), 2.03 - 2.15 (m, 2 H), 2.85 (d, *J*=7.03 Hz, 2 H).


Step D: *N*-(4-[(4,4-Difluorocyclohexyl)methyl]amino)-3-nitrophenyl)acetamide



N-(4-Fluoro-3-nitrophenyl)acetamide (1.15 g, 5.84 mmol) and [(4,4-difluorocyclohexyl)methyl]amine hydrochloride (1.30 g, 7.59 mmol) were stirred in 30 mL of EtOH containing TEA (2.40 mL, 17.5 mmol) at 80°C for 48 h. The solvent was evaporated.

The residue was dissolved in EtOAc and washed with aqueous 5% KHSO₄ solution, saturated aqueous NaHCO₃ solution, saturated aqueous NaCl solution and dried over anhydrous Na₂SO₄. The product was crystallized from EtOAc. The left over mother liquor was purified by flash chromatography on silica gel using hexane/acetone (2:1) as eluent. Yield: 1.50 g (78%); ¹H NMR (400 MHz, CDCl₃) δ 1.33 - 1.47 (m, 2 H), 1.66 - 1.77 (m, 2 H), 1.77 - 1.86 (m, 1 H), 1.89 - 1.93 (m, 1 H), 1.93 - 1.97 (m, 1 H), 2.10 - 2.17 (m, 2 H), 2.18 (s, 3 H), 3.23 (dd, *J*=6.74, 5.76 Hz, 2 H), 6.83 (d, *J*=9.37 Hz, 1 H), 7.15 (s, 1 H), 7.80 (dd, *J*=9.18, 2.54 Hz, 1 H), 8.09 (d, *J*=2.54 Hz, 2 H).

Step E: *N*-(3-Amino-4-[(4,4-difluorocyclohexyl)methyl]amino}phenyl) acetamide




N-(4-[(4,4-Difluorocyclohexyl)methyl]amino}-3-nitrophenyl)acetamide (1.48 g, 4.52 mmol) was dissolved in 50 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H₂ atmosphere (45 psi) at rt for 24 h. The solution was filtered through Celite and the solvent was evaporated. Yield: 1.32 g (98%); ¹H

NMR (400 MHz, CDCl₃) δ 1.31 - 1.43 (m, 2 H), 1.64 - 1.73 (m, 2 H), 1.74 - 1.82 (m, 1 H), 1.89 - 1.93 (m, 1 H), 1.93 - 1.96 (m, 1 H), 2.08 - 2.17 (m, 5 H), 3.00 (d, $J=6.64$ Hz, 2 H), 3.27 - 3.46 (m, 2 H), 6.55 (d, $J=8.40$ Hz, 1 H), 6.70 (dd, $J=8.40, 2.34$ Hz, 1 H), 7.01 (s, 1 H), 7.13 (d, $J=2.34$ Hz, 1 H).

5


Step F: *N*-{2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}acetamide



- 10 *N*-(3-Amino-4-[(4,4-difluorocyclohexyl)methyl]amino)phenyl acetamide (1.32 g, 4.44 mmol) was dissolved in 100 mL of DCM containing DMAP (108 mg, 0.89 mmol). Trimethylacetyl chloride (0.60 mL, 4.88 mmol) was added dropwise and the solution was stirred at rt for 2 h. The solution was washed with saturated aqueous NaHCO₃ solution, saturated aqueous NaCl solution and dried over anhydrous Na₂SO₄. Part of the product
- 15 precipitated during the washings and was filtered. The organic phase was evaporated and combined with the precipitate. The product was dissolved in 30 mL of AcOH and placed in 6 sealed tubes (5 mL/tube). Each tube was heated at 150°C in a Personal Chemistry microwaves instrument for 2.5 h. The fractions were pooled and the solvent was evaporated. The product was dissolved in EtOAc and washed with aqueous NaHCO₃ solution, saturated aqueous NaCl
- 20 solution and dried over anhydrous Na₂SO₄. The product was purified by flash chromatography on silica gel using acetone/hexanes (2:1) as eluent. Yield: 1.11 g (68%); ¹H NMR (400 MHz, CD₃OD) δ 1.40 - 1.49 (m, 2 H), 1.52 (s, 9 H), 1.60 - 1.65 (m, 2 H), 1.67 - 1.77 (m, 1 H), 1.96 - 2.06 (m, 3 H), 2.11 (s, 3 H), 2.15 - 2.23 (m, 1 H), 4.28 (d, $J=7.62$ Hz, 2 H), 7.35 - 7.39 (m, 1 H), 7.40 - 7.44 (m, 1 H), 7.85 (d, $J=1.76$ Hz, 1 H).


25

Step G: 2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-amine



N-{2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}acetamide (500 mg, 1.37 mmol) was dissolved in 10 mL of 2 *M* HCl-EtOH (1:1). The solution was divided into two sealed tubes (5 mL/tube). Each tube was heated at 120 °C in a Personal Chemistry microwaves instrument for 1h. The fractions were pooled and the solvent was evaporated. The residue was diluted with 2 *M* NaOH and extracted (3X) with EtOAc. The organic phase was washed with saturated aqueous NaCl solution and dried over anhydrous Na₂SO₄. The solvent was evaporated. Yield: 440 mg (99%); ¹H NMR (400 MHz, CDCl₃) δ 1.40 - 1.52 (m, 2 H), 1.52 - 1.54 (m, 9 H), 1.56 - 1.66 (m, 4 H), 1.68 - 1.75 (m, 2 H), 2.07 - 2.17 (m, 3 H), 4.14 (d, *J*=7.62 Hz, 2 H), 6.65 (dd, *J*=8.50, 2.25 Hz, 1 H), 7.04 - 7.09 (m, 2 H).


Step H. 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride



A solution of NaNO₂ (1.8 g, 26 mmol) in water (6 mL) was slowly added to a solution of 2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-amine (7.7g, 23 mmol) in 60 mL of 37% HCl-AcOH (2:1) at 0 °C. The reaction mixture was stirred for 1 h at 0 °C. The reaction mixture was added to a mixture of liquid SO₂ (~60 mL), CuCl₂·2H₂O (1.6 g, 9 mmol)


and AcOH (30 mL) at -20°C . The resulting mixture was allowed to warm to 0°C and stirred for 5 h. The reaction mixture was poured over ice (500 mL) while vigorously shaking. The quenched reaction mixture was stirred for 30 min at 0°C . The product was extracted with cold DCM and the organic layers were combined and dried over anhydrous Na_2SO_4 . The solvent was concentrated to provide the pure title compound as beige solid. Yield: 9.5 g (95%); MS (ESI) $(\text{M}+\text{H})^+ = 404.9$.

Step I. 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carbaldehyde



2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (0.8 g, 1.9 mmol) was added to a solution of 1*H*-pyrazole-4-carbaldehyde (0.6 g, 6.2 mmol) and DMAP (1.5 g, 12 mmol) in DCE (70 mL) at 0°C . The reaction mixture was allowed to warm to ambient temperature and stirred for 3 h. The solvent was concentrated and the product was purified by flash chromatography on silica gel using DCM/EtOAc (1:1) as eluent to provide the title compound as white solid. Yield: 0.34 g (36%); MS (ESI) $(\text{M}+\text{H})^+ = 465.0$.


Step J. 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid



Oxone® (0.60 g, 0.97 mmol) was added to a solution of 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carbaldehyde (0.41 g, 0.88 mmol) in DMF (15 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The product was recovered in DCM, washed with 10% HCl solution, brine and dried over anhydrous Na₂SO₄. The solvent was concentrated to provide the pure title compound as white solid. Yield: 0.38 g (89%); ¹H NMR (400 MHz, CDCl₃) δ 1.42 - 1.53 (m, 2 H), 1.56 (s, 9 H), 1.59 - 1.75 (m, 4 H), 2.02 - 2.20 (m, 3 H), 4.25 (d, *J*=7.42 Hz, 2 H), 7.46 (d, *J*=8.59 Hz, 1 H), 7.99 (dd, *J*=8.69, 1.86 Hz, 1 H), 8.01 - 8.08 (m, 2 H), 8.47 (d, *J*=1.56 Hz, 1 H), 8.68 (d, *J*=0.59 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 481.0.

Example 73

1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethyl-1*H*-pyrazole-4-carboxamide




Following the same procedure in example 72, step A, using ethylamine (51 uL, 2 *M* in THF, 0.10 mmol), HATU (39 mg, 0.10 mmol), 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid (45 mg, 0.09 mmol) and

DIPEA (20 μ L, 0.11 mmol) in DMF (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 20 mg (34%); ¹H NMR (400 MHz, CDCl₃) δ 1.20 (t, J=7.32 Hz, 3 H), 1.43 - 1.57 (m, 2 H), 1.59 (s, 9 H), 1.61 - 1.76 (m, 3 H), 2.03 - 2.23 (m, 2 H), 3.28 - 3.47 (m, 4 H), 4.29 (d, J=7.42 Hz, 2 H), 6.35 (t, J=5.57 Hz, 1 H), 7.49 (d, J=8.59 Hz, 1 H), 7.94 (d, J=0.59 Hz, 1 H), 7.97 (dd, J=8.69, 1.86 Hz, 1 H), 8.48 (d, J=0.59 Hz, 1 H), 8.49 (d, J=1.56 Hz, 1 H); MS (ESI) (M+H)⁺ = 507.8; Anal. Calcd for C₂₄H₃₁F₂N₅O₃S + 0.4 TFA + 0.2 H₂O: C, 53.32; H, 5.77; N, 12.54. Found: C, 53.36; H, 5.77; N, 12.53.

Example 74


1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-propyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 72, step A, using *n*-propylamine (120 μ L, 86 mg, 1.5 mmol), HATU (39 mg, 0.10 mmol), 1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-1H-pyrazole-4-carboxylic acid (45 mg, 0.09 mmol) and DIPEA (20 μ L, 0.11 mmol) in DMF (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 19 mg (31%); ¹H NMR (400 MHz, CDCl₃) δ 0.95 (t, J=7.42 Hz, 3 H), 1.5 (m, 2 H), 1.56 (s, 9 H), 1.58 - 1.76 (m, 4 H), 2.01 - 2.20 (m, 3 H), 2.31 (m, 2 H), 3.28 - 3.38 (m, 2 H), 4.25 (d, J=7.42 Hz, 2 H), 6.03 (t, J=5.66 Hz, 1 H), 7.44 (d, J=8.79 Hz, 1 H), 7.88 - 7.97 (m, 2 H), 8.42 (d, J=1.56 Hz, 1 H), 8.47 (s, 1 H); MS (ESI) (M+H)⁺ = 521.8.

Example 75


1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-cyclopropyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 72, step A, using cyclopropylamine (120 μ L, 98 mg, 1.7 mmol), HATU (39 mg, 0.10 mmol), 1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-1H-pyrazole-4-carboxylic acid (45 mg, 0.09 mmol) and DIPEA (20 μ L, 0.11 mmol) in DMF (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 20 mg (33%); ¹H NMR (400 MHz, CDCl₃) δ 0.53 - 0.64 (m, 2 H), 0.76 - 0.88 (m, 2 H), 1.38 - 1.53 (m, 2 H), 1.52 - 1.59 (m, 9 H), 1.59 - 1.77 (m, 3 H), 2.01 - 2.22 (m, 3 H), 2.73 - 2.93 (m, 2 H), 4.26 (d, J=7.42 Hz, 2 H), 6.39 (d, J=1.95 Hz, 1 H), 7.45 (d, J=8.59 Hz, 1 H), 7.85 - 7.96 (m, 2 H), 8.39 (d, J=1.56 Hz, 1 H), 8.46 (s, 1 H); MS (ESI) (M+H)⁺ = 519.8; Anal. Calcd for C₂₅H₃₁F₂N₅O₃S + 1.0 TFA + 0.1 MeCN: C, 51.23; H, 5.11; N, 11.20. Found: C, 51.37; H, 5.06; N, 11.17.

Example 76


1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-cyclobutyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 72, step A, using cyclobutylamine (120 μ L, 100 mg, 1.4 mmol), HATU (39 mg, 0.10 mmol), 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid (45 mg, 0.09 mmol) and
 5 DIPEA (20 μ L, 0.11 mmol) in DMF (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 22 mg (36%); ¹H NMR (400 MHz, CDCl₃) δ 1.40 - 1.55 (m, 2 H), 1.57 (s, 9 H), 1.60 - 1.81 (m, 4 H), 1.87 - 2.02 (m, 2 H), 2.03 - 2.22 (m, 3 H), 2.28 - 2.45 (m, 2 H), 2.68 (m, 2 H), 4.26 (d, *J*=7.42 Hz, 2 H), 4.43 - 4.58 (m, 1 H), 6.22 (d, *J*=7.62 Hz,
 10 1 H), 7.45 (d, *J*=8.79 Hz, 1 H), 7.89 - 7.96 (m, 2 H), 8.42 (d, *J*=1.76 Hz, 1 H), 8.46 (d, *J*=0.78 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 533.8; Anal. Calcd for C₂₆H₃₃F₂N₅O₃S + 0.6 TFA + 0.2 H₂O: C, 53.94; H, 5.66; N, 11.56. Found: C, 53.92; H, 5.51; N, 11.57.

Example 77


15 1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-(cyclopropylmethyl)-1*H*-pyrazole-4-carboxamide



Following the same procedure in Example 72, step A, using (cyclopropylmethyl)amine (120 uL, 98 mg, 1.4 mmol), HATU (39 mg, 0.10 mmol), 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid (45 mg, 0.09 mmol) and DIPEA (20 uL, 0.11 mmol) in DMF (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 17 mg (28%); ¹H NMR (400 MHz, CDCl₃) δ 0.20 - 0.28 (m, 2 H), 0.49 - 0.57 (m, 2 H), 0.94 - 1.07 (m, 1 H), 1.42 - 1.55 (m, 2 H), 1.57 (s, 9 H), 1.60 - 1.76 (m, 3 H), 2.02 - 2.20 (m, 3 H), 3.24 (dd, J=7.23, 5.47 Hz, 2 H), 3.32 (s, 1 H), 4.27 (d, J=7.42 Hz, 2 H), 6.29 (t, J=5.37 Hz, 1 H), 7.46 (d, J=8.40 Hz, 1 H), 7.93 (dd, J=8.69, 1.86 Hz, 1 H), 7.96 (d, J=0.78 Hz, 1 H), 8.43 (d, J=1.56 Hz, 1 H), 8.49 (d, J=0.78 Hz, 1 H); MS (ESI) (M+H)⁺ 533.8; Anal. Calcd for C₂₆H₃₃F₂N₅O₃S + 1.0 TFA: C, 51.93; H, 5.29; N, 10.81. Found: C, 51.98; H, 5.31; N, 10.81.

Example 78

1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-(cyclobutylmethyl)-1*H*-pyrazole-4-carboxamide




Following the same procedure in Example 72, step A, using (cyclobutylmethyl)amine (120 uL, 100 mg, 1.17 mmol), HATU (39 mg, 0.10 mmol), 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid (45 mg, 0.09 mmol) and DIPEA (20 uL, 0.11 mmol) in DMF (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 23 mg (37%); ¹H NMR

(400 MHz, CDCl₃) δ 1.41 - 1.54 (m, 1 H), 1.56 (s, 9 H), 1.60 - 1.77 (m, 5 H), 1.83 - 1.98 (m, 2 H), 2.00 - 2.20 (m, 5 H), 2.26 (s, 2 H), 2.45 - 2.59 (m, 1 H), 3.40 (dd, $J=7.32, 5.76$ Hz, 2 H), 4.25 (d, $J=7.62$ Hz, 2 H), 5.97 (t, $J=5.66$ Hz, 1 H), 7.44 (d, $J=8.59$ Hz, 1 H), 7.88 - 7.95 (m, 2 H), 8.41 (d, $J=1.37$ Hz, 1 H), 8.46 (d, $J=0.78$ Hz, 1 H); MS (ESI) $(M+H)^+ = 547.8$; Anal. Calcd for C₂₇H₃₅F₂N₅O₃S + 0.3 TFA + 0.2 H₂O: C, 56.62; H, 6.15; N, 11.96. Found: C, 56.71; H, 6.16; N, 11.86.

Example 79


1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-isopropyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 72, step A, using isopropylamine (120 μ L, 83 mg, 1.4 mmol), HATU (39 mg, 0.10 mmol), 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-1H-pyrazole-4-carboxylic acid (45 mg, 0.09 mmol) and DIPEA (20 μ L, 0.11 mmol) in DMF (10 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 28 mg (47%); ¹H NMR (400 MHz, CDCl₃) δ 1.22 (d, $J=6.44$ Hz, 6 H), 1.43 - 1.54 (m, 2 H), 1.57 (s, 9 H), 1.59 - 1.75 (m, 3 H), 2.03 - 2.20 (m, 3 H), 2.81 (s, 1 H), 4.16 - 4.23 (m, 1 H), 4.26 (d, $J=7.42$ Hz, 2 H), 5.89 (d, $J=7.81$ Hz, 1 H), 7.42 - 7.49 (m, 1 H), 7.89 - 7.95 (m, 2 H), 8.41 (d, $J=1.56$ Hz, 1 H), 8.46 (d, $J=0.78$ Hz, 1 H); MS (ESI) $(M+H)^+ = 521.8$; Anal. Calcd for C₂₅H₃₃F₂N₅O₃S + 0.3 TFA + 0.3 H₂O: C, 54.79; H, 6.09; N, 12.48. Found: C, 54.78; H, 6.19; N, 12.46.


Example 80

1-{[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-methylpyrrolidine-3-carboxamide



5


Step A. 1-{[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-methylpyrrolidine-3-carboxamide



- 10 HATU (70 mg, 0.18 mmol) and methylamine (0.6 mL, 2 M s in THF, 1.2 mmol) were added to a solution of 1-{[2-*tert*-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}pyrrolidine-3-carboxylic acid (75 mg, 0.16 mmol) (see following steps B and C for preparation) and DIPEA (35 μ L, 0.20 mmol) in DMF (5 mL). The reaction mixture was stirred for 4 h and the solvent was concentrated. The crude product was purified by reverse-phase
- 15 preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 25 mg (26%); ¹H NMR (400 MHz, CDCl₃) δ 1.51 - 1.66 (m, 4 H), 1.73 (s, 9 H), 1.84 - 1.96 (m, 1 H), 2.11 - 2.25 (m, 1 H), 2.25 - 2.39 (m, 1 H), 2.72 (d, J=4.49 Hz, 4 H), 3.01 - 3.14 (m, 1 H), 3.25 - 3.45 (m, 4 H), 3.85 (dd, J=10.64, 8.11 Hz, 1 H), 4.04 (d, J=11.13 Hz, 2 H), 4.41 (d, J=7.42 Hz, 2 H), 7.63 (d, J=8.59 Hz, 1 H), 7.86 (d, J=8.79


Hz, 1 H), 8.33 (s, 1 H); MS (ESI) (M+H)⁺ = 462.8; Anal. Calcd for C₂₃H₃₄N₄O₄S + 1.7 TFA + 0.2 H₂O: C, 48.04; H, 5.51; N, 8.49. Found: C, 48.01; H, 5.46; N, 8.33.

Step B. methyl 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}pyrrolidine-3-carboxylate



A suspension of 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (1.21 g, 3.26 mmol) in DCE (25 mL) was slowly added to a solution of 3-(methoxycarbonyl)pyrrolidine hydrochloride (0.46 g, 3.58 mmol) and DIPEA (5.6 mL, 32.6 mmol) in DCE (80 mL). The reaction mixture was stirred for 3 h and the solvent was concentrated. The product was purified by MPLC on silica gel using EtOAc as eluent to provide the title compound as white solid. Yield: 0.60 g (39%); ¹H NMR (400 MHz, CDCl₃) δ 1.49 - 1.56 (m, 3 H), 1.55 - 1.58 (m, 1 H), 1.59 (s, 9 H), 1.93 - 2.13 (m, 2 H), 2.20 - 2.36 (m, 1 H), 2.89 - 3.01 (m, 1 H), 3.28 - 3.41 (m, 5 H), 3.60 (s, 3 H), 3.61 - 3.66 (m, 1 H), 3.94 - 4.06 (m, 2 H), 4.25 (d, *J*=7.42 Hz, 2 H), 7.44 (dd, *J*=8.50, 0.49 Hz, 1 H), 7.72 (dd, *J*=8.59, 1.76 Hz, 1 H), 8.24 (dd, *J*=1.76, 0.59 Hz, 1 H); MS (ESI) (M+H)⁺ = 464.0.


Step C. 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}pyrrolidine-3-carboxylic acid



NaOH (2 mL, 2 M, 4.0 mmol) was added to a solution of methyl 1-([2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)pyrrolidine-3-carboxylate (570 mg, 1.22 mmol) in a 1:1 mixture of MeOH:H₂O (30 mL) at ambient temperature. The reaction mixture
 5 was stirred overnight and diluted with water (100 mL). The solvent was concentrated to 100 mL. The resulting solution was neutralized with HCl solution, the product was extracted with EtOAc and dried over anhydrous Na₂SO₄. The solvent was concentrated to provide the title compound as white solid. Yield: 480 mg (87%); MS (ESI) (M+H)⁺ = 450.1.

10 Example 81

1-([2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)-*N*-cyclopropylpyrrolidine-3-carboxamide




15 Following the same procedure in Example 80, step A, using cyclopropylamine (100 uL, 82 mg, 1.4 mmol), HATU (70 mg, 0.18 mmol), 1-([2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)pyrrolidine-3-carboxylic acid (75 mg, 0.16 mmol) and DIPEA (35 uL, 0.20 mmol) in DMF (5 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as
 20 the corresponding TFA salt. Yield: 27 mg (26%); ¹H NMR (400 MHz, CDCl₃) δ 0.39 - 0.52

(m, 2 H), 0.62 - 0.74 (m, 2 H), 1.50 - 1.67 (m, 4 H), 1.74 (s, 9 H), 1.82 - 1.95 (m, 1 H), 2.04 - 2.21 (m, 1 H), 2.26 - 2.40 (m, 1 H), 2.54 - 2.75 (m, 2 H), 3.02 - 3.14 (m, 1 H), 3.26 (t, $J=9.96$ Hz, 1 H), 3.31 - 3.46 (m, 3 H), 3.69 (dd, $J=10.35, 8.01$ Hz, 1 H), 4.03 (d, $J=11.13$ Hz, 2 H), 4.42 (d, $J=7.23$ Hz, 2 H), 6.95 (d, $J=2.73$ Hz, 1 H), 7.65 (d, $J=8.59$ Hz, 1 H), 7.79 (dd, $J=8.69, 1.27$ Hz, 1 H), 8.18 (s, 1 H); MS (ESI) $(M+H)^+ = 488.7$; Anal. Calcd for $C_{25}H_{36}N_4O_4S + 1.6$ TFA + 0.4 H_2O : C, 49.94; H, 5.71; N, 8.26. Found: C, 49.87; H, 5.70; N, 8.29.

Example 82


1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-isopropylpyrrolidine-3-carboxamide



Following the same procedure in Example 80, step A, using isopropylamine (100 μ L, 69 mg, 1.17 mmol), HATU (70 mg, 0.18 mmol), 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}pyrrolidine-3-carboxylic acid (75 mg, 0.16 mmol) and DIPEA (35 μ L, 0.20 mmol) in DMF (5 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/ H_2O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 47 mg (46%); 1H NMR (400 MHz, $CDCl_3$) δ 1.08 (dd, $J=6.44, 2.73$ Hz, 6 H), 1.53 - 1.68 (m, 4 H), 1.74 (s, 9 H), 1.84 - 1.99 (m, 1 H), 2.01 - 2.16 (m, 1 H), 2.27 - 2.42 (m, 1 H), 2.60 - 2.76 (m, 1 H), 3.04 - 3.17 (m, 1 H), 3.20 - 3.29 (m, 1 H), 3.30 - 3.45 (m, 3 H), 3.62 (dd, $J=10.25, 8.11$ Hz, 1 H), 3.88 - 4.00 (m, 1 H), 4.03 (d, $J=11.13$ Hz, 2 H), 4.43 (d, $J=7.23$ Hz, 2 H), 6.41 (d, $J=7.62$ Hz, 1 H), 7.66 (d, $J=8.79$ Hz, 1 H), 7.76 (dd, $J=8.79, 1.37$ Hz, 1 H), 8.11 (d, $J=1.17$ Hz, 1 H); MS (ESI) $(M+H)^+ = 491.0$; Anal. Calcd for $C_{25}H_{38}N_4O_4S + 2.1$ TFA: C, 48.04; H, 5.54; N, 7.67. Found: C, 48.06; H, 5.56; N, 7.60.

Example 83


1-{[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclobutylpyrrolidine-3-carboxamide




Following the same procedure in Example 80, step A, using cyclobutylamine (100 μ L, 83 mg, 1.17 mmol), HATU (70 mg, 0.18 mmol), 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}pyrrolidine-3-carboxylic acid (75 mg, 0.16 mmol) and DIPEA (35 μ L, 0.20 mmol) in DMF (5 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 72 mg (70%); ¹H NMR (400 MHz, CDCl₃) δ 1.53 - 1.63 (m, 4 H), 1.66 (dd, *J*=10.55, 7.81 Hz, 2 H), 1.74 (s, 9 H), 1.79 - 1.95 (m, 3 H), 2.02 - 2.15 (m, 1 H), 2.16 - 2.28 (m, 2 H), 2.28 - 2.40 (m, 1 H), 2.62 - 2.74 (m, 1 H), 3.05 - 3.15 (m, 1 H), 3.24 (t, *J*=9.96 Hz, 1 H), 3.29 - 3.43 (m, 3 H), 3.67 (dd, *J*=10.25, 8.11 Hz, 1 H), 4.03 (d, *J*=11.33 Hz, 2 H), 4.19 - 4.32 (m, 1 H), 4.42 (d, *J*=7.23 Hz, 2 H), 6.81 (d, *J*=7.62 Hz, 1 H), 7.64 (d, *J*=8.79 Hz, 1 H), 7.77 (dd, *J*=8.69, 1.07 Hz, 1 H), 8.17 (s, 1 H); MS (ESI) (*M*+*H*)⁺ = 503.0; Anal. Calcd for C₂₆H₃₈N₄O₄S + 1.6 TFA + 0.2 H₂O: C, 50.92; H, 5.85; N, 8.13. Found: C, 50.95; H, 5.85; N, 7.89.

Example 84

(3*S*)-1-{[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropylpiperidine-3-carboxamide




Step A. (3S)-1-([2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl)-N-cyclopropylpiperidine-3-carboxamide




HATU (198 mg, 0.52 mmol) and cyclopropylamine (30 mg, 0.52 mmol) were added to a solution of (3S)-1-([2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl)piperidine-3-carboxylic acid (220 mg, 0.47 mmol) (see following steps B and C for preparation) and DIPEA (100 μ L, 0.56 mmol) in DMF (20 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 108 mg (37%); $[\alpha]_D^{25}$ -66.0° (c = 1.28, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 0.44 - 0.59 (m, 2 H), 0.68 - 0.80 (m, 2 H), 1.37 - 1.50 (m, 1 H), 1.51 - 1.64 (m, 5 H), 1.65 - 1.82 (m, 11 H), 2.24 - 2.43 (m, 2 H), 2.53 (td, J=11.38, 2.25 Hz, 1 H), 2.62 - 2.75 (m, 2 H), 3.28 - 3.44 (m, 2 H), 3.55 (d, J=11.91 Hz, 1 H), 3.66 (dd, J=12.40, 3.22 Hz, 1 H), 3.96 - 4.10 (m, 2 H), 4.38 (d, J=7.23 Hz, 2 H), 6.63 (d, J=2.93 Hz, 1 H), 7.59 (d, J=8.79 Hz, 1 H), 7.70 (dd, J=8.69, 1.66 Hz, 1 H), 8.20 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 502.8; Anal. Calcd for C₂₆H₃₈N₄O₄S + 1.2 TFA + 0.5 H₂O Calculated: C, 52.60; H, 6.25; N, 8.64. Found: C, 52.53; H, 6.19; N, 8.63.

Step B. Ethyl (3*S*)-1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}piperidine-3-carboxylate



- 5 A suspension of 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (300 mg, 0.80 mmol) in DCE (5 mL) was slowly added to a solution of ethyl (3*S*)-piperidine-3-carboxylate (140 mg, 0.88 mmol) and DIPEA (1.4 mL, 8.0 mmol) in DCE (25 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The product was purified by MPLC on silica gel using 60-90% EtOAc/heptane as
- 10 eluent to provide the title compound as white solid. Yield: 276 mg (69%). ¹H NMR (400 MHz, CDCl₃) δ 1.26 (t, *J*=7.13 Hz, 3 H), 1.33 (td, *J*=12.21, 3.32 Hz, 1 H), 1.50 - 1.57 (m, 3 H), 1.59 (s, 9 H), 1.62 - 1.73 (m, 2 H), 1.73 - 1.83 (m, 1 H), 1.91 - 2.01 (m, 1 H), 2.30 (td, *J*=11.43, 2.93 Hz, 2 H), 2.44 (t, *J*=11.13 Hz, 1 H), 2.58 - 2.69 (m, 1 H), 3.28 - 3.40 (m, 2 H), 3.65 - 3.74 (m, 1 H), 3.91 (dd, *J*=11.43, 3.81 Hz, 1 H), 4.01 (dd, *J*=11.33, 2.93 Hz, 2 H), 4.13 (q, *J*=7.23 Hz, 2
- 15 H), 4.25 (d, *J*=7.42 Hz, 2 H), 7.43 (d, *J*=8.59 Hz, 1 H), 7.64 (dd, *J*=8.59, 1.76 Hz, 1 H), 8.19 (d, *J*=1.76 Hz, 1 H). MS (ESI) (*M*+*H*)⁺ = 492.0.


Step C. (3*S*)-1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}piperidine-3-carboxylic acid




NaOH (0.15 mL, 2M, 0.3 mmol) was added to a solution of ethyl (3*S*)-1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}piperidine-3-carboxylate (265 mg, 0.54 mmol) in a 1:1 mixture of MeOH:H₂O (10 mL) at ambient temperature. The reaction mixture was stirred overnight and diluted with water (50 mL). The solvent was concentrated to 50 mL. The resulting solution was neutralized with HCl solution, the product was extracted with EtOAc and dried over anhydrous Na₂SO₄. The solvent was concentrated to provide the title compound as white solid. Yield: 220 mg (88%); MS (ESI) (M+H)⁺ = 464.1.

Example 85

(3*R*)-1-{{2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-cyclopropylpiperidine-3-carboxamide




Step A. (3*R*)-1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-cyclopropylpiperidine-3-carboxamide



HATU (212 mg, 0.56 mmol) and cyclopropylamine (32 mg, 0.56 mmol) were added to a solution of (3*R*)-1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}piperidine-3-carboxylic acid (236 mg, 0.51 mmol) (see following steps B and C for preparation) and DIPEA (105 μ L, 0.61 mmol) in DMF (20 mL). The reaction mixture was


stirred overnight at ambient temperature and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 164 mg (52%); $[\alpha]_D^{25} +64.9^\circ$ ($c = 1.34$, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 0.45 - 0.58 (m, 2 H), 0.67 - 0.82 (m, 2 H), 1.50 - 1.64 (m, 5 H), 1.63 - 1.84 (m, 12 H), 2.25 - 2.46 (m, 2 H), 2.55 (t, $J=9.67$ Hz, 1 H), 2.62 - 2.78 (m, 2 H), 3.26 - 3.44 (m, 2 H), 3.50 - 3.61 (m, 1 H), 3.62 - 3.74 (m, 1 H), 3.95 - 4.11 (m, 2 H), 4.37 (d, $J=7.03$ Hz, 2 H), 7.59 (d, $J=8.98$ Hz, 1 H), 7.68 - 7.79 (m, 1 H), 8.16 - 8.28 (m, 1 H); MS (ESI) ($M+H$)⁺ = 502.8; Anal. Calcd for C₂₆H₃₈N₄O₄S + 1.2 TFA + 0.7 H₂O: C, 52.31; H, 6.28; N, 8.59. Found: C, 52.24; H, 6.23; N, 8.59.

Step B. Ethyl (3*R*)-1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}piperidine-3-carboxylate



A suspension of 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (300 mg, 0.80 mmol) in DCE (5 mL) was slowly added to a solution of ethyl (3*R*)-piperidine-3-carboxylate (140 mg, 0.88 mmol) and DIPEA (1.4 mL, 8.0 mmol) in DCE (25 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The product was purified by MPLC on silica gel using 60-90% EtOAc/Heptane to provide the title compound as white solid. Yield: 265 mg (66%); ¹H NMR (400 MHz, CDCl₃) δ 1.26 (t, $J=7.13$ Hz, 3 H), 1.33 (td, $J=12.55$, 4.00 Hz, 1 H), 1.50 - 1.57 (m, 3 H), 1.59 (s, 9 H), 1.62 - 1.71 (m, 2 H), 1.72 - 1.84 (m, 1 H), 1.90 - 2.02 (m, 1 H), 2.22 - 2.38 (m, 2 H), 2.44 (t, $J=11.03$ Hz, 1 H), 2.57 - 2.69 (m, 1 H), 3.28 - 3.41 (m, 2 H), 3.70 (d, $J=11.33$ Hz, 1 H), 3.91 (dd, $J=11.43$, 3.81 Hz, 1 H), 4.01 (dd, $J=11.23$, 2.83 Hz, 2 H), 4.13 (q, $J=7.16$ Hz, 2 H), 4.25 (d, $J=7.42$ Hz, 2 H), 7.43 (d, $J=8.59$ Hz, 1 H), 7.64 (dd, $J=8.40$, 1.76 Hz, 1 H), 8.18 (d, $J=1.17$ Hz, 1 H); MS (ESI) ($M+H$)⁺ = 492.0.


Step C. (3*R*)-1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}piperidine-3-carboxylic acid




NaOH (0.5 mL, 2 M, 1.0 mmol) was added to a solution of ethyl (3*R*)-1-{{2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}piperidine-3-carboxylate (255 mg, 0.52 mmol) in a 1:1 mixture of MeOH:H₂O (10 mL) at ambient temperature. The reaction mixture was stirred overnight and diluted with water (50 mL). The solvent was concentrated to 50 mL. The resulting solution was neutralized with HCl solution, the product was extracted with EtOAc and dried over anhydrous Na₂SO₄. The solvent was concentrated to provide the title compound as white solid. Yield: 236 mg (98%); MS (ESI) (M+H)⁺ = 464.1.

Example 86

4-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropylmorpholine-2-carboxamide




Step A. 4-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropylmorpholine-2-carboxamide



2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (0.95 g, 2.35 mmol) was added to a solution of *N*-cyclopropylmorpholine-2-carboxamide (0.8 g, 2.6 mmol) (see following steps B and C for preparation) and DIPEA (0.82 mL, 4.7 mmol) in DCE (80 mL) at 80°C. The reaction mixture was stirred for 1 h and the solvent was concentrated.

The product was purified by MPLC on silica gel using 60-90% EtOAc/Heptane to provide the title compound as white solid. Yield: 1.1 g (71%); ¹H NMR (400 MHz, CDCl₃) δ 0.39 - 0.54 (m, 2 H), 0.69 - 0.80 (m, 2 H), 1.49 - 1.69 (m, 3 H), 1.72 (s, 9 H), 1.75 - 1.86 (m, 3 H), 2.09 (t, J=10.84 Hz, 1 H), 2.2 (m, 3 H), 2.38 - 2.50 (m, 1 H), 2.61 - 2.71 (m, 1 H), 3.56 (d, J=11.91 Hz, 1 H), 3.67 (td, J=11.52, 1.95 Hz, 1 H), 3.91 - 4.06 (m, 3 H), 4.44 (d, J=7.03 Hz, 2 H), 6.58 (d, J=3.12 Hz, 1 H), 7.63 - 7.73 (m, 2 H), 8.04 (s, 1 H); MS (ESI) (M+H)⁺ = 538.8; Anal. Calcd for C₂₆H₃₆F₂N₄O₄S + 2.2 TFA: C, 46.25; H, 4.88; N, 7.10. Found: C, 46.26; H, 5.00; N, 6.95.


Step B. 9*H*-fluoren-9-ylmethyl 2-[(cyclopropylamino)carbonyl]morpholine-4-carboxylate



HATU (1.17 g, 3.0 mmol) and cyclopropylamine (0.17 g, 3.0 mmol) were added to a solution of 4-[(9*H*-fluoren-9-ylmethoxy)carbonyl]morpholine-2-carboxylic acid (1.0 g, 2.9 mmol) and DIPEA (0.56 mL, 3.2 mmol) in DMF (50 mL). The reaction mixture was stirred for 2 hrs. at ambient temperature and the solvent was concentrated. The product was recovered in EtOAc and washed with water, saturated NaHCO₃ solution, water and brine. The organic layer was

dried over anhydrous MgSO_4 and the solvent was concentrated to provide the title compound that was used for the next step without further purification. MS (ESI) $(\text{M}+\text{H})^+ = 393.0$.

Step C. *N*-cyclopropylmorpholine-2-carboxamide




NaOH (1 mL, 2 *M*, 2.0 mmol) was slowly added to a solution of 9*H*-fluoren-9-ylmethyl 2-[(cyclopropylamino)carbonyl]morpholine-4-carboxylate (1.0 g, 2.6 mmol) in MeOH (70 mL) at ambient temperature. The reaction mixture was stirred for 3 h and the solvent was concentrated.

The product was recovered in water (50 mL) and the mixture was neutralized to pH 7 using HCl solution. The product was extracted with EtOAc and dried over anhydrous Na_2SO_4 . The solvent was concentrated to provide the title compound that was used for the next step without further purification. Yield: 0.8 g.

Example 87

4-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclopropylmorpholine-2-carboxamide




2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (0.50 g, 1.3 mmol) was added to a solution of *N*-cyclopropylmorpholine-2-carboxamide (0.34 g, 2.0 mmol) and DIPEA (1.1 mL, 6.7 mmol) in DCE at 50°C . The reaction mixture was stirred for 4 h and the solvent was concentrated. The crude product was purified by reverse-phase


preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 0.38 g (46%); ¹H NMR (400 MHz, CDCl₃) δ 0.37 - 0.55 (m, 2 H), 0.68 - 0.80 (m, 2 H), 1.52 - 1.65 (m, 4 H), 1.72 (s, 9 H), 2.11 (t, J=11.72 Hz, 1 H), 2.26 - 2.38 (m, 1 H), 2.47 (td, J=11.62, 2.93 Hz, 1 H), 2.60 - 2.71 (m, 1 H), 3.30 - 3.43 (m, 2 H), 3.59 (d, J=11.72 Hz, 1 H), 3.68 (td, J=11.57, 2.44 Hz, 1 H), 3.92 - 4.10 (m, 5 H), 4.41 (d, J=7.23 Hz, 2 H), 6.54 (d, J=3.52 Hz, 1 H), 7.63 - 7.69 (m, 1 H), 7.70 - 7.77 (m, 1 H), 8.14 (d, J=1.37 Hz, 1 H); MS (ESI) (M+H)⁺ = 504.8.

Example 88

(3S)-1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-cyclopropylpyrrolidine-3-carboxamide




Step A. (3S)-1-{{2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-cyclopropylpyrrolidine-3-carboxamide



2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (95 mg, 0.25 mmol) was added to a solution of (3S)-3-[(cyclopropylamino)carbonyl]pyrrolidinium

trifluoroacetate (100 mg, 0.38 mmol) (see following step B for preparation) and DIPEA (0.22 mL, 1.27 mmol) in DCE (15 mL) at 50°C. The reaction mixture was stirred for 3h and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 41 mg (26%); $[\alpha]_D -10.5^\circ$ (c = 0.43, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 0.40 - 0.56 (m, 2 H), 0.62 - 0.74 (m, 2 H), 1.50 - 1.66 (m, 4 H), 1.73 (s, 9 H), 1.85 - 1.99 (m, 1 H), 2.05 - 2.21 (m, 1 H), 2.25 - 2.41 (m, 1 H), 2.57 - 2.68 (m, 1 H), 2.71 - 2.84 (m, 1 H), 3.04 - 3.16 (m, 1 H), 3.26 (t, J=9.96 Hz, 1 H), 3.30 - 3.43 (m, 3 H), 3.72 (dd, J=10.16, 8.01 Hz, 1 H), 4.02 (d, J=11.33 Hz, 2 H), 4.41 (d, J=7.42 Hz, 2 H), 7.01 (s, 1 H), 7.64 (d, J=8.59 Hz, 1 H), 7.79 (d, J=8.01 Hz, 1 H), 8.29 (s, 1 H); MS (ESI) (M+H)⁺ = 488.7.


Step B. (3S)-3-[(cyclopropylamino)carbonyl]pyrrolidinium trifluoroacetate



HATU (0.97 g, 2.5 mmol) and cyclopropylamine (0.14 g, 2.5 mmol) were added to a solution of (3S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (0.50 g, 2.3 mmol) and DIPEA (0.48 mL, 2.7 mmol) in DMF (15 mL). The reaction mixture was stirred for 3 h and the solvent was concentrated. The product was recovered in EtOAc and washed with water, saturated NaHCO₃ solution, water and brine. The organic layer was dried over anhydrous MgSO₄ and the solvent was concentrated to provide *tert*-butyl (3S)-3-[(cyclopropylamino)carbonyl]pyrrolidine-1-carboxylate as white solid. The intermediate was recovered in TFA (5 mL) and stirred for 2 h. The solvent was concentrated to provide the title compound as yellow oil that was used for the next step without further purification. Yield: 0.21 g (33%).

Example 89

(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-cyclopropylpyrrolidine-3-carboxamide




- 5 2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazole-5-sulfonyl chloride (103 mg, 0.25 mmol) was added to a solution of (3S)-3-[(cyclopropylamino)carbonyl]pyrrolidinium trifluoroacetate (100 mg, 0.38 mmol) and DIPEA (0.22 mL, 1.27 mmol) in DCE (15 mL) at 50°C. The reaction mixture was stirred for 3 h and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 53 mg (32%);
- 10 ¹H NMR (400 MHz, CDCl₃) δ 0.39 - 0.52 (m, 2 H), 0.62 - 0.73 (m, 2 H), 1.48 - 1.85 (m, 16 H), 2.03 - 2.28 (m, 4 H), 2.62 (s, 1 H), 2.66 - 2.77 (m, 1 H), 3.04 - 3.19 (m, 1 H), 3.26 (t, J=9.28 Hz, 1 H), 3.35 (t, J=8.11 Hz, 1 H), 3.64 - 3.76 (m, 1 H), 4.42 (d, J=7.03 Hz, 2 H), 6.87 (s, 1 H), 7.61 (d, J=8.20 Hz, 1 H), 7.78 (d, J=8.01 Hz, 1 H), 8.23 (s, 1 H); MS (ESI) (M+H)⁺ = 522.8.

15


Example 90

(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-methylpiperidine-3-carboxamide



Step A. (3S)-1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-methylpiperidine-3-carboxamide


5



HATU (80 mg, 0.21 mmol) and methylamine (0.1 mL, 2 M in THF, 0.21 mmol) were added to a solution of (3S)-1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid (100 mg, 0.20 mmol) (see following steps B and C for preparation) and DIPEA (40 μ L, 0.22 mmol) in DMF (15 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 75 mg (60%); $[\alpha]_D -46.2^\circ$ ($c = 1.17$, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.31 - 1.67 (m, 6 H), 1.71 (s, 9 H), 1.8 (m, 4 H), 2.08 - 2.28 (m, 4 H), 2.34 - 2.52 (m, 2 H), 2.66 (t, $J=11.43$ Hz, 1 H), 2.78 (d, $J=4.49$ Hz, 3 H), 3.78 (dd, $J=12.01, 3.22$ Hz, 1 H), 4.42 (d, $J=7.23$ Hz, 2 H), 6.84 (d, $J=4.49$ Hz, 1 H), 7.55 - 7.63 (m, 1 H), 7.64 - 7.73 (m, 1 H), 8.22 (s, 1 H); MS (ESI) ($M+H$)⁺ = 510.8.


Step B. ethyl (3S)-1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylate

20



2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (1.2 g, 2.9 mmol) was slowly added to a solution of ethyl (3*S*)-piperidine-3-carboxylate (0.7 g, 4.4 mmol) and DIPEA (2.6 mL, 14 mmol) in DCE (50 mL) at 80°C. The reaction mixture was stirred for 1 h and the solvent was concentrated. The product was purified by MPLC on silica gel using 60-90% EtOAc/Heptane to provide the title compound as white solid. Yield: 1.5 g (96%); MS (ESI) ($M+H$)⁺ = 526.0.

10 **Step C. (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid**




NaOH (2 mL, 2 M, 4.0 mmol) was added to a solution of ethyl (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylate (1.4 g, 2.7 mmol) in 80 mL of MeOH-H₂O (1:1) at ambient temperature. The reaction mixture was stirred overnight and diluted with water (80 mL). The solvent was concentrated to 80 mL. The resulting solution was neutralized with 2 *N* HCl. The product was extracted with EtOAc and dried over anhydrous Na₂SO₄. The solvent was concentrated to provide the title compound as white solid. Yield: 1.3 g (95%); ¹H NMR (400 MHz, CDCl₃) δ 1.24 - 1.27 (m, 1 H), 1.27 - 1.39

(m, 1 H), 1.45 - 1.59 (m, 2 H), 1.62 (s, 9 H), 1.68 (s, 3 H), 1.70 - 1.86 (m, 4 H), 1.93 - 2.06 (m, 1 H), 2.08 - 2.25 (m, 2 H), 2.33 (t, $J=12.11$ Hz, 1 H), 2.46 (t, $J=10.94$ Hz, 1 H), 2.53 - 2.66 (m, 1 H), 3.69 (d, $J=11.72$ Hz, 1 H), 3.89 (d, $J=9.96$ Hz, 1 H), 4.31 (d, $J=7.23$ Hz, 2 H), 7.48 (d, $J=8.79$ Hz, 1 H), 7.67 (d, $J=8.20$ Hz, 1 H), 8.26 (s, 1 H); MS (ESI) $(M+H)^+ = 498.1$.

5

Example 91

(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-ethylpiperidine-3-carboxamide




10

Following the same procedure in Example 90, step A, using ethylamine (0.1 mL, 2 M in TH, 0.21 mmol), HATU (80 mg, 0.21 mmol), (3S)-1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (40 μ L, 0.22 mmol) in DMF (15 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 64 mg (50%); $[\alpha]_D -51.4^\circ$ ($c = 1.16$, MeOH); ^1H NMR (400 MHz, CDCl₃) δ 1.13 (t, $J=7.23$ Hz, 3 H), 1.36 - 1.66 (m, 4 H), 1.71 (s, 11 H), 1.74 - 1.87 (m, 4 H), 2.09 - 2.28 (m, 3 H), 2.35 - 2.53 (m, 2 H), 2.66 (t, $J=11.03$ Hz, 1 H), 3.19 - 3.33 (m, 2 H), 3.57 (d, $J=12.30$ Hz, 1 H), 3.72 (dd, $J=11.72, 2.73$ Hz, 1 H), 4.41 (d, $J=7.23$ Hz, 2 H), 6.58 (t, $J=5.37$ Hz, 1 H), 7.59 (d, $J=8.59$ Hz, 1 H), 7.65 - 7.73 (m, 1 H), 8.20 (s, 1 H); MS (ESI) $(M+H)^+ = 524.8$;

20

Example 92


(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-propylpiperidine-3-carboxamide



- 5 Following the same procedure in Example 90, step A, using *n*-propylamine (0.15 mL, 108 mg, 1.8 mmol), HATU (80 mg, 0.21 mmol), (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (40 μ L, 0.22 mmol) in DMF (15 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized
- 10 affording the title compound as the corresponding TFA salt. Yield: 60 mg (45%); $[\alpha]_D -54.6^\circ$ ($c = 1.18$, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 0.91 (t, $J=7.32$ Hz, 3 H), 1.40 - 1.58 (m, 5 H), 1.58 - 1.66 (m, 1 H), 1.66 - 1.71 (m, 10 H), 1.71 - 1.84 (m, 4 H), 2.10 - 2.26 (m, 3 H), 2.38 - 2.47 (m, 1 H), 2.53 (t, $J=10.06$ Hz, 1 H), 2.69 (t, $J=11.03$ Hz, 1 H), 3.14 - 3.25 (m, 2 H), 3.53 (d, $J=11.91$ Hz, 1 H), 3.67 (dd, $J=12.30, 3.12$ Hz, 1 H), 4.40 (d, $J=7.42$ Hz, 2 H), 6.50 (t, $J=5.27$
- 15 Hz, 1 H), 7.57 (d, $J=8.79$ Hz, 1 H), 7.68 (dd, $J=8.59, 1.56$ Hz, 1 H), 8.21 (d, $J=1.37$ Hz, 1 H); MS (ESI) (M+H)⁺ = 538.8;

Example 93


- (3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-cyclopropylpiperidine-3-carboxamide**
- 20



Following the same procedure in Example 90, step A, using cyclopropylamine (0.15 mL, 123 mg, 2.1 mmol), HATU (80 mg, 0.21 mmol), (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (40 μ L, 0.22 mmol) in DMF (15 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 72 mg (55%); $[\alpha]_D -56.6^\circ$ ($c = 1.14$, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 0.46 - 0.57 (m, 2 H), 0.68 - 0.81 (m, 2 H), 1.35 - 1.50 (m, 1 H), 1.50 - 1.62 (m, 3 H), 1.63 - 1.69 (m, 2 H), 1.68 - 1.73 (m, 9 H), 1.73 - 1.87 (m, 4 H), 2.10 - 2.28 (m, 3 H), 2.31 - 2.43 (m, 1 H), 2.51 (t, $J=10.16$ Hz, 1 H), 2.60 - 2.74 (m, 2 H), 3.54 (d, $J=12.69$ Hz, 1 H), 3.66 (d, $J=10.74$ Hz, 1 H), 4.41 (d, $J=7.23$ Hz, 2 H), 6.65 (d, $J=1.37$ Hz, 1 H), 7.55 - 7.63 (m, 1 H), 7.65 - 7.72 (m, 1 H), 8.12 - 8.21 (m, 1 H); MS (ESI) $(M+H)^+ = 536.8$.

Example 94


(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclobutylpiperidine-3-carboxamide



Following the same procedure in Example 90, step A, using cyclobutylamine (0.15 mL, 124 mg, 1.8 mmol), HATU (80 mg, 0.21 mmol), (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (40 μ L, 0.22 mmol) in DMF (15 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 68 mg (51%); $[\alpha]_D -63.0^\circ$ ($c = 1.23$, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.40 - 1.63 (m, 4 H), 1.63 - 1.69 (m, 2 H), 1.70 - 1.73 (m, 11 H), 1.73 - 1.84 (m, 4 H), 1.83 - 1.99 (m, 2 H), 2.11 - 2.24 (m, 3 H), 2.24 - 2.33 (m, 2 H), 2.33 - 2.43 (m, 1 H), 2.49 (t, $J=10.35$ Hz, 1 H), 2.63 (t, $J=11.13$ Hz, 1 H), 3.53 (d, $J=12.69$ Hz, 1 H), 3.64 (dd, $J=12.40, 3.22$ Hz, 1 H), 4.27 - 4.38 (m, 1 H), 4.41 (d, $J=7.42$ Hz, 2 H), 6.53 (d, $J=7.62$ Hz, 1 H), 7.55 - 7.63 (m, 1 H), 7.64 - 7.71 (m, 1 H), 8.15 (d, $J=1.17$ Hz, 1 H); MS (ESI) ($M+H$)⁺ = 551.0.

Example 95

(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-(cyclopropylmethyl)piperidine-3-carboxamide




Following the same procedure in Example 90, step A, using (cyclopropylmethyl)amine (0.15 mL, 122 mg, 1.7 mmol), HATU (80 mg, 0.21 mmol), (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (40 μ L, 0.22 mmol) in DMF (15 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 60 mg (44%); $[\alpha]_D -55.5^\circ$ ($c = 1.11$, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 0.20 (m, 2 H), 0.45 - 0.54 (m, 2 H), 0.89 -

1.02 (m, 1 H), 1.42 - 1.63 (m, 4 H), 1.70 (s, 10 H), 1.72 - 1.86 (m, 5 H), 2.10 - 2.26 (m, 3 H), 2.39 - 2.54 (m, 2 H), 2.65 (t, J=10.94 Hz, 1 H), 3.05 - 3.13 (m, 2 H), 3.56 (d, J=11.52 Hz, 1 H), 3.70 (dd, J=11.72, 2.73 Hz, 1 H), 4.41 (d, J=7.42 Hz, 2 H), 6.51 (t, J=5.08 Hz, 1 H), 7.56 - 7.62 (m, 1 H), 7.68 (dd, J=8.79, 1.37 Hz, 1 H), 8.19 (d, J=1.37 Hz, 1 H); MS (ESI) (M+H)⁺ = 550.8.

5

Example 96

(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-(cyclobutylmethyl)piperidine-3-carboxamide



10


Following the same procedure in Example 90, step A, using (cyclobutylmethyl)amine (0.15 mL, 124 mg, 1.5 mmol), HATU (80 mg, 0.21 mmol), (3S)-1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (40 uL, 0.22 mmol) in DMF (15 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 55 mg (40%); [α]_D -53.4° (c = 1.12, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.42 - 1.62 (m, 4 H), 1.62 - 1.68 (m, 2 H), 1.70 (s, 11 H), 1.73 - 1.82 (m, 4 H), 1.82 - 1.95 (m, 2 H), 1.98 - 2.09 (m, 2 H), 2.11 - 2.25 (m, 3 H), 2.38 - 2.51 (m, 2 H), 2.55 (t, J=10.74 Hz, 1 H), 2.71 (t, J=10.94 Hz, 1 H), 3.21 - 3.31 (m, 2 H), 3.49 (d, J=12.11 Hz, 1 H), 3.61 (dd, J=12.30, 3.32 Hz, 1 H), 4.41 (d, J=7.23 Hz, 2 H), 6.39 (t, J=5.76 Hz, 1 H), 7.59 (d, J=8.79 Hz, 1 H), 7.69 (dd, J=8.69, 1.27 Hz, 1 H), 8.18 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 564.8.

15

20

Example 97


(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-isopropylpiperidine-3-carboxamide




- 5 Following the same procedure in Example 90, step A, using isopropylamine (0.15 mL, 104 mg, 1.75 mmol), HATU (80 mg, 0.21 mmol), (3S)-1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)piperidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (40 μ L, 0.22 mmol) in DMF (15 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized
- 10 affording the title compound as the corresponding TFA salt. Yield: 75 mg (57%); $[\alpha]_D -55.1^\circ$ (c = 1.35, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.15 (d, J=6.93 Hz, 6 H), 1.44 - 1.62 (m, 4 H), 1.62 - 1.73 (m, 11 H), 1.73 - 1.84 (m, 4 H), 2.10 - 2.27 (m, 3 H), 2.32 - 2.43 (m, 1 H), 2.50 (t, J=10.55 Hz, 1 H), 2.65 (t, J=11.03 Hz, 1 H), 3.53 (d, J=11.72 Hz, 1 H), 3.63 (dd, J=11.23, 3.03 Hz, 1 H), 3.95 - 4.09 (m, 1 H), 4.41 (d, J=7.42 Hz, 2 H), 6.13 (d, J=7.03 Hz, 1 H), 7.56 -
- 15 7.63 (m, 1 H), 7.65 - 7.72 (m, 1 H), 8.15 (s, 1 H); MS (ESI) (M+H)⁺ = 538.8.

Example 98

(3S)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-methylpyrrolidine-3-carboxamide




Step A. (3S)-1-((2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl)sulfonyl)-N-methylpyrrolidine-3-carboxamide




HATU (86 mg, 0.22 mmol) and methylamine (0.8 mL, 2 M in THF, 1.6 mmol) were added to a solution of (3S)-1-((2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl)sulfonyl)pyrrolidine-3-carboxylic acid (100 mg, 0.20 mmol) (see following steps B and C for preparation) and DIPEA (72 μ L, 0.22 mmol) in DMF (15 mL). The reaction mixture was stirred for 1 h. and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 65 mg (53%); $[\alpha]_D -7.3^\circ$ (c = 1.04, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.50 - 1.69 (m, 3 H), 1.72 (s, 9 H), 1.74 - 1.84 (m, 3 H), 1.86 - 1.97 (m, 1 H), 2.10 - 2.25 (m, 4 H), 2.72 (d, J=4.69 Hz, 4 H), 3.02 - 3.12 (m, 1 H), 3.27 (t, J=10.16 Hz, 1 H), 3.36 (td, J=9.37, 3.32 Hz, 1 H), 3.78 (dd, J=10.45, 7.91 Hz, 1 H), 4.43 (d, J=7.42 Hz, 2 H), 6.98 (d, J=4.30 Hz, 1 H), 7.60 (d, J=8.79 Hz, 1 H), 7.79 (dd, J=8.69, 1.46 Hz, 1 H), 8.29 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 497.2.

Step B. (3S)-3-carboxypyrrolidinium trifluoroacetate



(3*S*)-1-(*tert*-Butoxycarbonyl)pyrrolidine-3-carboxylic acid (0.5 g, 2.34 mmol) was stirred in TFA (20 mL) for 3 h. The solvent was removed to provide the title compound as yellow oil that was used for the next step without further purification. Yield: 0.50 g (99%).


Step C. (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidine-3-carboxylic acid



2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (1.2 g, 2.9 mmol) was added to a solution of (3*S*)-3-carboxypyrrolidine trifluoroacetate (0.50 g, 2.3 mmol) and DIPEA (3 mL, 17 mmol) in DCE (20 mL) at 80°C. The reaction mixture was stirred for 2 hrs. and the solvent was concentrated. The product was purified by MPLC on silica gel using 30% acetone in DCM containing 1% of AcOH to provide the title compound as white solid. Yield: 600 mg (42%); MS (ESI) ($M+H$)⁺ = 484.1.

Example 99


(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethylpyrrolidine-3-carboxamide



Following the same procedure in Example 98, step A, using ethylamine (0.11 mL, 2 M in THF, 0.22 mmol), HATU (86 mg, 0.22 mmol), (3S)-1-((2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl)sulfonyl)pyrrolidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (72 μ L, 0.22 mmol) in DMF (15 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 52 mg (40%); $[\alpha]_D -8.9^\circ$ (c = 1.17, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 1.07 (t, J=7.32 Hz, 3 H), 1.49 - 1.62 (m, 2 H), 1.63 - 1.70 (m, 1 H), 1.72 (s, 9 H), 1.75 - 1.84 (m, 3 H), 1.85 - 1.98 (m, 1 H), 2.05 - 2.28 (m, 4 H), 2.64 - 2.79 (m, 1 H), 3.04 - 3.14 (m, 1 H), 3.14 - 3.30 (m, 3 H), 3.35 (td, J=9.28, 3.71 Hz, 1 H), 3.73 (dd, J=10.45, 8.11 Hz, 1 H), 4.43 (d, J=7.42 Hz, 2 H), 6.76 (t, J=4.78 Hz, 1 H), 7.61 (d, J=8.79 Hz, 1 H), 7.77 (dd, J=8.79, 1.17 Hz, 1 H), 8.24 (s, 1 H); MS (ESI) (M+H)⁺ = 511.3.

Example 100


(3S)-1-((2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl)sulfonyl)-N-isopropylpyrrolidine-3-carboxamide



Following the same procedure in Example 98, step A, using isopropylamine (0.15 mL, 103 mg, 1.75 mmol), HATU (86 mg, 0.22 mmol), (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidine-3-carboxylic acid (100 mg, 0.20 mmol) and DIPEA (72 μ L, 0.22 mmol) in DMF (15 mL) provided the TFA salt of the title compound as white solid. Yield: 51 mg (39%); $[\alpha]_D -10.7^\circ$ ($c = 1.10$, MeOH); ^1H NMR (400 MHz, CDCl_3) δ 1.08 (dd, $J=6.64, 2.54$ Hz, 6 H), 1.49 - 1.63 (m, 2 H), 1.63 - 1.70 (m, 1 H), 1.73 (s, 9 H), 1.76 - 1.85 (m, 3 H), 1.85 - 1.99 (m, 1 H), 2.00 - 2.12 (m, 1 H), 2.12 - 2.27 (m, 4 H), 2.62 - 2.76 (m, 1 H), 3.06 - 3.17 (m, 1 H), 3.19 - 3.28 (m, 1 H), 3.32 (td, $J=9.18, 3.91$ Hz, 1 H), 3.61 (dd, $J=10.35, 8.20$ Hz, 1 H), 3.88 - 4.00 (m, 1 H), 4.44 (d, $J=7.23$ Hz, 2 H), 6.32 (d, $J=7.81$ Hz, 1 H), 7.73 (dd, $J=8.79, 1.37$ Hz, 1 H), 8.12 (d, $J=1.17$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 525.3$.

Example 101

tert-Butyl [1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]carbamate




Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (0.41 g, 1.0 mmol), *tert*-butyl azetidin-3-ylcarbamate (0.17 g, 1.0 mmol) and DMAP (0.37 g, 3.0 mmol) in MeCN (20 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 0.40 g (74%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.33 (s, 9 H), 1.48 - 1.62 (m, 2 H), 1.64 (s, 9 H), 1.67 - 1.87 (m, 4 H), 1.98 - 2.15 (m, 2 H), 2.19 - 2.35 (m, 1 H), 3.62 (t, $J=7.03$ Hz, 2 H), 3.96 (t, $J=8.11$ Hz, 2 H), 4.05 - 4.16 (m, 1 H), 4.51 (d, $J=7.42$ Hz, 2 H), 7.86 (dd, $J=9.18, 1.17$ Hz, 1 H), 7.98 (d, $J=8.79$ Hz, 1 H), 8.14 (d, $J=1.56$ Hz,

1 H); MS (ESI) (M+H)⁺ = 541.3; Anal. Calcd for C₂₆H₃₈F₂N₄O₄S+1.00 TFA+ 0.20 EtOAc(674.72): C, 51.62; H, 6.07; N, 8.30; Found: C, 51.73; H, 5.94; N, 8.27.

Example 102


5 1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-amine



Following the same procedure in Example 37, Step A, using *tert*-butyl [1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]carbamate
 10 (0.34 g, 0.63 mmol) and TFA (5 mL) in CH₂Cl₂ (10 mL). Yield: 0.26 g (93%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.47 - 1.57 (m, 2 H), 1.61 (s, 9 H), 1.63 - 1.84 (m, 4 H), 1.98 - 2.13 (m, 2 H), 2.16 - 2.32 (m, 1 H), 3.79 - 3.90 (m, 3 H), 3.97 - 4.08 (m, 2 H), 4.45 (d, J=7.42 Hz, 2 H), 7.75 - 7.84 (m, 1 H), 7.86 - 7.92 (m, 1 H), 8.14 (d, J=1.37 Hz, 1 H); MS (ESI) (M+H)⁺ =
 15 441.3; Anal. Calcd for C₂₁H₃₀F₂N₄O₂S+2.10 TFA (680.01): C, 44.51; H, 4.76; N, 8.24; Found: C, 44.48; H, 4.65; N, 8.43.

Example 103


20 *N*-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]cyclopropanecarboxamide



Cyclopropane carbonylchloride (16 uL, 19 mg, 0.18 mmol) was added to a solution of 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-amine (52 mg, 0.12 mmol) (see Example 102 for preparation) and DIPEA (41 uL, 31 mg, 0.24 mmol) in CH₂Cl₂ (5 mL). The reaction mixture was stirred for 4 h at room temperature, diluted with EtOAc (50 mL), washed with NaHCO₃ (2x10 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using Hex/EtOAc (1:4) on silica gel to give 60 mg (99%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 0.66 - 0.71 (m, 2 H), 0.71 - 0.77 (m, 2 H), 1.38 - 1.48 (m, 1 H), 1.51 - 1.64 (m, 2 H), 1.65 (s, 9 H), 1.68 - 1.86 (m, 4 H), 1.99 - 2.13 (m, 2 H), 2.19 - 2.35 (m, 1 H), 3.67 (dd, J=8.69, 6.15 Hz, 2 H), 4.00 (dd, J=8.8, 7.8 Hz, 2 H), 4.23 - 4.37 (m, 1 H), 4.53 (d, J=7.62 Hz, 2 H), 7.90 (dd, J=8.79, 1.76 Hz, 1 H), 8.03 (d, J=8.59 Hz, 1 H), 8.16 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺ = 509.3; Anal. Calcd for C₂₅H₃₄F₂N₄O₃S+1.20 TFA+ 0.1 H₂O (647.26): C, 50.85; H, 5.51; N, 8.66; Found: C, 50.81; H, 5.52; N, 8.43.

Example 104

N-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]propanamide




Following the same procedure in Example 103, using propionic anhydride (50 uL, 51 mg, 0.39 mmol), 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-amine (51 mg, 0.12 mmol) (see Example 102 for preparation) and DIPEA (41 uL, 31 mg, 0.24 mmol) in CH₂Cl₂ (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:4) on silica gel to give 60 mg (100%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.00 (t, J=7.62 Hz, 3 H), 1.48 - 1.63 (m,


2 H), 1.66 (s, 9 H), 1.68 - 1.84 (m, 4 H), 2.01 - 2.06 (m, 2 H), 2.07 (q, J=7.62 Hz, 2 H), 2.18 - 2.35 (m, 1 H), 3.68 (dd, J=8.69, 6.15 Hz, 2 H), 4.00 (dd, J=8.8, 7.8 Hz, 2 H), 4.22 - 4.33 (m, 1 H), 4.53 (d, J=7.42 Hz, 2 H), 7.90 (dd, J=8.79, 1.76 Hz, 1 H), 8.04 (d, J=8.79 Hz, 1 H), 8.16 (d, J=1.76 Hz, 1 H); MS (ESI) (M+H)⁺ = 497.2; Anal. Calcd for C₂₄H₃₄F₂N₄O₃S+1.20 TFA+ 0.40 H₂O (640.66): C, 49.49; H, 5.66; N, 8.75 Found: C, 49.49; H, 5.58; N, 8.82.

Example 105

N-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N'*-ethylurea




Step A: *N*-[1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N'*-ethylurea



A solution of 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-5-[(3-isocyanatoazetidin-1-yl)sulfonyl]-1*H*-benzimidazole in THF (4.0 mL, 0.095 mmol) (see following step B for preparation) was added to a solution of ethylamine (100 μ L, 2.0 M in THF, 0.2 mmol) in THF (2.0 mL). The reaction mixture was stirred for 4 h at room temperature, diluted with EtOAc (50 mL), washed with NaHCO₃ (2x5 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 21 mg (44%) of a white solid as the

title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.02 (t, $J=7.13$ Hz, 3 H), 1.51 - 1.64 (m, 2 H), 1.66 (s, 9 H), 1.69 - 1.87 (m, 4 H), 2.01 - 2.15 (m, 2 H), 2.21 - 2.37 (m, 1 H), 3.04 (q, $J=7.16$ Hz, 2 H), 3.62 (dd, $J=8.11$, 6.74 Hz, 2 H), 3.99 (t, $J=8.10$ Hz, 2 H), 4.16 - 4.29 (m, 1 H), 4.54 (d, $J=7.62$ Hz, 2 H), 7.90 (dd, $J=8.59$, 1.56 Hz, 1 H), 8.03 (d, $J=8.59$ Hz, 1 H), 8.17 (d, $J=1.76$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 512.3$; Anal. Calcd for $\text{C}_{24}\text{H}_{35}\text{F}_2\text{N}_5\text{O}_3\text{S}+1.40$ TFA+ 0.50 H_2O (680.28): C, 47.32; H, 5.54; N, 10.29; Found: C, 47.36; H, 5.57; N, 10.32.


Step B: 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-5-[(3-isocyanatoazetidin-1-yl)sulfonyl]-1*H*-benzimidazole



A solution of 1-[(2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl)sulfonyl]azetidin-3-amine (125 mg, 0.29 mmol) (see Example 102 for preparation) and DIPEA (109 μL , 81 mg, 0.63 mmol) in THF (6 mL) was added to a solution of triphosgene (34 mg, 0.14 mmol) in THF (6 mL) at 0 $^\circ\text{C}$. The reaction mixture was stirred for 30 min at 0 $^\circ\text{C}$ and 30 min at room temperature, then directly used for next step.

Example 106


N-[1-[(2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl)sulfonyl]azetidin-3-yl]-*N'*-cyclopropylurea



Following the same procedure in Example 105, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-5-[(3-isocyanatoazetidin-1-yl)sulfonyl]-1*H*-benzimidazole (0.095 mmol) and cyclopropylamine (13 μ L, 11 mg, 0.19 mmol) in THF (6.0 mL). The crude product was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 22 mg (44%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 0.29 - 0.40 (m, 2 H), 0.57 - 0.66 (m, 2 H), 1.49 - 1.64 (m, 2 H), 1.67 (s, 9 H), 1.70 - 1.86 (m, 4 H), 1.99 - 2.15 (m, 2 H), 2.20 - 2.31 (m, 1 H), 2.31 - 2.41 (m, 1 H), 3.65 - 3.78 (m, 2 H), 3.94 - 4.06 (m, 2 H), 4.15 - 4.30 (m, 1 H), 4.55 (d, $J=7.42$ Hz, 2 H), 7.92 (dd, $J=8.69$, 1.66 Hz, 1 H), 8.05 (d, $J=8.79$ Hz, 1 H), 8.18 (d, $J=1.56$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 524.3$; Anal. Calcd for $\text{C}_{25}\text{H}_{35}\text{F}_2\text{N}_5\text{O}_3\text{S}+1.20 \text{ TFA}+0.60 \text{ H}_2\text{O}+0.40 \text{ EtOAc}$ (711.33): C, 49.64; H, 5.75; N, 9.85; Found: C, 49.62; H, 5.71; N, 9.83.

Example 107

N-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N'*-(2-hydroxyethyl)urea




Following the same procedure in Example 105, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-5-[(3-isocyanatoazetidin-1-yl)sulfonyl]-1*H*-benzimidazole (0.095 mmol) and ethanolamine (12 μ L, 12 mg, 0.19 mmol) in THF (6.0 mL). The crude product was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 22 mg (44%) of a white solid as the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.49 - 1.65 (m, 2 H), 1.68 (s, 9 H), 1.70 - 1.86 (m, 4 H), 2.02 - 2.14 (m, 2 H), 2.19 - 2.36 (m, 1 H), 3.13 (t, $J=5.57$ Hz, 2 H), 3.48 (t, $J=5.57$ Hz, 2 H), 3.64 (dd, $J=8.50$, 6.35 Hz, 2 H), 3.99 (t, $J=8.11$ Hz, 2 H), 4.17 - 4.27 (m, 1 H), 4.55 (d, $J=7.42$ Hz, 2 H), 7.93 (dd, $J=8.79$, 1.76 Hz, 1 H), 8.06 (d, $J=8.79$

Hz, 1 H), 8.17 (d, $J=1.37$ Hz, 1 H); MS (ESI) $(M+H)^+ = 528.3$; Anal. Calcd for $C_{24}H_{35}F_2N_5O_4S+0.90$ TFA+ 1.0 $H_2O+0.10$ EtOAc (658.29): C, 47.99; H, 5.93; N, 10.64; Found: C, 47.99; H, 5.95; N, 10.68.

Example 108


5-(Azetidin-1-ylsulfonyl)-2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (122 mg, 0.3 mmol), azetidine (41 μ L, 34 mg, 0.6 mmol) and DMAP (73 mg, 0.6 mmol) in MeCN (5 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 88 mg (69%) of a white solid as the title compound. 1H NMR (400 MHz, METHANOL- D_4) δ 1.49 - 1.63 (m, 2 H), 1.65 (s, 9 H), 1.69 - 1.93 (m, 4 H), 1.98 - 2.19 (m, 4 H), 2.21 - 2.34 (m, 1 H), 3.73 - 3.82 (m, 4 H), 4.51 (d, $J=7.42$ Hz, 2 H), 7.84 (dd, $J=8.59$, 1.76 Hz, 1 H), 7.98 (d, $J=8.59$ Hz, 1 H), 8.13 (d, $J=1.76$ Hz, 1 H); MS (ESI) $(M+H)^+ = 426.2$.

Example 109

2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-5-(1*H*-pyrazol-1-ylsulfonyl)-1*H*-benzimidazole




5 Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (202 mg, 0.5 mmol) and pyrazol (186 mg, 2.7 mmol) in MeCN (6 mL). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 164 mg (75%) of a white solid as the title compound. ¹H

10 NMR (400 MHz, CHLOROFORM-D) δ 1.43 - 1.54 (m, 1 H), 1.56 (s, 9 H), 1.59 - 1.80 (m, 4 H), 2.01 - 2.22 (m, 3 H), 2.49 - 2.79 (m, 1 H), 4.24 (d, $J=7.42$ Hz, 2 H), 6.38 (dd, $J=2.73$, 1.56 Hz, 1 H), 7.43 (d, $J=8.59$ Hz, 1 H), 7.70 (d, $J=0.98$ Hz, 1 H), 7.96 (dd, $J=8.69$, 1.66 Hz, 1 H), 8.15 (d, $J=2.73$ Hz, 1 H), 8.40 (d, $J=1.76$ Hz, 1 H); MS (ESI) ($M+H$)⁺ = 437.3; Anal. Calcd for C₂₁H₂₆F₂N₄O₂S+0.2 H₂O (440.13): C, 57.31; H, 6.05; N, 12.73; Found: C, 57.23; H, 6.05; N, 12.83.

Example 110


1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-ol



3-Hydroxyazetidine hydrochloride (162 mg, 1.5 mmol) was dissolved in 7 mL of dry dichloromethane. *N,N*-diisopropylethylamine (0.7 mL, 4 mmol) was added and the mixture was cooled down to 0 °C. 2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (400 mg, 1 mmol) was slowly added to the reaction mixture which was
 5 allowed to warm to room temperature for 2 hours. The mixture was diluted with EtOAc which was washed with water then brine and dried over Na₂SO₄. The solvent was removed in vacuo to give a crude product that was purified by LCMS using high pH column 40-70% acetonitrile gradient to give 340 mg (62%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.56 - 1.66 (m, 2 H), 1.69 (s, 9 H), 1.73 - 1.84 (m, 4 H), 2.01 - 2.14 (m, 3
 10 H), 3.45 - 3.51 (m, 2 H), 4.01 (dd, J=8.79, 6.84 Hz, 2 H), 4.34 - 4.43 (m, 1 H), 4.58 (d, J=7.62 Hz, 2 H), 7.97 (dd, J=8.79, 1.56 Hz, 1 H), 8.13 (d, J=8.79 Hz, 1 H), 8.18 (d, J=1.76 Hz, 1 H); MS (APPI) (M+H)⁺=442.3; Anal. Calc. for C₂₁H₂₉F₂N₃O₃S + 4.9 C₂HO₂F₃ + 5.0 H₂O + 2.7 CH₃CN: C, 39.47; H, 4.14; N, 6.31; Found: C, 39.48; H, 4.14; N, 6.30

15 Example 111

1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl ethylcarbamate




To a solution of 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-ol (100 mg, 0.23 mmol) in 2 mL of dry dichloromethane was added triethylamine (3 uL, 0.023 mmol) and ethyl isocyanate (0.11 mL, 1.4 mmol), respectively. The reaction mixture was stirred at room temperature for 1 hour and then concentrated. The crude product was purified by LCMS using high pH column 40-70% acetonitrile gradient to give 100
 25 mg (85%) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.00 (t, J=7.23 Hz, 3 H), 1.48 - 1.57 (m, 2 H), 1.59 (s, 9 H), 1.63 - 1.83 (m, 4 H), 2.04 (d,

J=26.56 Hz, 2 H), 2.18 - 2.31 (m, 1 H), 3.00 (q, J=7.23 Hz, 2 H), 3.63 (dd, J=9.18, 5.08 Hz, 2 H), 4.01 - 4.09 (m, 2 H), 4.42 (d, J=7.62 Hz, 2 H), 7.70 - 7.75 (m, 1 H), 7.79 - 7.84 (m, 1 H), 8.10 (s, 1 H); MS (APPI) (M+H)⁺= 513.3; Anal. Calc. for C₂₄H₃₄F₂N₄O₄S + 1.1 TFA: C, 49.32; H, 5.54; N, 8.78; Found: C, 49.31; H, 5.42; N, 8.59.

5


Example 112 and 113

(2S)-4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethylmorpholine-2-carboxamide




10

(2R)-4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethylmorpholine-2-carboxamide



15 **Step A: 4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethylmorpholine-2-carboxamide**




4-(*{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}* sulfonyl)morpholine-2-carboxylic acid (500 mg, 1 mmol) (see following steps B and C for preparation) was dissolved in DMF (10 mL). Ethylamine hydrochloride (122 mg, 1.5 mmol) and *N,N*-diisopropylethylamine (1 mL, 5 mmol) were added and the reaction mixture was
5 cooled down to 0 °C. HATU (456 mg, 1.2 mmol) was added portionwise and the reaction was stirred overnight at room temperature. The reaction was concentrated, extracted with EtOAc and washed with sodium bicarbonate, water then brine and dried over anhydrous sodium sulfate. The crude product was purified by LCMS using high pH column 40-70% acetonitrile gradient to give 200 mg (40%) as white solid racemic mixture of the title compound. The two
10 enantiomers were separated on a chiral OD 5 microns column using 20% ethanol/hexane.

Example 112 (isomer-1): ¹H NMR (400 MHz, METHANOL-D₄) δ 1.04 (t, J=7.23 Hz, 3 H), 1.46 - 1.56 (m, 2 H), 1.57 (s, 9 H), 1.61 - 1.70 (m, 3 H), 1.70 - 1.81 (m, 1 H), 1.98 - 2.08 (m, 2 H), 2.12 - 2.23 (m, 1 H), 2.39 (m, 1 H), 2.74 (q, J=7.23 Hz, 2 H), 3.17 (dd, J=7.23, 3.91 Hz, 2 H), 3.68 (m, 1 H), 3.87 - 3.94 (m, 1 H), 4.01 (dd, J=10.45, 2.83 Hz, 2 H), 4.40 (d, J=7.62 Hz, 2 H), 7.64 (dd, J=8.59, 1.56 Hz, 1 H), 7.77 (d, J=8.59 Hz, 1 H), 8.03 (d, J=1.76 Hz, 1 H); MS (APPI) (M+H)⁺ = 527.3; Anal. Calc. for C₂₁H₂₉F₂N₃O₃S + 4.9 C₂HO₂F₃ + 5.0 H₂O + 2.7 CH₃CN: C, 39.47; H, 4.14; N, 6.31; Found: C, 39.48; H, 4.14; N, 6.30.


Example 113 (isomer-2): ¹H NMR (400 MHz, METHANOL-D₄) δ 1.04 (t, J=7.23 Hz, 3 H), 1.46 - 1.56 (m, 2 H), 1.57 (s, 9 H), 1.61 - 1.70 (m, 3 H), 1.70 - 1.81 (m, 1 H), 1.98 - 2.08 (m, 2 H), 2.12 - 2.23 (m, 1 H), 2.39 (m, 1 H), 2.74 (q, J=7.23 Hz, 2 H), 3.17 (dd, J=7.23, 3.91 Hz, 2 H), 3.68 (m, 1 H), 3.87 - 3.94 (m, 1 H), 4.01 (dd, J=10.45, 2.83 Hz, 2 H), 4.40 (d, J=7.62 Hz, 2 H), 7.64 (dd, J=8.59, 1.56 Hz, 1 H), 7.77 (d, J=8.59 Hz, 1 H), 8.03 (d, J=1.76 Hz, 1 H). MS (APPI) (M+H)⁺ = 527.3; Anal. Calc. for C₂₅H₃₆F₂N₄O₄S + 1.7 TFA: C, 47.34; H, 5.27; N, 7.78; Found: C, 47.44; H, 5.20; N, 7.71.

Step B: Morpholine-2-carboxylic acid hydrochloride



(R,S)-Boc-2-carboxymorpholine (3 g, 13 mmol) was added to 4 N HCl in dioxane (15 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred overnight. Removal of solvent produced 2.2 g (100%) of the desired product as an HCl salt. ¹H NMR (400 MHz, METHANOL-D₄) δ 2.79 - 2.86 (m, 1 H), 2.87 - 2.94 (m, 2 H), 3.21 (dd, *J*=12.50, 3.52 Hz, 1 H), 3.51 (m, 1 H), 3.79 (m, 1 H), 4.07 (dd, *J*=9.77, 3.12 Hz, 1 H).

Step C: 4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)morpholine-2-carboxylic acid




Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (1.6 g, 4 mmol), *N,N*-diisopropylethylamine (3.5 mL, 20 mmol) and morpholine-2-carboxylic acid hydrochloride (1.0 g, 6 mmol) in methylene chloride (10 mL). Obtained 1.5 g of crude product which was carried over to step A. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.53 (d, *J*=13.67 Hz, 2 H), 1.59 (s, 12 H), 1.63 - 1.78 (m, 6 H), 1.98 - 2.12 (m, 3 H), 3.22 (q, *J*=7.36 Hz, 1 H), 3.72 (m, 1 H), 4.42 (d, *J*=7.42 Hz, 2 H), 7.69 (d, *J*=8.40 Hz, 1 H), 7.81 (d, *J*=8.40 Hz, 1 H), 8.05 (s, 1 H).

Example 114 and 115

(2*S*)-2-*tert*-Butyl-5-[(4-methylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole

(2*R*)-2-*tert*-Butyl-5-[(4-methylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole




Following the same procedure in Example 112, Step A, using 4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)morpholine-2-carboxylic acid (500 mg, 1 mmol), *N,N*-diisopropylethylamine (1 mL, 5 mmol), isopropylamine hydrochloride (143 mg, 1.5 mmol) and HATU (456 mg, 1.2 mmol) in (10 mL) DMF. The crude product was purified by LCMS using high pH column 40-70% acetonitrile gradient to give 410 mg (76%) as white solid racemic mixture of the title compound. The two enantiomers were separated on a chiral OD 5 microns column using 20% ethanol/hexane.

Example 114 (Isomer 1): $[\alpha]_D$: -49.6° ($c = 1.05$, MeOH); ^1H NMR (400 MHz, METHANOL- D_4) δ 0.97 (d, $J=6.64$ Hz, 3 H), 1.02 (d, $J=6.64$ Hz, 3 H), 1.38 - 1.47 (m, 2 H), 1.49 (s, 9 H), 1.53 - 1.61 (m, 3 H), 1.62 - 1.73 (m, 1 H), 1.89 - 2.02 (m, 2 H), 2.05 - 2.17 (m, 2 H), 2.31 (m, 1 H), 3.48 (d, $J=13.09$ Hz, 1 H), 3.60 (m, 1 H), 3.78 - 3.84 (m, 1 H), 3.84 - 3.89 (m, 1 H), 3.92 (dd, $J=10.35, 2.93$ Hz, 2 H), 4.31 (d, $J=7.42$ Hz, 2 H), 7.57 (dd, $J=8.69, 1.46$ Hz, 1 H), 7.69 (d, $J=8.59$ Hz, 1 H), 7.94 (d, $J=1.76$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 541.3$; Anal. Calc. for $\text{C}_{26}\text{H}_{38}\text{F}_2\text{N}_4\text{O}_4\text{S} + 1.1$ TFA: C, 50.85; H, 5.92; N, 8.41; Found: C, 50.93; H, 5.88; N, 7.75;

Example 115 (Isomer 2): $[\alpha]_D$: $+50.0^\circ$ ($c = 1.05$, MeOH); ^1H NMR (400 MHz, METHANOL- D_4) δ 0.97 (d, $J=6.64$ Hz, 3 H), 1.02 (d, $J=6.64$ Hz, 3 H), 1.38 - 1.47 (m, 2 H), 1.49 (s, 9 H), 1.53 - 1.61 (m, 3 H), 1.62 - 1.73 (m, 1 H), 1.89 - 2.02 (m, 2 H), 2.05 - 2.17 (m, 2 H), 2.31 (m, 1 H), 3.48 (d, $J=13.09$ Hz, 1 H), 3.60 (m, 1 H), 3.78 - 3.84 (m, 1 H), 3.84 - 3.89 (m, 1 H), 3.92 (dd, $J=10.35, 2.93$ Hz, 2 H), 4.31 (d, $J=7.42$ Hz, 2 H), 7.57 (dd, $J=8.69, 1.46$ Hz, 1 H), 7.69 (d, $J=8.59$ Hz, 1 H), 7.94 (d, $J=1.76$ Hz, 1 H). MS (APPI) $(\text{M}+\text{H})^+ = 541.3$; Anal. Calc. for $\text{C}_{26}\text{H}_{38}\text{F}_2\text{N}_4\text{O}_4\text{S} + 2.0$ TFA: C, 46.87; H, 5.24; N, 7.29; Found: C, 46.90; H, 5.18; N, 7.18.

Example 116


(2R)-4-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-methylmorpholine-2-carboxamide



Following the same procedure in Example 112, Step A, using 4-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)morpholine-2-carboxylic acid (500 mg, 1 mmol), *N,N*-diisopropylethylamine (1 mL, 5 mmol), methylamine (0.75 mL, 2.0M in THF, 1.5 mmol) and HATU (456 mg, 1.2 mmol) in DMF (10 mL). The crude product was purified by LCMS using high pH column 40-70% acetonitrile gradient to give 400 mg (78% yield) as white solid racemic mixture of the title compound. The two enantiomers were separated on a chiral OD 5 microns column using 20% ethanol:hexane. $[\alpha]_D$: +37.4 ($c = 1.00$, MeOH). ^1H NMR (400 MHz, METHANOL- D_4) δ 1.37 - 1.46 (m, 2 H), 1.48 (s, 9 H), 1.53 - 1.73 (m, 4 H), 1.88 - 2.01 (m, 2 H), 2.04 - 2.18 (m, 2 H), 2.29 (m, 1 H), 2.59 (s, 3 H), 3.43 - 3.49 (m, 1 H), 3.59 (m, 1 H), 3.77 - 3.85 (m, 1 H), 3.87 - 3.96 (m, 2 H), 4.30 (d, $J=7.62$ Hz, 2 H), 7.54 (dd, $J=8.69$, 1.66 Hz, 1 H), 7.67 (d, $J=8.59$ Hz, 1 H), 7.93 (d, $J=1.76$ Hz, 1 H); MS (APPI) $(\text{M}+\text{H})^+ = 513.3$; Anal. Calc. for $\text{C}_{24}\text{H}_{34}\text{F}_2\text{N}_4\text{O}_4\text{S} + 1.5 \text{ TFA}$: C, 47.44; H, 5.23; N, 8.20; Found: C, 47.54; H, 4.91; N, 8.00.

Example 117


(3R)-1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-ol



Following the same procedure in Example 1, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (50 mg, 0.12 mmol), *N,N*-diisopropylethylamine (0.1 mL, 0.48 mmol) and (R)-(-)-3-pyrrolidinol hydrochloride (23 mg, 0.19 mmol) in (1 mL) methylene chloride. The crude product was purified by LCMS using high pH column 40-70% acetonitrile gradient to give 42 mg (61% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.43 - 1.52 (m, 2 H), 1.56 (s, 9 H), 1.60 - 1.69 (m, 3 H), 1.90 - 2.01 (m, 3 H), 2.09 - 2.21 (m, 1 H), 3.05 - 3.11 (m, 1 H), 3.20 - 3.25 (m, 2 H), 3.26 - 3.34 (m, 3 H), 4.13 - 4.18 (m, 1 H), 4.44 (d, J=7.62 Hz, 2 H), 7.81 (dd, J=8.79, 1.76 Hz, 1 H), 7.89 - 7.93 (m, 1 H), 8.04 (d, J=1.17 Hz, 1 H); MS (ESI) (M+H)⁺=455.2; Anal. Calc. for C₂₂H₃₁F₂N₃O₃S + 1.3 TFA + 0.50 H₂O + 0.2 CH₃CN: C, 48.75; H, 5.46; N, 7.16; Found: C, 48.78; H, 5.48; N, 7.11.

Example 118

N-[(3R)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]acetamide




Following the same procedure in Example 1, step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (300 mg, 0.74 mmol), *N,N*-diisopropylethylamine (0.5 mL, 3 mmol) and (3R)-(+)-3-acetamidopyrrolidine (142 mg, 1.1 mmol) in (1 mL) methylene chloride. The crude product was purified by LCMS using high pH column 40-70% acetonitrile gradient to give 15 mg (4% yield) of a white solid as the title compound. ¹H NMR (400 MHz, METHANOL-D₄) δ 1.51 - 1.65 (m, 3 H), 1.69 (s, 9 H), 1.71 - 1.77 (m, 4 H), 1.78 (s, 3 H), 1.93 - 2.12 (m, 3 H), 2.21 - 2.33 (m, 1 H), 3.15 (dd, J=10.35, 4.69 Hz, 1 H), 3.21 - 3.28 (m, 1 H), 3.37 - 3.49 (m, 2 H), 4.00 - 4.11 (m, 1 H), 4.58 (d, J=7.42 Hz, 2 H), 7.91 (d, J=8.59 Hz, 1 H), 8.09 (d, J=8.79 Hz, 1 H), 8.12 (s, 1 H); MS (ESI) (M+H)⁺=496.6;


Anal. Calc. for $C_{24}H_{34}F_2N_4O_3S$ + 4.2 TFA + 2.9 H_2O + 2.4 CH_3CN : C, 39.67; H, 4.58; N, 7.16; Found: C, 39.69; H, 4.61; N, 7.96.

Example 119

(3S)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-amine



Step A: (3S)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-amine




Following the same procedure in Example 112, step B, using *tert*-butyl [(3S)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]carbamate (2.8 g, 5 mmol) (see the following step B for preparation), and 4N HCl in dioxane (50 mL).

Yield: 2.0 g (82 %). 1H NMR (400 MHz, METHANOL- D_4) δ 1.45 - 1.56 (m, 3 H), 1.63 (s, 9 H), 1.65 - 1.80 (m, 4 H), 1.94 - 2.05 (m, 2 H), 3.10 - 3.18 (m, 1 H), 3.33 - 3.42 (m, 2 H), 3.46 - 3.54 (m, 1 H), 3.54 - 3.59 (m, 2 H), 3.70 - 3.80 (m, 1 H), 4.53 (d, $J=7.23$ Hz, 2 H), 7.96 (d, $J=8.98$ Hz, 1 H), 8.11 (d, $J=8.98$ Hz, 1 H), 8.16 (s, 1 H); MS (APPI) $(M+H)^+=455.3$; Anal.

Calc. for $C_{22}H_{32}F_2N_4O_2S$ + 2.5 HCl + 1.2 H_2O : C, 46.57; H, 6.56; N, 9.88; Found: C, 46.73; H, 6.55; N, 9.40.


Step B: *tert*-butyl [(3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]carbamate



Following the same procedure in Example 1, step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (2 g, 5 mmol), *N,N*-diisopropylethylamine (3.5 mL, 20 mmol) and (3*S*)-(-)-3-(*tert*-butoxycarbonylamino)pyrrolidine (1.4 g, 7.5 mmol) in (10 mL) methylene chloride. The crude product was purified by MPLC on silica gel using 8-70% EtOAc/hexane. Yield: 2.77 g (100%).
¹H NMR (400 MHz, METHANOL-D₄) δ 1.35 (s, 9 H) 1.52 (d, *J*=11.72 Hz, 4 H) 1.58 (s, 9 H) 1.62 - 1.73 (m, 4 H) 1.75 - 1.81 (m, 1 H) 1.93 - 2.00 (m, 1 H) 3.03 - 3.10 (m, 1 H) 3.24 - 3.29 (m, 2 H) 3.35 - 3.47 (m, 3 H) 4.40 (d, *J*=7.42 Hz, 2 H) 7.71 - 7.78 (m, 2 H) 8.09 (d, *J*=1.37 Hz, 1 H).

Example 120

N-[(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]cyclopropanecarboxamide




(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-amine hydrochloride (200 mg, 0.41 mmol) was dissolved in methylene chloride (3 mL) followed by addition of *N,N*-diisopropylethylamine (0.3 mL, 1.64 mmol). The reaction mixture was cooled down to 0 °C followed by addition of cyclopropanecarbonyl

chloride (43 mg, 0.41 mmol) dropwise and the mixture was allowed to warm to room temperature. The reaction was quenched with methylamine and concentrated under vacuum. The crude product was purified on LCMS using low pH column 30-60% acetonitrile gradient to afford 160 mg (65%) white solid of the title compound. $[\alpha]_D -2.2^\circ$ ($c = 0.98$, MeOH); ^1H NMR (400 MHz, METHANOL- D_4) δ 1.45 - 1.56 (m, 3 H), 1.63 (s, 9 H), 1.65 - 1.80 (m, 4 H), 1.94 - 2.05 (m, 2 H), 3.10 - 3.18 (m, 1 H), 3.33 - 3.42 (m, 2 H), 3.46 - 3.54 (m, 1 H), 3.54 - 3.59 (m, 2 H), 3.70 - 3.80 (m, 1 H), 4.53 (d, $J=7.23$ Hz, 2 H), 7.96 (d, $J=8.98$ Hz, 1 H), 8.11 (d, $J=8.98$ Hz, 1 H), 8.16 (s, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 523$; Anal. Calc. for $\text{C}_{26}\text{H}_{36}\text{F}_2\text{N}_4\text{O}_3\text{S} + 2.0$ TFA: C, 48.00; H, 5.10; N, 7.46; Found: C, 48.15; H, 5.02; N, 7.25.

Example 121

N-[(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]propanamide




Following the same procedure in Example 120, using (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-amine hydrochloride (200 mg, 0.41 mmol), *N,N*-diisopropylethylamine (0.3 mL, 1.64 mmol), propionic anhydride (53 μL , 0.41 mmol) in methylene chloride (3 mL). The crude product was purified on LCMS using low pH column 30-60% acetonitrile gradient to afford 160 mg (62%) white solid of the title compound. $[\alpha]_D -2.9^\circ$ ($c = 1.10$, MeOH); ^1H NMR (400 MHz, METHANOL- D_4) δ 1.01 (t, $J=7.62$ Hz, 3 H), 1.56 - 1.65 (m, 2 H), 1.69 (s, 9 H), 1.72 - 1.83 (m, 5 H), 1.95 - 2.04 (m, 3 H), 2.04 - 2.12 (m, 2 H), 2.22 - 2.31 (m, 1 H), 3.15 (dd, $J=10.45, 4.98$ Hz, 1 H), 3.25 - 3.29 (m, 1 H), 3.44 (dd, $J=10.55, 6.25$ Hz, 1 H), 3.46 - 3.51 (m, 1 H), 4.02 - 4.09 (m, 1 H), 4.58 (d, $J=7.62$ Hz, 2 H), 7.94 (dd, $J=8.79, 1.76$ Hz, 1 H), 8.09 (d, $J=8.79$ Hz, 1 H), 8.15 (d, $J=1.56$ Hz,

1 H); MS (ESI) (M+H)⁺=511; Anal. Calc. for C₂₅H₃₆F₂N₄O₃S + 1.8 TFA + 0.2 H₂O: C, 47.74; H, 5.35; N, 7.79; Found: C, 47.75; H, 5.33; N, 7.78.

Example 122


5 *N*-[(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]acetamide




Following the same procedure in Example 120, using (3*S*)-1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-amine (200 mg, 0.41 mmol), *N,N*-diisopropylethylamine (0.3 mL, 1.64 mmol), acetic anhydride (39 μ L, 0.41 mmol) in methylene chloride (3 mL). The crude product was purified on LCMS using low pH column 30-60% acetonitrile gradient to afford 160 mg (64%) white solid of the title compound. $[\alpha]_D - 3.4^\circ$ (c = 1.10, MeOH); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.53 - 1.65 (m, 3 H), 1.70 (s, 9 H), 1.72 - 1.77 (m, 3 H), 1.78 (s, 3 H), 1.95 - 2.13 (m, 4 H), 2.21 - 2.33 (m, 1 H), 3.16 (dd, $J=10.35, 4.69$ Hz, 1 H), 3.24 - 3.28 (m, 1 H), 3.39 - 3.42 (m, 1 H), 3.43 - 3.50 (m, 1 H), 4.01 - 4.09 (m, 1 H), 4.59 (d, $J=7.62$ Hz, 2 H), 7.92 (dd, $J=8.79, 1.56$ Hz, 1 H), 8.10 (d, $J=8.98$ Hz, 1 H), 8.12 (d, $J=1.17$ Hz, 1 H); MS (ESI) (M+H)⁺=497;

Example 123 and 124

20 (2*S*)-4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropylmorpholine-2-carboxamide




(2R)-4-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropylmorpholine-2-carboxamide



5

Step A. (2R)-4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropylmorpholine-2-carboxamide



10


2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (1.1 g, 2.7 mmol) was added to a solution of 2-[(cyclopropylamino)carbonyl]morpholin-4-ium trifluoroacetate (0.92 g, 3.2 mmol) (see the following step B for preparation) and DIPEA (1.5 mL, 8.1 mmol) in DCE at 80°C. The reaction mixture was stirred for 1 h and washed with saturated NaHCO₃ solution, water and brine. The solvent was concentrated to provide the racemic title compound as white solid. The enantiomers were separated by chiral preparative HPLC to provide the title compounds.

15

Example 123 (isomer-1): 76 mg (4%); $[\alpha]_D$: -35.1° ($c = 1.29$, CD_3OD); ^1H NMR (400 MHz, CD_3OD) δ 0.39 - 0.53 (m, 2 H), 0.62 - 0.75 (m, 2 H), 1.49 - 1.65 (m, 2 H), 1.68 (s, 9 H), 1.70 - 1.86 (m, 4 H), 2.00 - 2.14 (m, 2 H), 2.24 (dd, $J=11.62$, 10.45 Hz, 2 H), 2.45 (td, $J=11.52$, 3.32 Hz, 1 H), 2.57 - 2.66 (m, 1 H), 3.60 (d, $J=11.52$ Hz, 1 H), 3.68 (m, 1 H), 3.86 - 3.94 (m, 1 H), 3.96 - 4.05 (m, 2 H), 4.56 (d, $J=7.62$ Hz, 2 H), 7.88 (dd, $J=8.69$, 1.66 Hz, 1 H), 8.08 (d, $J=8.79$ Hz, 1 H), 8.12 (d, $J=1.56$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 539.3$.

Example 124 (isomer-2): Yield: 70 mg (4%); $[\alpha]_D$ $+40.2^\circ$ ($c = 1.05$, CD_3OD); ^1H NMR (400 MHz, CD_3OD) δ 0.40 - 0.54 (m, 2 H), 0.62 - 0.74 (m, 2 H), 1.48 - 1.63 (m, 2 H), 1.65 (s, 9 H), 1.68 - 1.76 (m, $J=15.62$ Hz, 4 H), 1.77 - 1.84 (m, 1 H), 1.99 - 2.13 (m, 2 H), 2.22 (dd, $J=11.43$, 10.45 Hz, 2 H), 2.43 (m, 1 H), 2.57 - 2.66 (m, 1 H), 3.67 (td, $J=11.47$, 2.83 Hz, 1 H), 3.86 - 3.93 (m, 1 H), 3.96 - 4.06 (m, 2 H), 4.52 (d, $J=7.42$ Hz, 2 H), 7.82 (dd, $J=8.79$, 1.56 Hz, 1 H), 8.01 (d, $J=8.79$ Hz, 1 H), 8.09 (d, $J=1.37$ Hz, 1 H); MS (ESI) $(\text{M}+\text{H})^+ = 539.3$.


Step B. 2-[(cyclopropylamino)carbonyl]morpholin-4-ium trifluoroacetate



HATU (3.7 g, 9.7 mmol) and cyclopropylamine (0.53 g, 9.3 mmol) were added to a solution of 4-(*tert*-butoxycarbonyl)morpholine-2-carboxylic acid (2.0 g, 8.9 mmol) in DMF. The reaction mixture was stirred for 3 h and the solvent was concentrated. The residue was recovered in EtOAc and washed with saturated NaHCO_3 solution, water and brine. The solvent was concentrated and the resulting beige solid was treated with TFA (50 mL) for 3 hrs. The solvent was concentrated to provide the title compound as yellow oil that was used for the next step without further purification. Yield: 2.1 g (99%).

Example 125


1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-1H-pyrazole-4-carboxamide




- 5 Following the same procedure in Example 72, step A, using HATU (87 mg, 0.22 mmol), 1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-1H-pyrazole-4-carboxylic acid (100 mg, 0.20 mmol), DIPEA (0.36 mL, 2.8 mmol) and gaseous ammonia in DMF (6 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt.
- 10 Yield: 46 mg (46%); ¹H NMR (400 MHz, CD₃OD) δ 1.42 - 1.57 (m, 2 H), 1.60 (s, 9 H), 1.62 - 1.71 (m, 3 H), 1.71 - 1.80 (m, 1 H), 1.96 - 2.10 (m, 4 H), 2.11 - 2.26 (m, 1 H), 4.44 (d, J=7.42 Hz, 2 H), 7.88 - 7.94 (m, 1 H), 7.97 - 8.03 (m, 1 H), 8.06 (d, J=0.59 Hz, 1 H), 8.36 (d, J=1.56 Hz, 1 H), 8.79 (d, J=0.59 Hz, 1 H); MS (ESI) (M+H)⁺ 479.9.

15 **Example 126**

1-({2-tert-Butyl-1-[(4-fluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-methyl-1H-pyrrole-3-carboxamide




Step A. 1-({2-*tert*-butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-methyl-1*H*-pyrrole-3-carboxamide




HATU (0.24 g, 0.64 mmol) and methylamine (0.32 mL, 2 *M* in THF, 0.64 mmol) were added to a solution of 1-({2-*tert*-butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrrole-3-carboxylic acid (0.28 g, 0.58 mmol) (see following steps B, C, D, E, F, G, H, I, and J for preparation) and DIPEA (0.12 mL, 0.69 mmol) in DMF (5 mL). The reaction mixture was stirred for 1 h and the solvent was concentrated. The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 0.13 g (55%); ¹H NMR (400 MHz, CDCl₃) δ 1.15 - 1.33 (m, 1 H), 1.33 - 1.58 (m, 4 H), 1.59 - 1.67 (m, 10 H), 1.67 - 1.81 (m, 1 H), 1.90 - 2.27 (m, 1 H), 2.90 (d, *J*=4.88 Hz, 3 H), 4.19 - 4.34 (m, 2 H), 4.36 - 4.98 (m, 1 H), 6.49 - 6.59 (m, 1 H), 6.58 - 6.89 (m, 1 H), 7.04 - 7.15 (m, 1 H), 7.42 - 7.58 (m, 1 H), 7.63 - 7.74 (m, 1 H), 7.82 - 7.95 (m, 1 H), 8.48 - 8.65 (m, 1 H); MS (ESI) (*M*+*H*)⁺ = 475.3.

Step B: *tert*-Butyl [(4-fluorocyclohex-3-en-1-yl)methyl]carbamate




4-N-Boc-aminomethyl cyclohexanone (4.95g, 21.8 mmol) was dissolved in THF (80 mL). DAST (4.3 mL, 32.7 mmol) was added dropwise and the solution was stirred at 50 °C for 5 h. The solvent was concentrated and the product purified by flash chromatography on silica gel using hexanes/EtOAc (3:1) as eluent. Yield: 1.62 g (30%). ¹H NMR (400 MHz, CDCl₃) δ 1.36 - 1.42 (m, 1 H), 1.44 (s, 9 H), 1.70 - 1.80 (m, 2 H), 1.82 - 1.90 (m, 1 H), 2.09 - 2.17 (m, 1 H), 2.17 - 2.29 (m, 2 H), 3.04 - 3.11 (m, 2 H), 4.61 (s, 1 H), 5.11 - 5.19 (m, 1 H).

Step C: [(4-Fluorocyclohex-3-en-1-yl)methyl]amine hydrochloride



tert-Butyl [(4-fluorocyclohex-3-en-1-yl)methyl]carbamate (1.62g, 7.06 mmol) was stirred in 25 mL of 1M HCl/AcOH at rt for 2 h. The solvent was evaporated and the product was precipitated in ether, filtered and dried under vacuum. Yield: 1.13g (97%). ¹H NMR (400 MHz, CD₃OD) δ 1.44 - 1.53 (m, 1 H), 1.80 - 1.89 (m, 2 H), 1.90 - 1.98 (m, 1 H), 2.16 - 2.23 (m, 2 H), 2.26 - 2.34 (m, 1 H), 2.88 (d, *J*=6.25 Hz, 2 H), 5.12 - 5.19 (m, 1 H).


Step D: *N*-(4-[(4-Fluorocyclohex-3-en-1-yl)methyl]amino)-3-nitrophenyl)acetamide



N-(4-Fluoro-3-nitrophenyl)acetamide (460 mg, 2.32 mmol) and [(4-fluorocyclohex-3-en-1-yl)methyl]amine hydrochloride (350 mg, 2.11 mmol) were stirred in 20 mL of EtOH containing TEA (0.735 mL, 5.28 mmol) at 75°C for 48 h. The solvent was concentrated. The residue was


dissolved in EtOAc and washed with aqueous 5% KHSO₄, saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash chromatography on silica gel using hexanes/acetone (2:1) as eluent. Yield: 553 mg (85%). ¹H NMR (400 MHz, CDCl₃) δ 1.51 - 1.61 (m, 1 H), 1.84 - 1.93 (m, 1 H), 1.96 - 2.03 (m, 2 H), 2.16 - 2.18 (m, 3 H), 2.22 - 2.32 (m, 3 H), 3.26 (td, *J*=6.05, 2.93 Hz, 2 H), 5.19 (dt, *J*=16.45, 2.61 Hz, 1 H), 6.84 (d, *J*=9.37 Hz, 1 H), 7.21 (s, 1 H), 7.79 (dd, *J*=9.18, 2.54 Hz, 1 H), 8.09 (d, *J*=2.54 Hz, 2 H).

Step E: *N*-(3-Amino-4-{[(4-fluorocyclohexyl)methyl]amino}phenyl)acetamide



N-(4-{[(4-Fluorocyclohex-3-en-1-yl)methyl]amino}-3-nitrophenyl)acetamide (340mg, 1.11 mmol) was dissolved in 25 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under H₂ atmosphere (40 psi) using a Parr hydrogenation apparatus at rt for 48h. The solution was filtered through Celite and the solvent was evaporated. Yield: 308 mg (99%). MS (ESI) (*M*+H)⁺ = 279.95.


Step F: *N*-(2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl)acetamide



N-(3-Amino-4-{[(4-fluorocyclohexyl)methyl]amino}phenyl)acetamide (300 mg, 1.07 mmol) and DMAP (25 mg, 0.214 mmol) were dissolved in DCM (10 mL). Trimethylacetyl chloride


(0.145 mL, 1.18 mmol) was added dropwise and the solution was stirred at rt for 1h. The solution was washed with aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The residue was dissolved in 5 mL of AcOH and was heated at 150°C for 2.5 h using a Personal Chemistry microwave apparatus. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash chromatography on silica gel using acetone/hexane (2:1) as eluent. Yield: 196 mg (53%). ¹H NMR (400 MHz, CDCl₃) δ 1.14 - 1.25 (m, 2 H), 1.37 - 1.45 (m, 1 H), 1.43 - 1.51 (m, 1 H), 1.54 - 1.57 (m, 9 H), 1.70 - 1.78 (m, 2 H), 1.70 - 1.77 (m, 1 H), 2.02 - 2.08 (m, 1 H), 2.10 - 2.17 (m, 1 H), 2.19 - 2.21 (m, 3 H), 4.12 - 4.19 (m, 2 H), 4.53 - 4.90 (m, 1 H), 7.21 - 7.29 (m, 1 H), 7.30 (s, 1 H), 7.50 - 7.57 (m, 1 H), 7.64 - 7.67 (m, 1 H).

Step G: 2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-amine




N-{2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}acetamide (190 mg, 0.550 mmol) was heated in 5 mL of 2 *M* HCl/EtOH (1:1) at 120°C for 1 h using a Personal Chemistry microwaves apparatus. The solvent was evaporated. The residue was basified with 2*M* NaOH and extracted (3X) with EtOAc. The organic phase was washed with saturated aqueous NaCl solution and dried over anhydrous Na₂SO₄. The solvent was evaporated. Yield: 154 mg (92%). ¹H NMR (400 MHz, CD₃OD) δ 1.28 - 1.39 (m, 2 H), 1.41 - 1.50 (m, 1 H), 1.53 - 1.59 (m, 1 H), 1.61 - 1.64 (m, 9 H), 1.69 (d, *J*=7.81 Hz, 2 H), 1.95 - 2.22 (m, 3 H), 4.37 - 4.83 (m, 3 H), 7.11 - 7.13 (m, 1 H), 7.15 - 7.18 (m, 1 H), 7.67 - 7.73 (m, 1 H).

Step H. 2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride



A solution of NaNO_2 (0.21 g, 3.0 mmol) in water (0.5 mL) was slowly added to a solution of 2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-amine (0.84 g, 2.7 mmol) in 6 mL of AcOH/HCl (1:2) at 0 °C. The reaction mixture was stirred for 1 h at 0 °C. The reaction mixture was added to a mixture of liquid SO_2 (~6 mL), $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ (0.19 g, 1.1 mmol) and AcOH (3 mL) at -20 °C. The resulting mixture was allowed to warm to 0 °C and stirred for 3 h. The reaction mixture was poured over ice (50 mL) while vigorously shaking. The quenched reaction mixture was stirred for 30 min at 0 °C. The product was extracted with cold DCM and the organic layers were combined and dried over anhydrous Na_2SO_4 . The solvent was concentrated to provide the pure title compound as beige solid. Yield: 0.98 g (92%); MS (ESI) $(\text{M}+\text{H})^+ = 387.2$.


Step I. 1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrrole-3-carbaldehyde



NaH (0.19 g, 60%, 4.8 mmol) was added to a solution of 1*H*-pyrrole-3-carbaldehyde (0.13 g, 1.4 mmol) in THF (30 mL) at 0 °C. The reaction mixture was allowed to warm to ambient temperature, stirred for 1 h and cooled to 0 °C. 2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-

1*H*-benzimidazole-5-sulfonyl chloride (0.37 g, 0.96 mmol) was added to the reaction mixture and stirred for 1 h. The reaction mixture was quenched with saturated NaHCO₃ solution (30 mL) and the solvent was concentrated. Water (50 mL) was added to the residue and the product was extracted with DCM (workup). The solvent was concentrated and the product was purified by MPLC on silica gel using 50-80% EtOAc/heptane to provide the title compound as white solid. Yield: 0.25 g (57%); MS (ESI) (M+H)⁺ = 445.9.


Step J. 1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrrole-3-carboxylic acid



Oxone® (0.36 g, 0.53 mmol) was added to a solution of 1-({2-*tert*-butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrrole-3-carbaldehyde (0.23 g, 0.53 mmol) in DMF (15 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The product was recovered in DCM, washed with 10% HCl solution, brine and dried over anhydrous Na₂SO₄. The solvent was concentrated to provide the pure title compound as white solid. Yield: 0.26 g (99%). MS (ESI) (M+H)⁺ = 462.1.

Example 127


1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrrole-3-carboxamide



Following the same procedure in Example 126, step A, using gaseous ammonia, HATU (58 mg, 0.15 mmol), 1-({2-*tert*-butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrrole-3-carboxylic acid (64 mg, 0.14 mmol) and DIPEA (30 μ L, 0.17 mmol) in DMF (5 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 29 mg (36%); ¹H NMR (400 MHz, CDCl₃) δ 1.10 - 1.34 (m, 1 H), 1.34 - 1.53 (m, 4 H), 1.52 - 1.64 (m, 10 H), 1.64 - 1.79 (m, 1 H), 1.88 - 2.24 (m, 1 H), 4.15 - 4.28 (m, 2 H), 4.33 - 4.97 (m, 1 H), 6.63 (dd, *J*=3.32, 1.56 Hz, 1 H), 7.09 - 7.22 (m, 1 H), 7.40 - 7.53 (m, 1 H), 7.76 (dd, *J*=8.69, 1.86 Hz, 1 H), 7.81 - 7.91 (m, 1 H), 8.32 (s, 1 H); MS (ESI) (*M*+*H*)⁺ = 461.2.

Example 128

1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropyl-1*H*-pyrrole-3-carboxamide




Following the same procedure in Example 126, step A, using cyclopropylamine (10mg, 0.17 mmol), HATU (58 mg, 0.15 mmol), 1-({2-*tert*-butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-


benzimidazol-5-yl)sulfonyl)-1*H*-pyrrole-3-carboxylic acid (64 mg, 0.14 mmol) and DIPEA (30 uL, 0.17 mmol) in DMF (5 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 36 mg (42%); ¹H NMR (400 MHz, CDCl₃) δ 0.59 (m, 2 H), 0.69 - 0.88 (m, 2 H), 1.12 - 1.33 (m, 2 H), 1.33 - 1.55 (m, 2 H), 1.57 - 1.70 (m, 10 H), 1.73 (m, 3 H), 1.89 - 2.31 (m, 1 H), 2.64 - 2.88 (m, 1 H), 4.24 - 4.38 (m, 2 H), 4.37 - 5.02 (m, 1 H), 6.45 - 6.62 (m, 1 H), 6.69 - 6.93 (m, 1 H), 7.08 (s, 1 H), 7.49 - 7.62 (m, 1 H), 7.65 (s, 1 H), 7.79 - 7.96 (m, 1 H), 8.40 - 8.57 (m, 1 H); MS (ESI) (M+H)⁺ = 501.3.

Example 129

1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-(2-hydroxyethyl)-1*H*-pyrrole-3-carboxamide




Following the same procedure in Example 126, step A, using 2-hydroxyethylamine (10 mg, 0.17 mmol), HATU (58 mg, 0.15 mmol), 1-({2-*tert*-butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrrole-3-carboxylic acid (64 mg, 0.14 mmol) and DIPEA (30 uL, 0.17 mmol) in DMF (5 mL). The crude product was purified by reverse-phase preparative HPLC using 10-90% MeCN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 26 mg (30%); ¹H NMR (400 MHz, CDCl₃) δ 1.14 - 1.30 (m, 1 H), 1.32 - 1.51 (m, 3 H), 1.51 - 1.64 (m, 10 H), 1.71 (d, J=12.50 Hz, 1 H), 1.89 - 2.24 (m, 3 H), 3.47 (q, J=5.08 Hz, 2 H), 3.60 - 3.78 (m, 2 H), 4.16 - 4.32 (m, 2 H), 4.35 - 4.97 (m, 1 H), 6.56 - 6.70 (m, 1 H), 7.08 - 7.21 (m, 1 H), 7.40 - 7.45 (m, 1 H), 7.46 - 7.62 (m, 1 H), 7.71 - 7.87 (m, 2 H), 8.30 (d, J=1.37 Hz, 1 H); MS (ESI) (M+H)⁺ = 505.3.

EXAMPLE 130**1-({2-tert-Butyl-1-[(4-fluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-ethyl-1H-pyrrole-3-carboxamide**

NaH (30 mg, 60%, 0.74 mmol) was added to a solution of *N*-ethyl-1*H*-pyrrole-3-carboxamide (50 mg, 0.36 mmol) in THF (5 mL) at 0 °C. The reaction mixture was allowed to warm to ambient temperature, stirred for 1 h and cooled to 0 °C. 2-*tert*-butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (90 mg, 0.24 mmol) was added to the reaction mixture and stirred for 1 hr. The reaction mixture was quenched with saturated NaHCO₃ solution (5 mL) and the solvent was concentrated. Water (15 mL) was added to the residue and the product was extracted with DCM (workup). The product was purified by preparative reverse-phase HPLC to provide the TFA salt of the title compound as white solid. Yield: 46 mg (31%); ¹H NMR (400 MHz, CDCl₃) δ 1.18 (t, J=7.23 Hz, 3 H), 1.25 (m, 2 H), 1.35 - 1.58 (m, 2 H), 1.58 - 1.68 (m, 9 H), 1.68 - 1.79 (m, 1 H), 1.95 - 2.23 (m, 2 H), 3.34 - 3.46 (m, 2 H), 4.27 (dd, J=15.14, 7.52 Hz, 2 H), 4.37 - 4.60 (m, 1 H), 4.77 - 4.98 (m, 1 H), 6.52 - 6.58 (m, 1 H), 7.08 - 7.16 (m, 1 H), 7.45 - 7.58 (m, 1 H), 7.65 - 7.71 (m, 1 H), 7.84 - 7.93 (m, 1 H), 8.54 (dd, J=18.85, 1.66 Hz, 1 H); MS (ESI) (M+H)⁺ = 437.7.


Example 131:**1-({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}sulfonyl)-N-(2-hydroxyethyl)-1H-pyrazole-4-carboxamide**



1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid (56 mg, 0.116 mmol), HATU (53 mg, 0.139 mmol) and ethanolamine (8 μ L, 0.139 mmol) were stirred in 5 mL of DMF containing DIPEA (30 μ L, 0.174 mmol) at rt for 2 h. The solvent was evaporated. The product was dissolved in EtOAc and washed with saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The solvent was evaporated and the product was purified by reversed-phase HPLC using 10-50% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 36 mg (49%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.45 - 1.57 (m, 2 H), 1.60 (s, 9 H), 1.61 - 1.70 (m, 2 H), 1.71 - 1.79 (m, 1 H), 1.81 - 1.88 (m, 1 H), 1.98 - 2.09 (m, 3 H), 2.14 - 2.23 (m, 1 H), 2.84 (d, J =7.03 Hz, 1 H), 3.40 (t, J =5.66 Hz, 2 H), 3.63 (t, J =5.66 Hz, 2 H), 4.45 (d, J =7.42 Hz, 2 H), 7.92 - 7.97 (m, 1 H), 8.00 - 8.04 (m, 1 H), 8.06 (s, 1 H), 8.37 (d, J =1.56 Hz, 1 H), 8.78 (s, 1 H); MS (ESI) (M+H)⁺ = 524.3.

Example 132


2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-5-[(3-fluoroazetidin-1-yl)sulfonyl]-1*H*-benzimidazole



1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-ol (78 mg, 0.177 mmol) was dissolved in 5 mL of DCM at 0 °C under nitrogen. DAST (0.035 mL, 0.266 mmol) was added dropwise and the solution was stirred at rt for 2 h. Another 0.035 mL of DAST was added and the solution was stirred at rt for another 2h. The solution was washed with saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The solvent was evaporated and the product was purified by reversed-phase HPLC using 10-50% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 37 mg (37%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.55 (t, 2 H), 1.64 (s, 9 H), 1.67 - 1.75 (m, 3 H), 1.75 - 1.82 (m, 1 H), 2.00 - 2.10 (m, 2 H), 2.20 - 2.29 (m, 1 H), 3.73 - 3.85 (m, 2 H), 4.05 - 4.16 (m, 2 H), 4.51 (d, *J*=7.42 Hz, 2 H), 5.00 - 5.21 (m, 1 H), 7.89 (dd, *J*=8.69, 1.66 Hz, 1 H), 8.01 (d, *J*=8.20 Hz, 1 H), 8.16 (d, *J*=1.17 Hz, 1 H); MS (ESI) (*M*+H)⁺ = 443.95.

Example 133

1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropyl-1*H*-pyrazole-4-carboxamide




1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid (30 mg, 0.0649 mmol) (see following steps B and C for preparation), HATU (30 mg, 0.0779 mmol) and cyclopropylamine (6 uL, 0.0779 mmol) were stirred in 1 mL of DMF containing DIPEA (17 uL, 0.0974 mmol) at rt for 1h. The solvent was evaporated. The product was dissolved in EtOAc and washed with saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The solvent was evaporated and the product was purified by reversed-phase HPLC using 10-50% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 25 mg (63%). ¹H NMR (400 MHz,

METHANOL-D₄) δ 0.52 - 0.58 (m, 2 H), 0.72 - 0.78 (m, 2 H), 1.24 - 1.41 (m, 4 H), 1.58 (s, 9 H), 1.60 - 1.67 (m, 2 H), 2.00 - 2.10 (m, 3 H), 2.71 - 2.79 (m, 1 H), 4.34 - 4.55 (m, 3 H), 7.85 - 7.89 (m, 1 H), 7.95 - 7.99 (m, 1 H), 8.03 (s, 1 H), 8.33 (d, $J=1.56$ Hz, 1 H), 8.74 (s, 1 H); MS (ESI) $(M+H)^+ = 501.94$.

5.


Step B: 1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carbaldehyde



10 2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (400 mg, 1.03 mmol), pyrazole-4-carboxaldehyde (300 mg, 3.09 mmol) (see Example 126, step H for preparation) and DMAP (catalytic) were stirred in 10 mL of DCM containing DIPEA (0.90 mL, 5.15 mmol) at rt for 3 h. The solution was washed with saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash
15 chromatography on silica gel using hexanes/EtOAc (1:1) as eluent. Yield: 131 mg (28%). ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.16 - 1.26 (m, 2 H), 1.35 - 1.48 (m, 2 H), 1.54 - 1.56 (m, 9 H), 1.72 (dd, $J=8.69$, 3.03 Hz, 2 H), 1.95 - 2.04 (m, 1 H), 2.11 - 2.19 (m, 2 H), 4.17 - 4.21 (m, 2 H), 4.37 - 4.46 (m, 1 H), 4.50 - 4.59 (m, 1 H), 7.44 (d, $J=8.59$ Hz, 1 H), 7.96 (dd, $J=8.69$, 1.86 Hz, 1 H), 8.08 (s, 1 H), 8.44 (d, $J=1.37$ Hz, 1 H), 8.64 (s, 1 H), 9.91 (s, 1 H).

20


Step C: 1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid



1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carbaldehyde (130 mg, 0.291 mmol) and oxone (215 mg, 0.349 mmol) were stirred in 10 mL of DMF at rt overnight. The solvent was evaporated. The residue was dissolved in DCM and washed with water, brine and dried over anhydrous MgSO_4 . Yield: 135 mg (99%). MS (ESI) $(\text{M}+\text{H})^+ = 463.06$.

Example 134

1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethyl-1*H*-pyrazole-4-carboxamide




Following the same procedure in Example 133, step A, using 1-({2-*tert*-butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid (30 mg, 0.0649 mmol), HATU (30 mg, 0.0779 mmol), DIPEA (0.017 mL, 0.0974 mmol) and ethylamine (40 μL , 2 *M* in THF, 0.0779 mmol) in DMF (1 mL). The product was purified by reversed-phase HPLC using 10-50% $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ and lyophilized affording the title compound as the corresponding TFA salt. Yield: 28 mg (71%). ^1H NMR (400 MHz, METHANOL- D_4) δ 1.15 (t, $J=7.23$ Hz, 3 H), 1.25 - 1.40 (m, 4 H), 1.59 (s, 9 H), 1.61 - 1.68 (m, 2 H), 2.01 - 2.09

(m, 3 H), 3.30 - 3.34 (m, 2 H) 4.35 - 4.53 (m, 3 H), 7.88 - 7.92 (m, 1 H), 7.97 - 8.02 (m, 1 H), 8.04 (s, 1 H), 8.35 (d, $J=1.37$ Hz, 1 H), 8.75 (s, 1 H); MS (ESI) $(M+H)^+ = 489.98$.

Example 135


5 **1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-(2-hydroxyethyl)-1*H*-pyrazole-4-carboxamide**



Following the same procedure in Example 133, step A, using 1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxylic acid (30 mg, 0.0649 mmol), HATU (30 mg, 0.0779 mmol), DIPEA (0.017 mL, 0.0974 mmol) and ethanolamine (0.005 mL, 0.0779 mmol) in DMF (1 mL). The product was purified by reversed-phase HPLC using 10-50% CH_3CN/H_2O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 28 mg (70%). 1H NMR (400 MHz, $METHANOL-D_4$) δ 1.24 - 1.43 (m, 4 H), 1.58 (s, 9 H), 1.60 - 1.68 (m, 2 H), 2.01 - 2.09 (m, 3 H), 3.40 (t, $J=5.76$ Hz, 2 H), 3.63 (t, $J=5.76$ Hz, 2 H), 4.33 - 4.54 (m, 3 H), 7.86 - 7.90 (m, 1 H), 7.96 - 8.01 (m, 1 H), 8.05 (d, $J=0.78$ Hz, 1 H), 8.34 (d, $J=1.37$ Hz, 1 H), 8.77 (s, 1 H); MS (ESI) $(M+H)^+ = 505.90$.

Example 136


20 **1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-methyl-1*H*-pyrazole-4-carboxamide**




Following the same procedure in Example 133, step A, using 1-(2-*tert*-butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl)sulfonyl)-1*H*-pyrazole-4-carboxylic acid (40 mg, 0.0849 mmol), HATU (40 mg, 0.102 mmol), DIPEA (0.023 mL, 0.127 mmol) and methylamine (52 μ L, 2 *M* in THF, 0.102 mmol) in DMF (1 mL). The product was purified by reversed-phase HPLC using 10-50% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 20 mg (39%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.26 - 1.40 (m, 4 H), 1.58 (s, 9 H), 1.60 - 1.67 (m, 2 H), 2.01 - 2.09 (m, 3 H), 2.82 (s, 3 H), 4.33 - 4.55 (m, 3H), 7.86 (d, *J*=8.79 Hz, 1 H), 7.95 - 7.99 (m, 1 H), 8.02 (d, *J*=0.59 Hz, 1 H), 8.33 (d, *J*=1.76 Hz, 1 H), 8.72 (d, *J*=0.78 Hz, 1 H); MS (ESI) (*M*+*H*)⁺ = 476.3.

Example 137

2-(1-([2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl)sulfonyl]azetidin-3-yl)-*N*-ethylacetamide




Step A: 2-(1-([2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl)sulfonyl]azetidin-3-yl)-*N*-ethylacetamide



Following the same procedure in Example 24, Step A, using ethylamine hydrochloride (36 mg, 0.44 mmol), DIPEA (1 mL), (1-([2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)azetidin-3-yl)acetic acid (100 mg, 0.22 mmol) (see following step
 5 B for preparation) and HATU (161 mg, 0.44 mmol) in DMF (2.5 mL), provided the title compound as its TFA salt (32 mg, 23 %). ¹H NMR (400 MHz, CDCl₃) δ 1.06 (t, J=7.4 Hz, 3 H), 1.66 (m, 4 H), 1.73 (s, 9 H), 2.28 (d, J = 7.8 Hz, 2 H), 2.32 (m, 1 H), 2.88 (m, 1 H), 3.17 (m, 2 H), 3.35 (m, 4 H), 3.88 (t, J=8.0 Hz, 2 H), 4.02 (d, J=8.2 Hz, 2 H), 4.43 (d, J=7.3 Hz, 2 H), 6.31 (m, 1H), 7.75 (s, 2 H), 8.05 (s, 1 H); MS (ESI) (M+H)⁺ = 477.2.

10


Step B: (1-([2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl)azetidin-3-yl)acetic acid



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (700 mg, 1.9 mmol), azetidin-3-ylacetic acid hydrochloride (495 mg, 3.3 mmol) and DIPEA (4 mL) in DMF (20 mL), provided
 15 the title compound as a crude product (600 mg, 70 %), which was used directly in Step A.

Example 138


2-(1-{{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}azetidin-3-yl)-*N*-(2-fluoroethyl)acetamide



Following the same procedure in Example 24, Step A, using (2-fluoroethyl)amine hydrochloride (44 mg, 0.44 mmol), DIPEA (1 mL), (1-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}azetidin-3-yl)acetic acid (100 mg, 0.22 mmol) and HATU (161 mg, 0.44 mmol) in DMF (2.5 mL), provided the title compound as its TFA salt (16 mg, 12 %). MS (ESI) ($M+H$)⁺ 495.3.

Example 139

1-{{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-(2-fluoroethyl)-1*H*-pyrrole-3-carboxamide




Following the same procedure in Example 31, method B, using 2-fluoroethylamine hydrochloride (0.70 g, 6.98 mmol), *N,N*-diisopropylethylamine (2.13 mL, 12.3 mmol), HATU (1.46 g, 3.83 mmol) and 1-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxylic acid (3.49 mmol) in DMF (90 mL). The crude product was purified by MPLC on silica gel using EtOAc to provide the title compound as white solid. Yield: 0.74 g (35%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.40 - 1.46 (m, 5 H), 1.51 (dd, *J*=13.28, 3.71 Hz, 2 H), 1.57 (s, 9 H), 3.52 (td, *J*=26.02, 5.15 Hz, 2 H), 3.86 (dd,

$J=11.52, 3.52$ Hz, 2 H), 4.39 (d, $J=7.81$ Hz, 2 H), 4.43 (m, 2 H), 6.64 (dd, $J=3.32, 1.56$ Hz, 1 H), 7.26 - 7.28 (m, 1 H), 7.80 - 7.83 (m, 1 H), 7.87 - 7.93 (m, 2 H), 8.24 (d, $J=1.17$ Hz, 1 H); MS (APPI) $(M+H)^+=491.3$.

Example 140


1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-(2,2-difluoroethyl)-1*H*-pyrrole-3-carboxamide




Following the same procedure in Example 31, method B, using 2,2-difluoroethylamine (138 mg, 1.7 mmol), *N,N*-diisopropylethylamine (0.8 ml, 4.4 mmol), HATU (646 mg, 1.7 mmol) and 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxylic acid (1.1 mmol) in DMF (15 mL). The crude product was purified on LCMS using high pH column 40-70% acetonitrile gradient to afford 9 mg (2 % yield) of the title compound. ^1H NMR (400 MHz, METHANOL- D_4) δ 1.43 - 1.51 (m, 3 H), 1.51 - 1.58 (m, 2 H), 1.60 (s, 9 H), 3.22 (q, $J=7.36$ Hz, 1 H), 3.33 (d, $J=2.93$ Hz, 1 H), 3.62 (m, 1 H), 3.68 - 3.76 (m, 1 H), 3.90 (dd, $J=10.64, 3.42$ Hz, 2 H), 4.43 (d, $J=7.42$ Hz, 2 H), 5.90 (m, 1 H), 6.68 (dd, $J=3.03, 1.46$ Hz, 1 H), 7.30 - 7.34 (m, 1 H), 7.87 (s, 1 H), 7.90 - 7.99 (m, 2 H), 8.28 (s, 1 H); MS (APPI) $(M+H)^+=509.3$.

Example 141

N-{[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl)methyl}propanamide



Step A: *N*-{[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl)methyl}propanamide



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (81 mg, 0.2 mmol), *N*-(azetidin-3-ylmethyl)propanamide (TFA salt, 102 mg, 0.4 mmol) (see following step B for preparation) and DIPEA (1 mL) in CH₂Cl₂ (10 mL), provided the title compound as its TFA salt (64 mg, 51 % yield). ¹H NMR (400 MHz, CD₃OD) δ 0.99 (t, J=7.7 Hz, 3H), 1.58 (m, 2 H), 1.68 (s, 9 H), 1.73 (m, 4H), 2.00 (d, J = 7.7 Hz, 2 H), 2.04 (m, 2H), 2.26 (m, 1H), 2.54 (m, 1 H), 3.00 (d, J=6.8 Hz, 2H), 3.46 (t, J=8.2 Hz, 2 H), 3.80 (t, J=8.2 Hz, 2 H), 4.57 (d, J=7.5 Hz, 2 H), 7.86 (d, J=8.8 Hz, 1H), 8.08 (s, 1H), 8.09 (d, J=8.8 Hz, 1H); MS (ESI) (M+H)⁺ = 511.3.


Step B: *N*-(Azetidin-3-ylmethyl)propanamide




Propanoic anhydride (286 mg, 2.2 mmol) was added into a solution of *tert*-butyl 3-(aminomethyl)azetidine-1-carboxylate (200 mg, 1.08 mmol) and triethylamine (1 mL) in CH₂Cl₂ (20 mL) at r.t. After 2 hr, the reaction mixture was condensed. The residue was dissolved in CH₂Cl₂ (10 mL) and treated with TFA (10 mL) at r.t. for 1 h. Evaporation of solvents provided the desired product as its TFA salt, which was used in Step A directly.

Example 142

***N*-{[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl)sulfonyl}azetidin-3-yl)methyl]cyclopropanecarboxamide**




Step A: *N*-{[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl)sulfonyl}azetidin-3-yl)methyl]cyclopropanecarboxamide



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (81 mg, 0.2 mmol), *N*-(azetidin-3-ylmethyl)cyclopropanecarboxamide (TFA salt, 107 mg, 0.4 mmol) (see following step B for preparation) and DIPEA (1 mL) in CH₂Cl₂ (10 mL), provided the title compound as its TFA salt (39 mg, 31 % yield). ¹H NMR (400 MHz, CD₃OD) δ 0.64 (m, 2H), 0.70 (m, 2H), 1.38 (m, 1H), 1.58 (m, 2 H), 1.67 (s, 9 H), 1.73 (m, 4H), 2.02 (m, 2H), 2.25 (m, 1H), 2.52 (m, 1

H), 3.00 (d, J=6.8 Hz, 2H), 3.48 (t, J=8.2 Hz, 2 H), 3.84 (t, J=8.2 Hz, 2 H), 4.55 (d, J=7.5 Hz, 2 H), 7.89 (d, J=8.8 Hz, 1H), 8.07 (d, J=8.8 Hz, 1H), 8.12 (s, 1H); MS (ESI) (M+H)⁺ = 523.3.


Step B: *N*-(Azetidin-3-ylmethyl)cyclopropanecarboxamide



Cyclopropanecarbonyl chloride (315 mg, 3.0 mmol) was added into a solution of *tert*-butyl 3-(aminomethyl)azetidine-1-carboxylate (372 mg, 2.0 mmol) and triethylamine (1 mL) in CH₂Cl₂ (20 mL) at r.t. After 2 h, the reaction mixture was condensed. The residue was dissolved in CH₂Cl₂ (10 mL) and treated with TFA (10 mL) at r.t for 1 hr. Evaporation of solvents provided the desired product as its TFA salt, which was used in Step A directly.

Example 143


N-[(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}azetidin-3-yl)methyl]propanamide



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (74 mg, 0.2 mmol), *N*-(azetidin-3-ylmethyl)propanamide (TFA salt, 102 mg, 0.4 mmol) and DIPEA (1 mL) in CH₂Cl₂ (10 mL), provided the title compound as its TFA salt (58 mg, 49 %). ¹H NMR (400 MHz, CDCl₃) δ 0.99 (t, J=7.6 Hz, 3H), 1.58 (m, 4 H), 1.69 (s, 9 H), 2.01 (q, J=7.6 Hz, 2H), 2.38 (m, 1 H), 2.52 (m, 1 H), 2.99 (d, J=7.0 Hz, 2H), 3.33 (m, 2 H), 3.46 (m, 2 H), 3.80 (t, J=7.6 Hz, 2 H), 3.93 (m, 2 H), 4.56 (d, J=7.4 Hz, 2 H), 7.87 (d, J=8.8 Hz, 1H), 8.08 (s, 1H), 8.11 (d, J=8.8 Hz, 1H); MS (ESI) (M+H)⁺ = 477.2.

Example 144


***N*-[(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}azetidin-3-yl)methyl]cyclopropanecarboxamide**




- 5 Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (74 mg, 0.2 mmol), *N*-(azetidin-3-ylmethyl)cyclopropanecarboxamide (TFA salt, 107 mg, 0.4 mmol) and DIPEA (1 mL) in CH₂Cl₂ (10 mL), provided the title compound as its TFA salt (56 mg, 46 % yield). ¹H NMR (400 MHz, CDCl₃) δ 0.70 (m, 4H), 1.40 (m, 1H), 1.58 (m, 4 H), 1.71 (s, 9 H), 2.38 (m, 1 H),
 10 2.52 (m, 1 H), 3.00 (d, J=8.0 Hz, 2H), 3.35 (m, 2 H), 3.47 (m, 2 H), 3.83 (t, J=7.6 Hz, 2 H), 3.93 (m, 2 H), 4.58 (d, J=7.4 Hz, 2 H), 7.91 (d, J=8.8 Hz, 1H), 8.11 (s, 1H), 8.16 (d, J=8.8 Hz, 1H); MS (ESI) (M+H)⁺ = 489.3.

Example 145

- 15 **1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclopropyl-3-methyl-1*H*-pyrazole-4-carboxamide**




Step A: 1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclopropyl-3-methyl-1*H*-pyrazole-4-carboxamide



Sodium hydride (120 mg, 60%, 3.0 mmol) was added to a solution of *N*-cyclopropyl-3-methyl-1*H*-pyrazole-4-carboxamide (150 mg, 0.91 mmol) (see following step B for preparation) in 8 mL of DMF at -10 °C. After 20 min, 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (150 mg, 0.41 mmol) was added. The reaction mixture was stirred for 10 min at 0 °C, quenched with NH₄Cl (20 mL) and EtOAc (100 mL). The organic phases were washed with NaCl and dried over Na₂SO₄. The crude product was purified by HPLC to give the title compound as its TFA salt (82 mg, 33 % yield). ¹H NMR (400 MHz, CD₃OD) δ 0.55 (m, 2 H), 0.73 (m, 2H), 1.53 (m, 4 H), 1.59 (s, 9 H), 2.30 (m, 1H), 2.32 (s, 3 H), 2.71 (m, 1H), 3.29 (m, 2 H), 3.89 (m, 2 H), 4.41 (d, J=7.3 Hz, 2 H), 7.88 (d, J=8.88 Hz, 1H), 7.91 (d, J=8.88 Hz, 1H), 8.29 (s, 1 H), 8.65 (s, 1H); MS (ESI) (M+H)⁺ = 500.3.


Step B: *N*-Cyclopropyl-3-methyl-1*H*-pyrazole-4-carboxamide




Following the same procedure in Example 29 (Step B and C in Method B), using 3-methyl-1*H*-pyrazole-4-carboxylic acid (252 mg, 2.0 mmol) and cyclopropylamine (285 mg, 5.0 mmol), provided the desired crude compound (310 mg, 94 %), which was used in Step A directly.

Example 146

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-ethyl-3-methyl-1*H*-pyrazole-4-carboxamide




Step A: 1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-ethyl-3-methyl-1*H*-pyrazole-4-carboxamide



Following the same procedure in Example 145, using 2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (100 mg, 0.27 mmol) and *N*-ethyl-3-methyl-1*H*-pyrazole-4-carboxamide (150 mg, 1.0 mmol) (see following step B for preparation),
provided the title compound as its TFA salt (25 mg, 15 % yield). ¹H NMR (400 MHz, CD₃OD) δ 1.15 (d, J=7.2 Hz, 3 H), 1.53 (m, 4 H), 1.63 (s, 9 H), 2.31 (s, 4 H), 3.29 (m, 2 H), 3.88 (m, 2 H), 4.05 (m, 1 H), 4.48 (d, J=7.3 Hz, 2 H), 8.04 (s, 2 H), 8.37 (s, 1 H), 8.68 (s, 1H); MS (ESI) (M+H)⁺ = 488.3.


Step B: *N*-Ethyl-3-methyl-1*H*-pyrazole-4-carboxamide




Following the same procedure in Example 29 (Steps B and C in Method B), using 3-methyl-1*H*-pyrazole-4-carboxylic acid (252 mg, 2.0 mmol) and ethylamine (225 mg, 5.0 mmol), provided the desired crude compound (306 mg, 100 %), which was used in Step A directly.

Example 147

2-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N*-ethylacetamide



Step A: 2-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N*-ethylacetamide




Following the same procedure in Example 24, Step A, using ethylamine hydrochloride (164 mg, 2.0 mmol) (see following steps B and C for preparation), DIPEA (1 mL), [1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]acetic acid (310 mg, 0.64 mmol) (see following step C for preparation) and HATU (230 mg, 0.64 mmol) in DMF (6.0 mL), provided the title compound as its TFA salt (49 mg, 12 % yield). ¹H NMR (400 MHz, CD₃OD) δ 1.01 (t, J=7.4 Hz, 3H), 1.59 (m, 2 H), 1.70 (s, 9 H), 1.75 (m, 4H), 2.01 (m, 2H), 2.23 (d, J = 7.8 Hz, 2 H), 2.25 (m, 1H), 2.68 (m, 1 H), 3.05 (q, J=7.4 Hz, 2H), 3.47 (t, J=8.2 Hz, 2 H), 3.85 (t, J=8.2 Hz, 2 H), 4.58 (d, J=7.5 Hz, 2 H), 7.88 (d, J=8.8 Hz, 1H), 8.07 (s, 1H), 8.12 (d, J=8.8 Hz, 1H); MS (ESI) (M+H)⁺ = 511.0.

Step B: Azetidin-3-ylacetic acid hydrochloride



[1-(*tert*-Butoxycarbonyl)azetidin-3-yl]acetic acid (2.15 g, 10 mmol) was treated with 4 N HCl in dioxane (40 mL) for 4 h at r.t. The reaction mixture was condensed to provide the desired compound as its HCl salt, which was used directly in Step A.


Step C: [1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]acetic acid



Following the same procedure in Example 1, Step A, using 2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazole-5-sulfonyl chloride (1.06 g, 2.6 mmol), azetidin-3-ylacetic acid hydrochloride (1.17 g, 7.8 mmol) and DIPEA (4 mL) in CH₂Cl₂ (20 mL), provided the title compound as crude product (930 mg, 74 % yield), which was used directly in Step A.

Example 148

2-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N*-cyclopropylacetamide




Following the same procedure in Example 24, Step A, using cyclopropylamine (114 mg, 2.0 mmol), DIPEA (1 mL), [1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]acetic acid (310 mg, 0.64 mmol) and HATU (230 mg, 0.64 mmol) in DMF (6.0 mL), provided the title compound as its TFA salt (54 mg, 12 % yield).

¹H NMR (400 MHz, CD₃OD) δ 0.37 (m, 2 H), 0.59 (m, 2H), 1.54 (m, 2 H), 1.68 (s, 9 H), 1.77 (m, 4H), 2.02 (m, 2H), 2.19 (d, J = 7.8 Hz, 2 H), 2.22 (m, 1 H), 2.49 (m, 1 H), 2.67 (m, 1 H), 3.45 (m, 2 H), 3.83 (t, J=8.2 Hz, 2 H), 4.57 (d, J=7.5 Hz, 2 H), 7.86 (d, J=8.8 Hz, 1H), 8.05 (s, 1H), 8.11 (d, J=8.8 Hz, 1H); MS (ESI) (M+H)⁺ 523.3.

Example 149

2-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N*-methylacetamide




Following the same procedure in Example 24, Step A, using methylamine hydrochloride (136 mg, 2.0 mmol), DIPEA (1 mL), [1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]acetic acid (310 mg, 0.64 mmol) and HATU (230 mg, 0.64 mmol) in DMF (6.0 mL), provided the title compound as its TFA salt (41 mg, 10 % yield).


¹H NMR (400 MHz, CD₃OD) δ 1.59 (m, 2 H), 1.67 (s, 9 H), 1.72 (m, 4H), 2.05 (m, 2H), 2.25 (d, J = 7.8 Hz, 3 H), 2.57 (s, 3H), 2.68 (m, 1 H), 3.50 (t, J=8.2 Hz, 2 H), 3.86 (t, J=8.2 Hz, 2 H), 4.56 (d, J=7.5 Hz, 2 H), 7.90 (d, J=8.8 Hz, 1H), 8.08 (d, J=8.8 Hz, 1H), 8.13 (s, 1H); MS (ESI) (M+H)⁺ = 497.0.

Example 150

N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazole-4-carboxamide




Step A *N*-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazole-4-carboxamide




Sodium hydride (80 mg, 60%, 2.0 mmol) was added to a solution of *N*-cyclopropyl-1*H*-pyrazole-4-carboxamide (70 mg, 0.5 mmol) in 4 mL of DMF at -10 °C. After 10 min, 2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (100 mg, 0.23 mmol) (see following steps B, C and D for preparation) was added. The reaction mixture was stirred for 10 min at 0 °C, quenched with NH₄Cl (10 mL) and EtOAc (50 mL). The organic phases were washed with NaCl and dried over Na₂SO₄. The crude product was purified by HPLC to give the title compound as its TFA salt (12 mg, 11 % yield). ¹H NMR (400 MHz, METHANOL-D₄) δ 0.56 (m, 2H), 0.75 (m, 2H), 1.44 (m, 4 H), 2.24 (t, J=19.5 Hz, 3H), 2.26 (m, 1H), 2.75 (m, 1H), 3.88 (m, 2H), 4.37 (d, J=7.6 Hz, 2H), 7.92 (d, J=8.8 Hz, 1H), 7.99 (d, J=8.8 Hz, 1H), 8.03 (s, 1H), 8.44 (s, 1H), 8.74 (s, 1H); MS (APPI) (M+H)⁺=494.0.

Step B: *N*-[2-(1,1-Difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]acetamide



HATU (1.58 g, 4.17 mmol) and *N*-{3-amino-4-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]phenyl}acetamide (1.00 g, 3.79 mmol) were added to a solution of 2,2-difluoropropanoic acid (0.43 g, 3.98 mmol) and DIPEA (0.80 mL, 4.55 mmol) in DMF (100 mL) at ambient temperature. The reaction mixture was stirred overnight and the solvent was concentrated. The intermediate was heated to 80°C for 3 h in glacial AcOH (100 mL), and the solvent was concentrated. The crude product was recovered in DCM (300 mL), washed with saturated NaHCO₃ solution (3 x 100 mL), brine and dried over anhydrous MgSO₄. The solvent was concentrated and the product was purified by normal-phase MPLC using MeOH 5% and Acetone 10% in DCM to provide the title compound as a white solid. Yield: 1.07 g (83%); MS (ESI) (M+H)⁺ = 338.2.

Step C: 2-(1,1-Difluoroethyl)-1-((tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-amine



A mixture of *N*-[2-(1,1-difluoroethyl)-1-((tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]acetamide (1.07 g, 3.17 mmol), 6 M aqueous solution of NaOH (5 mL) and MeOH (5 mL) was heated to 70°C for 24 h. The reaction mixture was diluted with water (200 mL) and the product was extracted with EtOAc (4 x 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and the solvent was concentrated to provide the title compound as white solid. Yield: 0.90 g (96%); MS (ESI) (M+H)⁺ = 296.2.


Step D: 2-(1,1-Difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride




- 5 A solution of NaNO_2 (2.5g, 36.23 mmol) in 9 mL of water was added to a solution of 2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-amine (11.9g, 33.28 mmol) in 80 mL of AcOH/HCl (1:2v/v) at 0°C . The resulting mixture was stirred for 1 h at 0°C , which was then poured portion-wise to a mixture of SO_2 (~80 mL) and $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ (2.3g, 13.49 mmol) in AcOH (46 mL) at -30°C . The mixture was stirred at 0°C for 2h and then
- 10 warmed gradually to rt and stirred for 5 h. The mixture was poured over ice (500 mL) while shaken vigorously. The mixture was extracted with cold CH_2Cl_2 (2x500 mL). The combined organic phases were dried over anhydrous Na_2SO_4 . Removal of solvent in vacuo gave the desired product (HCl salt) as a beige solid (14.5g, yield 98.7%). MS (ESI) $(\text{M}+\text{H})^+ = 405.01$.

15 **Example 151**

1-{[2-(1,1-Difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-ethyl-1H-pyrazole-4-carboxamide



- 20 **Step A: 1-{[2-(1,1-Difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-ethyl-1H-pyrazole-4-carboxamide**



Following the same procedure in Example 150, using 2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (100 mg, 0.23 mmol) and *N*-ethyl-1H-pyrazole-4-carboxamide (60 mg, 0.47 mmol), provided the title compound as its TFA salt (10 mg, 9%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.15 (t, J=7.3 Hz, 3H), 1.44 (m, 4 H), 2.24 (t, J=19.5 Hz, 3H), 2.26 (m, 1H), 3.26 (m, 2H), 3.88 (m, 2H), 4.37 (d, J=7.6 Hz, 2H), 7.92 (d, J=8.8 Hz, 1H), 7.99 (d, J=8.8 Hz, 1H), 8.03 (s, 1H), 8.44 (s, 1H), 8.74 (s, 1H); MS (APPI) (M+H)⁺=481.85.


Step B: *N*-Ethyl-1H-pyrazole-4-carboxamide



Following the same procedure in Example 28 (Step C of Method B), using 1H-pyrazole-4-carbonyl chloride (0.47 g, 3.6 mmol), ethylamine (3.0 mL, 2.0 M in THF, 6.0 mmol) and triethylamine (1.01 g, 1.39 mL, 10 mmol) in CH₂Cl₂ (15 mL), provided the title compound as a white solid. Yield: 0.49 g (97% yield). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.18 (t, J=7.23 Hz, 3 H) 3.34 (q, J=7.23 Hz, 2 H) 7.92 (s, 1 H) 8.09 (s, 1 H)

Example 152

1-{[2-(1,1-Difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-ethyl-1H-pyrrole-3-carboxamide




N-Ethyl-1*H*-pyrrole-3-carboxamide (50 mg, 0.36 mmol) was dissolved in THF (3 mL) and the solution was cooled down to 0 °C. NaH (72 mg, 60%, 1.8 mmol) was then added and the reaction mixture was allowed to warm to room temperature and stirred for 1 hour at room temperature. The reaction mixture was cooled down to 0 °C again and 2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonyl chloride (114 mg, 0.30 mmol) was added slowly, allowing the reaction to warm to room temperature and stirred for 3 hours.


The reaction mixture was slowly added to a stirring mixture of EtOAc and NH₄Cl at -20 °C, which was extracted with EtOAc, washed with NH₄Cl, water then brine. Concentrated under vacuum and purified by LCMS using high pH column 40-70% acetonitrile gradient to afford the title compound as a white solid. Yield: 25 mg (17%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.14 (t, J=7.23 Hz, 3 H), 1.32 - 1.41 (m, 2 H), 1.40 - 1.43 (m, 3 H), 1.43 - 1.53 (m, 2 H), 2.25 (t, J=19.53 Hz, 5 H), 3.89 (dd, J=11.52, 2.54 Hz, 2 H), 4.37 (d, J=7.62 Hz, 2 H), 6.65 (s, 1 H), 7.31 (t, J=2.34 Hz, 1 H), 7.82 (s, 1 H), 7.88 - 7.94 (m, 1 H), 7.95 - 8.01 (m, 1 H), 8.40 (s, 1 H); MS (APPI) (M+H)⁺=481.2; Anal. Calc. for C₂₂H₂₆F₂N₄O₄S + 0.4 TFA: C, 52.05; H, 5.06; N, 10.65; Found: C, 52.41; H, 3.78; N, 10.41.

Example 153

***N*-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxamide**




Step A: *N*-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxamide



Oxone (1.33 g, 2.17 mmol) was added to a solution of 1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carbaldehyde (0.86 g, 1.97 mmol)(see following step B for preparation) in DMF (15 mL). The reaction mixture was stirred overnight at room temperature and then cooled down to 0 °C. Cyclopropylamine(0.23 g, 0.27 ml, 3.94 mmol) and *N,N*-diisopropylethylamine (1.02 g, 1.37 ml, 7.88 mmol) were added. Stirring for 20 min, HATU (1.35 g, 3.55 mmol) was added portionwise and the reaction was allowed to warm to room temperature. The reaction mixture was diluted with water (200 mL), and extracted with EtOAc (3x100 mL). The combined organic phases was washed with NaCl (2x20 mL) and dried over Na₂SO₄. The crude product was purified by normal-phase MPLC using EtOAc to provide the title compound as a light brown solid. Yield: 0.70 g (72%). ¹H NMR (400 MHz, METHANOL-D₄) δ 0.51 - 0.59 (m, 2 H), 0.68 - 0.78 (m, 2 H), 1.37 - 1.54 (m, 5 H), 2.25 (t, J=19.43 Hz, 3 H), 2.68 - 2.77 (m, 1 H), 3.27 (d, J=2.54 Hz, 1 H), 3.33 (d, J=2.93 Hz, 1 H), 3.84 - 3.94 (m, 2 H), 4.38 (d, J=7.62 Hz, 2 H), 6.65 (dd, J=3.32, 1.56 Hz, 1 H), 7.30 (dd, J=3.32, 2.34 Hz, 1 H), 7.81 - 7.84 (m, 1 H), 7.88 - 7.94 (m, 1 H), 7.94 - 8.00 (m, 1 H), 8.39 (d, J=1.56 Hz, 1 H); MS (APPI) (M+H)⁺=493.3; Anal. Calc. for C₂₃H₂₆F₂N₄O₄S + 0.8 TFA: C, 50.61; H, 4.63; N, 9.60; Found: C, 50.84; H, 3.87; N, 9.39.

Step B: 1-{{2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-1H-pyrrole-3-carbaldehyde




5

Sodium hydride (0.55 mg, 60%, 13.8 mmol) was added to a solution of 1H-Pyrrole-3-carbaldehyde (0.26 g, 2.7 mmol) in 30 mL of THF at 0 °C. After stirring for 1 h, 2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (0.95 g, 2.5 mmol) was added. The reaction mixture was stirred for 3 h at 0 °C, quenched with NaHCO₃ (10 mL) and diluted with EtOAc (150 mL). The organic phases were washed with NaCl (2x20 mL) and dried over Na₂SO₄. The product was purified by normal-phase MPLC using Hex/EtOAc (1:1) to provide the title compound as a white solid. Yield: 0.86 g (79%); MS (ESI) (M+H)⁺ = 437.88.

15

Example 154

2-(1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}azetidin-3-yl)-N-(2,2-difluoroethyl)acetamide




20

Following the same procedure in Example 24, Step A, using (2,2-difluoroethyl)amine (36 mg, 0.44 mmol), DIPEA (1 mL), (1-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl]sulfonyl}azetidin-3-yl)acetic acid (100 mg, 0.22 mmol) and HATU (161 mg, 0.44 mmol) in DMF (2.5 mL), provided the title compound as its TFA salt (58 mg, 41 % yield). ¹H NMR (400 MHz, CDCl₃) δ 1.60 (m, 4 H), 1.75 (s, 9 H), 2.36 (d, J = 7.6 Hz, 2 H), 2.89 (m, 1 H), 3.43 (m, 7 H), 4.02 (m, 4 H), 4.44 (t, J=7.4 Hz, 2 H), 5.62- 5.90 (m, 1H), 7.08 (s, 1H), 7.71 (d, J=8.8 Hz, 1H), 7.86 (d, J=8.8 Hz, 1H), 8.28 (s, 1 H); MS (ESI) (M+H)⁺ = 513.3.

Example 155


2-(1-[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl]azetidin-3-yl)-*N*-cyclopropylacetamide



Following the same procedure in Example 24, Step A, using cyclopropylamine (24 mg, 0.44 mmol), DIPEA (1 mL), (1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}azetidin-3-yl)acetic acid (100 mg, 0.22 mmol) and HATU (161 mg, 0.44 mmol) in DMF (2.5 mL), provided the title compound as its TFA salt (34 mg, 25 % yield). ¹H NMR (400 MHz, CDCl₃) δ 0.45 (m, 2 H), 0.65 (m, 2H), 1.66 (m, 4 H), 1.73 (s, 9 H), 2.25 (d, J = 7.8 Hz, 2 H), 2.58 (m, 1 H), 2.60 (m, 1 H), 2.86 (m, 1 H), 3.31 (m, 2 H), 3.38 (m, 2H), 3.86 (t, J=7.6 Hz, 2 H), 4.00 (m, 2 H), 4.44 (d, J=7.3 Hz, 2 H), 6.52 (m, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.77 (d, J=8.8 Hz, 1H), 8.00 (s, 1 H); MS (ESI) (M+H)⁺ = 489.3.

What is claimed is:

1. A compound of formula I, a pharmaceutically acceptable salt thereof, a diastereomer, an enantiomer, or a mixture thereof:



wherein:

R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{1-10} alkoxy, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)$ - C_{1-6} alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)$ - C_{1-6} alkyl, C_{6-10} aryl, C_{6-10} aryl- $C(=O)$ -, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, C_{3-6} heterocyclyl and C_{3-6} heterocyclyl- $C(=O)$ -; wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{1-10} alkoxy, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)$ - C_{1-6} alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)$ - C_{1-6} alkyl, C_{6-10} aryl, C_{6-10} aryl- $C(=O)$ -, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, C_{3-6} heterocyclyl or C_{3-6} heterocyclyl- $C(=O)$ - is optionally substituted by one or more groups selected from carboxy, $-(C=O)-NH_2$, halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, $-N(R^6)-C(=O)R^5$, $-S(=O)_2-NR^5R^6$, $-C(=O)-NR^5R^6$, $-NH-C(=O)-NR^5R^6$ and $-NR^5R^6$;

R^2 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl and C_{3-6} heterocycloalkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl or C_{3-6} heterocycloalkyl used in defining R^2 is optionally substituted by one or more groups selected from carboxy, $-(C=O)-NH_2$, halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$;

R^3 and R^4 are independently selected from $-H$, $-OH$, amino, R^7 and $-O-R^7$, wherein R^7 is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, phenyl and benzyl, wherein R^3 and R^4 are not $-H$ at the same time, and

wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, phenyl or benzyl in defining R⁷ is optionally substituted by one or more groups selected from carboxy, halogen, cyano, nitro, methoxy, ethoxy, hydroxy, and -NR⁵R⁶; or R³ and R⁴ together with the nitrogen connected thereto form a 5- or 6-membered heterocycle ring, wherein said
 5 ring is optionally substituted by one or more groups selected from carboxy, halogen, cyano, nitro, methoxy, ethoxy, hydroxy, -(CH₂)_m-C(=O)NR⁵R⁶, -(CH₂)_mNH-C(=O)NR⁵R⁶, -(CH₂)_m-N(R⁵)C(=O)R⁶, -(CH₂)_m-N(R⁵)C(=O)-OR⁶, -(CH₂)_m-C(=O)-OR⁶, -(CH₂)_m-O-C(=O)-R⁶, -(CH₂)_m-OR⁶, and -NR⁵R⁶; and

wherein R⁵ and R⁶ are independently selected from -H, C₁₋₆alkyl optionally substituted
 10 with -OH, methoxy, ethoxy or halogen, C₃₋₆cycloalkyl-C_{0-m}alkyl optionally substituted with -OH, methoxy, ethoxy or halogen, C₂₋₆alkenyl optionally substituted with -OH, methoxy, ethoxy or halogen, and a divalent C₁₋₆alkylene optionally substituted with -OH, methoxy, ethoxy or halogen that together with another divalent R⁵ or R⁶ form a portion of a ring; and

m is 0, 1, 2 or 3.

15 2. A compound as claimed in claim 1, wherein

R¹ is selected from C₃₋₇cycloalkyl-C₁₋₂alkyl and C₂₋₆heterocycloalkyl-C₁₋₂alkyl, wherein said C₃₋₇cycloalkyl or C₂₋₆heterocycloalkyl is optionally substituted with one or more groups selected from carboxy, -C(=O)-NH₂, halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl,
 20 hydroxy, and amino.

3. A compound as claimed in claim 1, wherein

R¹ is selected from cyclohexylmethyl and tetrahydropyranylmethyl wherein said cyclohexylmethyl or tetrahydropyranylmethyl is optionally substituted with one or more groups
 25 selected from carboxy, -C(=O)-NH₂, halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and amino.

4. A compound as claimed in claim 3, wherein

R^1 is selected from cyclohexylmethyl and tetrahydropyranylmethyl wherein said cyclohexylmethyl or tetrahydropyranylmethyl is optionally substituted with one or more groups selected from methyl, hydroxy, chloro, fluoro and bromo.

5

5. A compound as claimed in claim 4, R^1 is selected from cyclohexylmethyl and tetrahydropyran-4-ylmethyl wherein said cyclohexylmethyl or tetrahydropyran-4-ylmethyl is optionally substituted with one or more groups selected from chloro and fluoro.

10

6. A compound as claimed in claim 1, R^1 is selected from cyclohexylmethyl, (4,4-difluorocyclohexyl)methyl, (4-fluorocyclohexyl)methyl and tetrahydro-2H-pyran-4-ylmethyl.

7. A compound as claimed in any one of claims 1-6, wherein

15

R^2 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-2} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, or C_{3-6} cycloalkyl- C_{1-2} alkyl is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, and hydroxy.

8. A compound as claimed in any one of claims 1-6, wherein

20

R^2 is selected from ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1,1-dimethyl-1-propyl, 3-methyl-1-butyl, and 2,2 dimethyl-1-propyl, wherein said propyl, isopropyl, n-butyl, isobutyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1,1-dimethyl-1-propyl, 3-methyl-1-butyl, or 2,2 dimethyl-1-propyl is optionally substituted by one or more groups selected from halogen, methoxy and ethoxy.

25

9. A compound as claimed in any one of claims 1-6, wherein

R^2 is selected from 1,1-difluoroethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1,1-dimethyl-1-propyl, 3-methyl-1-butyl, and 2,2 dimethyl-1-propyl.

30


10. A compound as claimed in any one of claims 1-6, wherein

R^2 is selected from t-butyl, 1,1-difluoroethyl and 1,1-dimethyl-1-propyl.


11. A compound as claimed in any one of claims 1-10, wherein

R^3 and R^4 together with the nitrogen connected thereto form a 5- or 6-membered heterocycle ring, wherein said ring is optionally substituted by one or more groups selected from carboxy, halogen, cyano, nitro, methoxy, ethoxy, hydroxy, carboxy, $-(CH_2)_m-C(=O)NR^5R^6$ and $-NR^5R^6$, wherein R^5 and R^6 are independently selected from $-H$, C_{1-6} alkyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, C_{3-6} cycloalkyl- C_{0-m} alkyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, C_{2-6} alkenyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, and a divalent C_{1-6} alkylene optionally substituted with $-OH$, methoxy, ethoxy or halogen that together with another divalent R^5 , R^6 or R^7 form a portion of a ring; and m is 0, 1, 2 or 3.

12. A compound as claimed in any one of claims 1-10, wherein



of formula I is represented by



, wherein R^8 is selected

from hydrogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy- C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-2} alkyl, methoxy- C_{1-4} alkyl, ethoxy- C_{1-4} alkyl, and C_{2-4} alkenyl; R^9 is selected from hydrogen, hydroxy, halogen, isocyanato, methoxy, ethoxy, C_{1-4} alkyl, halogenated C_{1-4} alkyl, phenyl, benzyl, amino, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-2} alkyl, and C_{1-4} alkoxymethyl; X is selected from $-O-C(=O)-$, $-C(=O)-NH-$, $-NH-C(=O)-$, $-C(=O)-NHCH_2-$, $-NH-C(=O)CH_2-$, $-NH-C(=O)-NH-$, $-O-C(=O)-NH-$, $-C(=O)-O-$, and $-NH-C(=O)-O-$;

A is a 5 or 6-membered heterocycle which optionally contains one additional heteroatom selected from O and N on its ring in addition to the nitrogen shown.



13. A compound as claimed in claim 12, wherein said A is selected from piperidinyl, isoxazolindinyl, azetidiny, morpholinyl, pyrazolyl, pyrrolyl and pyrrolidinyl.

14. A compound as claimed in any one of claims 1-10, wherein

R³ and R⁴ together with the nitrogen connected thereto form a 5- or 6-membered heterocycle ring selected from piperidinyl, isoxazolindinyl, azetidiny, morpholinyl, pyrazolyl, pyrrolyl and pyrrolidinyl, wherein said piperidinyl, isoxazolindinyl, azetidiny, morpholinyl, pyrazolyl, pyrrolyl or pyrrolidinyl is optionally substituted by one or more groups selected from methyl, cyclopropyl, amino, cyclobutanylcabonylamino, hydrocarbonyl, 2-hydroxyethylaminocarbonyl, ispropylaminocarbonyl, cyclobutanylamino, ethylaminocarbonyl, cyclopropylaminocarbonyl, methoxycarbonyl, ethoxycarbonyl, hydroxycarbonyl, t-butoxycarbonyl, t-butoxycarbonylamino, allylamino, methylaminocarbonyl, fluoro, aminocarbonyl, 2-fluoroethylaminocarbonyl, propylaminocarbonyl, cyclopropylmethylaminocarbonyl, cyclobutylmethylaminocarbonyl, phenyl, trifluoromethyl, methoxy, ethyl, methoxymethyl, benzyl, t-butoxycarbonylamino, ethylaminocarbonylamino, isocyanato, cyclopropylaminocarbonylamino, 2-hydroxyethylaminocarbonylamino, hydroxy, ethylaminocarboxy, acetylaminomethyl, propionylaminomethyl, 2-fluoroethylaminocarbonylmethyl, 2,2-difluoroethylaminocarbonylmethyl, acetylaminomethyl, cyclopropylcarbonylamino, propionylaminomethyl, and methylaminocarbonylmethyl.

15. A compound as claimed in any one of claims 1-10, wherein

R³ and R⁴ are independently selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl, benzyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₂₋₆alkenyl and C₁₋₆alkoxy.

16. A compound selected from:

2-*tert*-Butyl-*N,N*-diethyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-5-(piperidin-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

2-*tert*-Butyl-5-(isoxazolidin-2-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

2-*tert*-Butyl-5-[(4-methylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

5-(Azetidin-1-ylsulfonyl)-2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

2-*tert*-Butyl-*N*-cyclobutyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-*N*-cyclopropyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-*N*-cyclohexyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-5-(morpholin-4-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

2-*tert*-Butyl-*N*-phenyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-5-(1*H*-pyrazol-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

2-*tert*-Butyl-*N*-methyl-*N*-phenyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-*N*-methyl-*N*-(3-methylbutyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-*N*-isobutyl-*N*-methyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

N,2-Di-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-*N*-cyclohexyl-*N*-methyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-*N*-methoxy-*N*-methyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole-5-sulfonamide;

2-*tert*-Butyl-5-[(3-cyclopropyl-1*H*-pyrazol-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

2-*tert*-Butyl-5-[(4-methyl-1*H*-pyrazol-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

2-*tert*-Butyl-5-[(3-methyl-1*H*-pyrazol-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazol-3-amine;

5 *N*-(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazol-3-yl)cyclobutanecarboxamide;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrazole-4-carbaldehyde;

10 1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-(2-hydroxyethyl)-1*H*-pyrazole-4-carboxamide;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-isopropyl-1*H*-pyrazole-4-carboxamide;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclobutyl-1*H*-pyrazole-4-carboxamide;

15 1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-ethyl-1*H*-pyrazole-4-carboxamide;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclopropyl-1*H*-pyrazole-4-carboxamide;

20 2-*tert*-Butyl-5-(1*H*-pyrrol-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

Methyl 1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxylate;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-ethyl-1*H*-pyrrole-3-carboxamide;

25 1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclopropyl-1*H*-pyrrole-3-carboxamide;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-*N*-cyclobutyl-1*H*-pyrrole-3-carboxamide;

30 *N*-Allyl-1-{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]sulfonyl}-1*H*-pyrrole-3-carboxamide;

1-{{2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-methyl-1*H*-pyrrole-3-carboxamide;

1-{{2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-(2-hydroxyethyl)-1*H*-pyrrole-3-carboxamide;

5 1-{{2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}azetidin-3-amine;

2-*tert*-Butyl-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

10 2-(1,1-Dimethylpropyl)-5-(1*H*-pyrazol-1-ylsulfonyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-methyl-1*H*-pyrazole-4-carboxamide;

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-ethyl-1*H*-pyrazole-4-carboxamide;

15 *N*-Cyclopropyl-1-{{2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrazole-4-carboxamide;

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-isopropyl-1*H*-pyrazole-4-carboxamide;

20 1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrazole-4-carboxamide;

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-(2-fluoroethyl)-1*H*-pyrazole-4-carboxamide;

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrrole-3-carboxamide;

25 1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-methyl-1*H*-pyrrole-3-carboxamide;

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-ethyl-1*H*-pyrrole-3-carboxamide;

30 *N*-Cyclopropyl-1-{{2-(1,1-dimethylpropyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrrole-3-carboxamide;

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-isopropyl-1H-pyrrole-3-carboxamide;

1-{{2-(1,1-Dimethylpropyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-(2-fluoroethyl)-1H-pyrrole-3-carboxamide;

5 1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-methyl-1H-pyrazole-4-carboxamide;

1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-propyl-1H-pyrazole-4-carboxamide;

10 1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-(cyclopropylmethyl)-1H-pyrazole-4-carboxamide;

1-{{2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-N-(cyclobutylmethyl)-1H-pyrazole-4-carboxamide;

2-tert-Butyl-5-[(3-methylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

15 2-tert-Butyl-5-[(3-phenylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-5-{{4-(trifluoromethyl)piperidin-1-yl}sulfonyl}-1H-benzimidazole;

20 2-tert-Butyl-5-[(4-methoxypiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

2-tert-Butyl-5-[(4,4-difluoropiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

2-tert-Butyl-5-[(3,3-difluoropiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

25 2-tert-Butyl-5-[(2-ethylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

2-tert-Butyl-5-[(3-phenylpyrrolidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

30 2-tert-Butyl-5-{{2-(methoxymethyl)pyrrolidin-1-yl}sulfonyl}-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

2-tert-Butyl-5-[(3,3-difluoropyrrolidin-1-yl)sulfonyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

2-tert-Butyl-5-(pyrrolidin-1-ylsulfonyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

5 5-[(3-Benzylpyrrolidin-1-yl)sulfonyl]-2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole;

1-([2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl)-N-cyclopropylpiperidine-4-carboxamide;

10 1-([2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl)-N-ethylpiperidine-3-carboxamide;

1-([2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl)-N-cyclopropylpiperidine-3-carboxamide;

1-([2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl]sulfonyl)-N-methyl-1H-pyrazole-4-carboxamide;

15 1-([2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl]sulfonyl)-N-ethyl-1H-pyrazole-4-carboxamide;

1-([2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl]sulfonyl)-N-propyl-1H-pyrazole-4-carboxamide;

20 1-([2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl]sulfonyl)-N-cyclopropyl-1H-pyrazole-4-carboxamide;

1-([2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl]sulfonyl)-N-cyclobutyl-1H-pyrazole-4-carboxamide;

1-([2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl]sulfonyl)-N-(cyclopropylmethyl)-1H-pyrazole-4-carboxamide;

25 1-([2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl]sulfonyl)-N-(cyclobutylmethyl)-1H-pyrazole-4-carboxamide;

1-([2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl]sulfonyl)-N-isopropyl-1H-pyrazole-4-carboxamide;

30 1-([2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl)-N-methylpyrrolidine-3-carboxamide;

1- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropylpyrrolidine-3-carboxamide;

1- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-isopropylpyrrolidine-3-carboxamide;

5 1- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclobutylpyrrolidine-3-carboxamide;

(3S)-1- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropylpiperidine-3-carboxamide;

10 (3R)-1- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropylpiperidine-3-carboxamide;

4- ({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-cyclopropylmorpholine-2-carboxamide;

4- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropylmorpholine-2-carboxamide;

15 (3S)-1- {[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-N-cyclopropylpyrrolidine-3-carboxamide;

(3S)-1- ({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-cyclopropylpyrrolidine-3-carboxamide;

20 (3S)-1- ({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-methylpiperidine-3-carboxamide;

(3S)-1- ({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-ethylpiperidine-3-carboxamide;

(3S)-1- ({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-propylpiperidine-3-carboxamide;

25 (3S)-1- ({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-cyclopropylpiperidine-3-carboxamide;

(3S)-1- ({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-cyclobutylpiperidine-3-carboxamide;

(3S)-1- ({2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-

30 (cyclopropylmethyl)piperidine-3-carboxamide;

- (3S)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-(cyclobutylmethyl)piperidine-3-carboxamide;
- (3S)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-isopropylpiperidine-3-carboxamide;
- 5 (3S)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-methylpyrrolidine-3-carboxamide;
- (3S)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-ethylpyrrolidine-3-carboxamide;
- (3S)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)-N-isopropylpyrrolidine-3-carboxamide;
- 10 *tert*-Butyl [1-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)azetidin-3-yl]carbamate;
- 1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)azetidin-3-amine;
- 15 *N*-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)azetidin-3-yl]cyclopropanecarboxamide;
- N*-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)azetidin-3-yl]propanamide;
- N*-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)azetidin-3-yl]-*N*⁷-ethylurea;
- 20 *N*-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)azetidin-3-yl]-*N*⁷-cyclopropylurea;
- N*-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)azetidin-3-yl]-*N*⁷-(2-hydroxyethyl)urea;
- 25 5-(Azetidin-1-ylsulfonyl)-2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazole;
- 2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-5-(1H-pyrazol-1-ylsulfonyl)-1H-benzimidazole;
- 1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} sulfonyl)azetidin-3-ol;

1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl ethylcarbamate;

(2*S*)-4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethylmorpholine-2-carboxamide;

5 (2*R*)-4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethylmorpholine-2-carboxamide;

(2*S*)-2-*tert*-Butyl-5-[(4-methylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

10 (2*R*)-2-*tert*-Butyl-5-[(4-methylpiperidin-1-yl)sulfonyl]-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazole;

(2*R*)-4-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-methylmorpholine-2-carboxamide;

(3*R*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-ol;

15 *N*-[(3*R*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]acetamide;

(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-amine;

20 *N*-[(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]cyclopropanecarboxamide;

N-[(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]propanamide;

N-[(3*S*)-1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)pyrrolidin-3-yl]acetamide;

25 (2*S*)-4-({2-*tert*-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropylmorpholine-2-carboxamide;

(2*R*)-4-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropylmorpholine-2-carboxamide;

30 1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrazole-4-carboxamide;

1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-methyl-1*H*-pyrrole-3-carboxamide;

1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-1*H*-pyrrole-3-carboxamide;

5 1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropyl-1*H*-pyrrole-3-carboxamide;

1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-(2-hydroxyethyl)-1*H*-pyrrole-3-carboxamide;

10 1-({2-*tert*-Butyl-1-[(4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethyl-1*H*-pyrrole-3-carboxamide;

1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-(2-hydroxyethyl)-1*H*-pyrazole-4-carboxamide;

2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-5-[(3-fluoroazetidin-1-yl)sulfonyl]-1*H*-benzimidazole;

15 1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-cyclopropyl-1*H*-pyrazole-4-carboxamide;

1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-ethyl-1*H*-pyrazole-4-carboxamide;

20 1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-(2-hydroxyethyl)-1*H*-pyrazole-4-carboxamide;

1-({2-*tert*-Butyl-1-[(*trans*-4-fluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)-*N*-methyl-1*H*-pyrazole-4-carboxamide;

2-(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}azetidin-3-yl)-*N*-ethylacetamide;

25 2-(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}azetidin-3-yl)-*N*-(2-fluoroethyl)acetamide;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-(2-fluoroethyl)-1*H*-pyrrole-3-carboxamide;

30 1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-(2,2-difluoroethyl)-1*H*-pyrrole-3-carboxamide;

N-{[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl)methyl}propanamide;

N-{[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl)methyl}cyclopropanecarboxamide;

5 *N*-[(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl)methyl]propanamide;

N-[(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl)methyl]cyclopropanecarboxamide;

10 1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-cyclopropyl-3-methyl-1*H*-pyrazole-4-carboxamide;

1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-ethyl-3-methyl-1*H*-pyrazole-4-carboxamide;

2-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N*-ethylacetamide;

15 2-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N*-cyclopropylacetamide;

2-[1-({2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl]-*N*-methylacetamide;

20 *N*-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrazole-4-carboxamide;

1-{[2-(1,1-Difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-ethyl-1*H*-pyrazole-4-carboxamide;

1-{[2-(1,1-Difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}-*N*-ethyl-1*H*-pyrrole-3-carboxamide;

25 *N*-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl}-1*H*-pyrrole-3-carboxamide;

2-(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl)-*N*-(2,2-difluoroethyl)acetamide;

30 2-(1-{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl}sulfonyl)azetidin-3-yl)-*N*-cyclopropylacetamide;

and pharmaceutically acceptable salts thereof.

17. N-Cyclopropyl-1-{{2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl}sulfonyl}-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof.

18. A compound according to any one of claims 1-17 for use as a medicament.

19. The use of a compound according to any one of claims 1-17 in the manufacture of a medicament for the therapy of pain.

20. The use of a compound according to any one of claims 1-17 in the manufacture of a medicament for the therapy of functional gastrointestinal disorders.

21. The use of a compound according to any one of claims 1-17 in the manufacture of a medicament for the treatment of irritable bowel syndrome.

22. The use of a compound according to any one of claims 1-17 in the manufacture of a medicament for the treatment of anxiety, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, and cardiovascular disorders.

23. A pharmaceutical composition comprising a compound according to any one of claims 1-17 and a pharmaceutically acceptable carrier.

24. A method for the therapy of functional gastrointestinal disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-17.

25. A method for the therapy of irritable bowel syndrome in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-17.


5 26. Use of a compound according to any one of claims 1-17, for the manufacture of a medicament for the treatment of gastroesophageal reflux disease (GERD) or, for the manufacture of a medicament for the prevention of reflux or for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations (TLESRs).

10 27. Use of a compound according to any one of claims 1-17, for the manufacture of a medicament for the treatment of functional gastrointestinal disorder or for the manufacture of a medicament for the treatment of functional dyspepsia or for the manufacture of a medicament for the treatment of irritable bowel syndrome (IBS).

15 28. A method for the treatment of gastroesophageal reflux disease (GERD) or prevention of reflux or inhibition of transient lower esophageal sphincter relaxations (TLESRs), whereby a pharmaceutically and pharmacologically effective amount of a compound according to any one of claims 1-17, is administered to a subject in need of such treatment.


20 29. A method for the treatment of treatment of functional gastrointestinal disorder or for the treatment of functional dyspepsia or for the treatment of irritable bowel syndrome (IBS), whereby a pharmaceutically and pharmacologically effective amount of a compound according to any one of claims 1-17, is administered to a subject in need of such treatment.

25 30. A method for preparing a compound of formula I,



I

comprising the step of reacting a compound of formula II,



with a compound of R^3R^4NH ,

wherein

Y is selected from Cl, Br, F, methoxy and OH;

R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{1-10} alkoxy, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)$ - C_{1-6} alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)$ - C_{1-6} alkyl, C_{6-10} aryl, C_{6-10} aryl- $C(=O)$ -, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, C_{3-6} heterocyclyl and C_{3-6} heterocyclyl- $C(=O)$ -; wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{1-10} alkoxy, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)$ - C_{1-6} alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)$ - C_{1-6} alkyl, C_{6-10} aryl, C_{6-10} aryl- $C(=O)$ -, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, C_{3-6} heterocyclyl or C_{3-6} heterocyclyl- $C(=O)$ - is optionally substituted by one or more groups selected from carboxy, $-(C=O)-NH_2$, halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, $-N(R^6)-C(=O)R^5$, $-S(=O)_2-NR^5R^6$, $-C(=O)-NR^5R^6$, $-NH-C(=O)-NR^5R^6$ and $-NR^5R^6$;

R^2 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl and C_{3-6} heterocycloalkyl, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl or C_{3-6} heterocycloalkyl used in defining R^2 is optionally substituted by one or more groups selected from carboxy, $-(C=O)-NH_2$, halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$;

R^3 and R^4 are independently selected from $-H$, $-OH$, amino, R^7 and $-O-R^7$, wherein R^7 is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, phenyl and benzyl, wherein R^3 and R^4 are not $-H$ at the same time, and wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl,

phenyl or benzyl in defining R^7 is optionally substituted by one or more groups selected from carboxy, halogen, cyano, nitro, methoxy, ethoxy, hydroxy, and $-NR^5R^6$; or R^3 and R^4 together with the nitrogen connected thereto form a 5- or 6-membered heterocycle ring, wherein said ring is optionally substituted by one or more groups selected from carboxy, halogen, cyano, nitro, methoxy, ethoxy, hydroxy, $-(CH_2)_m-C(=O)NR^5R^6$, $-(CH_2)_mNH-C(=O)NR^5R^6$, $-(CH_2)_m-N(R^5)C(=O)R^6$, $-(CH_2)_m-N(R^5)C(=O)-OR^6$, $-(CH_2)_m-C(=O)-OR^6$, $-(CH_2)_m-O-C(=O)-R^6$, $-(CH_2)_m-OR^6$, and $-NR^5R^6$; and

wherein R^5 and R^6 are independently selected from $-H$, C_{1-6} alkyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, C_{3-6} cycloalkyl- C_{0-m} alkyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, C_{2-6} alkenyl optionally substituted with $-OH$, methoxy, ethoxy or halogen, and a divalent C_{1-6} alkylene optionally substituted with $-OH$, methoxy, ethoxy or halogen that together with another divalent R^5 or R^6 form a portion of a ring; and

m is 0, 1, 2 or 3.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2007/000359

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM ABS DATA, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, File REGISTRY, see RN: 848855-83-4 --	1-2,7-9,11, 14
X	STN International, File CAPLUS, CAPLUS accession no. 1975:408737, Document no. 83:8737, Bieksa, V. et al.: 'Relation of the reactivity of chloroethyl derivatives of 3,4-diaminobenzenesulfopiperidides to the structure of alkylating group'; Lietuvos TSR Mokslu Akademijos Darbai, Serija B: Chemija, Technika, Fizinė Geografija (1974), (3), 91-8 --	1,7,11,14

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 6 August 2007	Date of mailing of the international search report 08-08-2007
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Per Renström/CM Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2007/000359

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 24-25, 28-29
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 24-25 and 28-29 relate to a method of treatment of the human or animal body by therapy (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims, based on the alleged effects of the compounds.
2. ☒ Claims Nos.: 1-2, 7-9, 11, 14-15, 18, 23 (all partly)
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

See next sheet.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2007/000359

Continuation of Box No. II.2

The initial phase of the search of claims 1-2, 7-9, 11, 14-15, 18 and 23 revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search of claims 1-2, 7-9, 11, 14-15, 18 and 23 has been restricted to the following:

the compounds of formula I in which R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl and C₄₋₈cycloalkenyl always substituted by at least one fluoro, cyano, nitro, methoxy or ethoxy; C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C(=O)-C₁₋₆alkyl, C₃₋₆heterocycloalkyl and C₃₋₆heterocycloalkyl-C(=O)- in which C₃₋₆heterocycloalkyl always contains oxygen as a ring hetero atom; and in which R² simultaneously is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl and C₄₋₈cycloalkenyl, optionally substituted by fluoro, cyano, nitro, methoxy or ethoxy.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2007/000359

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, File CAPLUS, CAPLUS accession no. 1973:515496, Document no. 79:115496, Bieksa, V. et al.: 'Chloroalkyl derivatives of benzimidazoles. 1. Chloroethyl derivatives of 2-methylbenzimidazole-5-sulfonamide'; Lietuvos TSR Mokslu Akademijos Darbai, Serija B: Chemija, Technika, Fizine Geografija (1973), (2), 93-103 --	1,7,15
X	WO 2004108688 A1 (ASTRAZENECA AB), 16 December 2004 (16.12.2004) --	1-30
X	WO 2005030732 A1 (ASTRAZENECA AB), 7 April 2005 (07.04.2005) --	1-30
X	WO 2005030761 A1 (ASTRAZENECA AB), 7 April 2005 (07.04.2005) --	1-30
X	WO 2005030762 A1 (ASTRAZENECA AB), 7 April 2005 (07.04.2005) --	1-30
X	WO 2006033630 A1 (ASTRAZENECA AB), 30 March 2006 (30.03.2006) --	1-30
X	WO 2006033631 A1 (ASTRAZENECA AB), 30 March 2006 (30.03.2006) --	1-30
X	WO 2006033633 A1 (ASTRAZENECA AB), 30 March 2006 (30.03.2006) -- -----	1-30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2007/000359

International patent classification (IPC)

C07D 405/06 (2006.01)
A61K 31/4184 (2006.01)
A61K 31/454 (2006.01)
A61P 1/04 (2006.01)
A61P 25/04 (2006.01)
A61P 25/16 (2006.01)
A61P 25/22 (2006.01)
A61P 25/28 (2006.01)
A61P 35/00 (2006.01)
A61P 9/00 (2006.01)
C07D 235/06 (2006.01)
C07D 403/12 (2006.01)
C07D 405/14 (2006.01)
C07D 413/14 (2006.01)

Download your patent documents at www.prv.se

The cited patent documents can be downloaded at www.prv.se by following the links:

- In English/Searches and advisory services/Cited documents (service in English) or
- e-tjänster/anförda dokument(service in Swedish).

Use the application number as username.

The password is **MRFUNTRPSL**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/07/2007

International application No.

PCT/SE2007/000359

WO	2004108688	A1	16/12/2004	AU	2003280944	A	00/00/0000
				AU	2004245296	A	16/12/2004
				BR	PI0411226	A	18/07/2006
				CA	2528924	A	16/12/2004
				CN	1805940	A	19/07/2006
				EP	1636193	A	22/03/2006
				IS	8220	A	04/01/2006
				JP	2006527247	T	30/11/2006
				KR	20060017863	A	27/02/2006
				MX	PA05013050	A	02/03/2006
				NO	20060146	A	07/03/2006
				RU	2005138371	A	27/07/2006
				SE	0301699	D	00/00/0000
				US	20070060583	A	15/03/2007

WO	2005030732	A1	07/04/2005	AU	2004276062	A	07/04/2005
				BR	PI0414780	A	21/11/2006
				CA	2539738	A	07/04/2005
				CN	1886379	A	27/12/2006
				EP	1670769	A	21/06/2006
				IS	8422	A	21/04/2006
				JP	2007506721	T	22/03/2007
				KR	20070001052	A	03/01/2007
				MX	PA06003197	A	23/06/2006
				NO	20061839	A	26/06/2006
				SE	0302573	D	00/00/0000

WO	2005030761	A1	07/04/2005	EP	1673369	A	28/06/2006
				JP	2007506718	T	22/03/2007
				SE	0302570	D	00/00/0000
				US	20070072853	A	29/03/2007

WO	2005030762	A1	07/04/2005	EP	1670790	A	21/06/2006
				JP	2007506724	T	22/03/2007
				SE	0302572	D	00/00/0000

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/07/2007

International application No.

PCT/SE2007/000359

WO 2006033630 A1 30/03/2006

AR	053096	A	25/04/2007
AU	2004276062	A	07/04/2005
AU	2005287426	A	30/03/2006
AU	2005287427	A	30/03/2006
AU	2005287429	A	30/03/2006
BR	PI0414780	A	21/11/2006
CA	2539738	A	07/04/2005
CA	2581232	A	30/03/2006
CA	2582507	A	30/03/2006
CA	2582512	A	30/03/2006
EP	1670769	A	21/06/2006
EP	1797070	A	20/06/2007
EP	1797077	A	20/06/2007
EP	1797078	A	20/06/2007
IS	8422	A	21/04/2006
JP	2007506721	T	22/03/2007
KR	20070054215	A	28/05/2007
MX	PA06003197	A	23/06/2006
NO	20061839	A	26/06/2006
NO	20072091	A	01/06/2007
US	20060264490	A	23/11/2006
WO	2006033631	A	30/03/2006
WO	2006033633	A	30/03/2006
AR	050955	A	06/12/2006
KR	20070054217	A	28/05/2007

WO 2006033631 A1 30/03/2006

AR	053096	A	25/04/2007
AU	2004276062	A	07/04/2005
AU	2005287426	A	30/03/2006
AU	2005287427	A	30/03/2006
AU	2005287429	A	30/03/2006
BR	PI0414780	A	21/11/2006
CA	2539738	A	07/04/2005
CA	2581232	A	30/03/2006
CA	2582507	A	30/03/2006
CA	2582512	A	30/03/2006
EP	1670769	A	21/06/2006
EP	1797070	A	20/06/2007
EP	1797077	A	20/06/2007
EP	1797078	A	20/06/2007
IS	8422	A	21/04/2006
JP	2007506721	T	22/03/2007
KR	20070054215	A	28/05/2007
MX	PA06003197	A	23/06/2006
NO	20061839	A	26/06/2006
NO	20072091	A	01/06/2007
US	20060264490	A	23/11/2006
WO	2006033630	A	30/03/2006
WO	2006033633	A	30/03/2006
AR	050956	A	06/12/2006

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/07/2007

International application No.

PCT/SE2007/000359

WO 2006033633 A1 30/03/2006

AR	051448 A	17/01/2007
AR	051449 A	17/01/2007
AR	053096 A	25/04/2007
AU	2005287429 A	30/03/2006
CA	2582512 A	30/03/2006
EP	1673369 A	28/06/2006
EP	1794150 A	13/06/2007
EP	1797070 A	20/06/2007
EP	1797074 A	20/06/2007
EP	1797075 A	20/06/2007
EP	1797076 A	20/06/2007
JP	2007506718 T	22/03/2007
US	20070072853 A	29/03/2007
WO	2006033627 A	30/03/2006
WO	2006033628 A	30/03/2006
WO	2006033629 A	30/03/2006
WO	2006033632 A	30/03/2006
AU	2004276062 A	07/04/2005
AU	2005287426 A	30/03/2006
AU	2005287427 A	30/03/2006
BR	PI0414780 A	21/11/2006
CA	2539738 A	07/04/2005
CA	2581232 A	30/03/2006
CA	2582507 A	30/03/2006
EP	1670769 A	21/06/2006
EP	1797077 A	20/06/2007
EP	1797078 A	20/06/2007
IS	8422 A	21/04/2006
JP	2007506721 T	22/03/2007
KR	20070054215 A	28/05/2007
MX	PA06003197 A	23/06/2006
NO	20061839 A	26/06/2006
NO	20072091 A	01/06/2007
US	20060264490 A	23/11/2006
WO	2006033630 A	30/03/2006
WO	2006033631 A	30/03/2006